University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2015

Near Infrared Fluorescent Choline Kinase Inhibitors for Cancer
Imaging and Therapy
Sean Philip Arlauckas
University of Pennsylvania, sean.arlauckas@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Pharmacology Commons

Recommended Citation
Arlauckas, Sean Philip, "Near Infrared Fluorescent Choline Kinase Inhibitors for Cancer Imaging and
Therapy" (2015). Publicly Accessible Penn Dissertations. 1007.
https://repository.upenn.edu/edissertations/1007

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1007
For more information, please contact repository@pobox.upenn.edu.

Near Infrared Fluorescent Choline Kinase Inhibitors for Cancer Imaging and
Therapy
Abstract
Choline kinase alpha (ChoKa) deregulation is associated with a more aggressive phenotype and greater
malignancy in many human cancers. Inhibitors of ChoKa induce apoptosis in tumorigenic cells, but
validation of their specificity is difficult in vivo. Alterations in the profile of choline metabolites are
detectable by magnetic resonance spectroscopy (MRS), but because of competing catabolic
contributions from the phospholipases, the relative role of ChoKa is not absolutely discernable in a
clinical setting. The goal of this work was to develop ChoKa-specific imaging probes to assist in the
development of ChoKa as a diagnostic biomarker and therapeutic target. A series of compounds were
synthesized for this purpose, and JAS239 was identified as the most promising choline-mimetic with
inherent near infrared fluorescence. Attenuation of choline phosphorylation by JAS239 in human breast
cancer cells was observed using 14C-choline radiotracing and high-resolution 1H MRS. Microscopy was
used to explore the interaction of JAS239 with the ChoKa protein. These in vitro studies, using the
established MN58b as a positive control, indicated that JAS239 functions as a competitive inhibitor of
ChoKa. Athymic nude mice inoculated with human breast cancer xenografts were injected i.v. with trace
doses of JAS239 for imaging studies. In vivo optical imaging of JAS239 accumulation delineated breast
tumor margins, and the signal intensity was capable of distinguishing both genetic overexpression and
pharmacologic inhibition of ChoKa in breast xenografts. At therapeutic doses, JAS239 and MN58b
reduced murine xenograft growth rates, and JAS239 was more effective than MN58b at reducing tumor
total choline levels. Histological assessment found both JAS239 and MN58b reduced tumor cell density,
decreased proliferation, and elicited an apoptotic response. In a parallel study, ChoKa inhibition was
shown for the first time to be an effective therapeutic strategy in glioma tumors, however, JAS239 was
not found to cross the blood-brain barrier. A library of derivatives were synthesized and these are being
investigated to improve the potency, biodistribution, and tumor specificity. These results represent a new
paradigm of multifunctional small molecules that can be used for ChoKa measurement, as companion
diagnostics to validate new ChoKa inhibitors, and as therapeutically-effective inhibitors of choline
metabolism.
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ABSTRACT

NEAR INFRARED FLUORESCENT CHOLINE KINASE ALPHA INHIBITORS FOR
CANCER IMAGING AND THERAPY

Sean Philip Arlauckas
E. James Delikatny, Ph.D.

Choline kinase alpha (ChoKα) deregulation is associated with a more aggressive phenotype and
greater malignancy in many human cancers. Inhibitors of ChoKα induce apoptosis in tumorigenic
cells, but validation of their specificity is difficult in vivo. Alterations in the profile of choline
metabolites are detectable by magnetic resonance spectroscopy (MRS), but because of competing
catabolic contributions from the phospholipases, the relative role of ChoKα is not absolutely
discernable in a clinical setting. The goal of this work was to develop ChoKα-specific imaging
probes to assist in the development of ChoKα as a diagnostic biomarker and therapeutic target. A
series of compounds were synthesized for this purpose, and JAS239 was identified as the most
promising choline-mimetic with inherent near infrared fluorescence. Attenuation of choline
phosphorylation by JAS239 in human breast cancer cells was observed using 14C-choline
radiotracing and high-resolution 1H MRS. Microscopy was used to explore the interaction of
JAS239 with the ChoKα protein. These in vitro studies, using the established MN58b as a
positive control, indicated that JAS239 functions as a competitive inhibitor of ChoKα. Athymic
nude mice inoculated with human breast cancer xenografts were injected i.v. with trace doses of
JAS239 for imaging studies. In vivo optical imaging of JAS239 accumulation delineated breast
tumor margins, and the signal intensity was capable of distinguishing both genetic overexpression
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and pharmacologic inhibition of ChoKα in breast xenografts. At therapeutic doses, JAS239 and
MN58b reduced murine xenograft growth rates, and JAS239 was more effective than MN58b at
reducing tumor total choline levels. Histological assessment found both JAS239 and MN58b
reduced tumor cell density, decreased proliferation, and elicited an apoptotic response. In a
parallel study, ChoKα inhibition was shown for the first time to be an effective therapeutic
strategy in glioma tumors, however, JAS239 was not found to cross the blood-brain barrier. A
library of derivatives were synthesized and these are being investigated to improve the potency,
biodistribution, and tumor specificity. These results represent a new paradigm of multifunctional
small molecules that can be used for ChoKα measurement, as companion diagnostics to validate
new ChoKα inhibitors, and as therapeutically-effective inhibitors of choline metabolism.
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CHAPTER 1
Introduction
1.1

Preamble

The purpose of this thesis is to explore the mechanisms surrounding choline kinase
alpha (ChoKα) and its involvement in cancer progression. Past studies have suggested
that ChoKα expression and activity may serve as valuable biomarkers in cancer. The goal
of this work is to explore the rationale behind targeting ChoKα to elicit a response in
tumors. Molecular imaging applications as well as pharmacologic studies are included in
the study of ChoKα’s clinical importance.

1.2

Hallmarks of cancer

The idea of a “magic bullet” was proposed by Paul Ehrlich during his investigations
of histological stains in human tissue (Ehrlich, 1911). His realization that dyes could
interact with specific targets in cells led to the concept of chemotherapy, wherein
molecules could be designed to bind and inactivate cellular targets at the pathological
source of cancer (Strebhardt and Ullrich, 2008). The War on Cancer was declared in 1971
when scientists and legislators promised a universal “cure” for the ailment we now know
to be caused by hundreds of pathologically-unique diseases (Sporn, 1996). After several
decades and billions of dollars’ worth of research funding, the scientific community has
dramatically tempered its expectations for universal “magic bullets” as the complexities
of these diseases have become realized. The treatment options for many cancers are so
limited that life extensions of one or two months can be sufficient for FDA approval of
new and often prohibitively expensive drugs. There have been success stories for specific
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patient populations, notably paclitaxel in ovarian cancer, cisplatin in testicular cancer,
imatinib mesylate treatment in chronic myeloid leukemia and gastrointestinal stromal
tumors, and bevacizumab in VHL-mutated renal and colon cancers (Chabner and
Roberts, 2005). These breakthroughs are becoming increasingly possible as we continue
to classify cancers by their genetic and environmental driving factors, tissue of origin,
and response to therapy, understanding the pathways of each cancer type so that potential
susceptibilities can be explored for therapeutic intervention (Sawyers, 2004). Certain
attributes have also been identified that are common to all cancers. These have been
known since 2000 as the “Hallmarks of Cancer” and include: self-sustaining growth
signaling, evading growth inhibitors, resisting apoptosis, acquiring replicative
immortality, inducing angiogenesis, and promoting cell motility to surrounding tissues
(Hanahan and Weinberg, 2000). These hallmarks were updated in 2011 to include four
additional trends: genome instability, immune system evasion, tumor-promoting
inflammation, and altered cellular energetics (Hanahan and Weinberg, 2011).
As signal transduction-targeted drugs have begun to replace traditional chemotoxic
agents, the need for novel therapeutic targets has left researchers scrambling to identify
clinical markers of tumor malignancy that can be exploited for pharmaceutical
intervention. The cancer hallmarks include a host of promising biomarkers for imaging
and therapeutic intervention. Bevacizumab was developed as an anti-angiogenic agent
when it was proposed that cancers grow and spread by highjacking the mechanism for
blood vessel formation (Los et al., 2007). The epidermal growth factor receptor (EGFR)
is commonly mutated and hyperactive in tumors, leading to the identification of EGFR
inhibitors to treat lung, colon, and glioblastoma multiforme cancers in which these
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mutations are common (Kris et al., 2003; Cunningham et al., 2004). Therapies like these
have made remarkable strides toward prolonged patient survival, but new agents are
needed to overcome the challenges of treatment resistance, cancer metastasis, and tumor
recurrence. Promising therapeutic strategies based upon the new cancer hallmarks are
emerging, for instance the CAR-T therapies designed to train the immune system to
recognize and kill tumor cells (Maude et al., 2014). In many instances, methods of early
detection would allow a therapeutic regimen to be started at an earlier pathological stage
where there is a greater likelihood of tumor response (Etzioni et al., 2003). Recognizing
that areas of chronic inflammation are more susceptible to malignant transformation has
helped guide the location and frequency of screening procedures (Mantovani and Sica,
2010). The drive to improve cancer detection led to a number of advances in our
understanding of how cancers use nutrients and produce energy in ways that can provide
distinction from normal tissue.
The work of Otto Warburg was first to report that tumors exhibit aerobic glycolysis,
although the advantage this provides to cancer cells has only recently begun to be
elucidated (Warburg, 1956; Burk and Schade, 1956; Gatenby and Gillies, 2004). Besides
the immune-protective effect of microenvironment acidosis, this metabolic
transformation produces glycolytic intermediates that the tumor can use for biosynthetic
precursors to support the growing biomass (Kroemer and Pouyssegur, 2008). A number
of the most common oncogenic mutations upregulate hypoxia inducible factor-alpha
(HIFα), a transcription factor that causes global changes in gene expression and result,
among other cancer-associated outcomes, in promotion of the glycolytic pathway
(Semenza, 2003). It is seemingly counter-productive for cancers to switch from the more
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energy-efficient aerobic ATP production in the mitochondria even in situations where
oxygen levels are not low. This glycolytic shift, however, permits the shunting of carbon
atoms to other important factors required for growth, including nucleosides and amino
acids (Vander Heiden et al., 2009). Upregulation of the glycolytic pathway enhances
uptake of 18F-fluoro-D-glucose (FDG), which has been useful for identification of tumors
using positron emission tomography (PET) imaging (Mankoff et al., 2007). The clinical
success of FDG has sparked efforts to develop radiotracers derivative of many naturally
occurring metabolites relevant to tumorigenesis. These metabolites include estrogens
(Katzenellenbogen et al., 1997), thymidine (Shields et al., 1998), folate (Muller, 2013),
pyruvate (Toyoda et al., 1989), glutamine (Lieberman et al., 2011), and, notably, choline
(Hara et al., 1997).

1.3

Choline metabolism

Magnetic resonance spectroscopy (MRS) provides a profile of endogenous
metabolites within an MRI-selected voxel, and is complementary to PET studies of
exogenous metabolite distribution. MRS is capable of detecting the density of any nonzero spin nuclei such as 1H, 31P, and 13C (Glunde et al., 2010). By studying cancer cell
and tumor extracts, a number of biomarkers unique to malignant tissue have been
reported (Daly and Cohen, 1989; Gillies and Morse, 2005). One such phenomenon that
has been described in a range of cancers, including breast, ovarian, prostate, lung, bone,
colon, brain, hepatic, and lymphocytic, is the concomitant increases in
phosphomonoesters (PME) observed in 31P spectra and total choline-containing
metabolites (tCho) observed in 1H spectra (de Certaines et al., 1993; Glunde and Serkova,
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2006; Podo et al., 2011). PME and tCho accumulation is one way that cancer cells are
able to provide the metabolic precursors necessary for proliferation, and has been linked
to overall poorer prognosis in numerous cancers (Negendank, 1992). Similarly, early
drops in PMEs and tCho are predictive of responsiveness to both chemo- and
radiotherapies (Shukla-Dave et al., 2002; Podo et al., 2011). The nine chemically
equivalent protons in the methyl groups adjacent to the quaternary nitrogen of choline
yield a strong singlet resonance at 3.2 ppm that is detectable by 1H MRS (Fig. 1.1). This
technique can be adapted to study whole animals, perfused cell models, biopsy tissue, and
cell extracts, with the capacity to resolve individual contributors to the PME and tCho
peaks improving in that order (Ackerstaff et al., 2003).
A

B

C

Figure 1.1. MRS detection of elevated tumor choline levels. (A) Glioblastoma multiforme
tumor visible in a gadolinium-enhanced T1-weighted MRI image is demarcated by the right voxel.
(B) Using chemical shift imaging at 3.2 ppm, a map of choline distribution (Cho) demonstrates
elevated tCho in the tumor region. (C) MR spectra acquired for the tumor (right voxel) or the
contralateral normal tissue (left voxel) confirm elevated tCho in cancer and diminished Nacetylaspartate (NAA) in the cancer tissue. Figure adapted with permission from Horská and
Barker, 2010.
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The tCho peak is a composite resonance in in vivo 1H MRS spectra consisting of the
sum of the choline-containing metabolites: free choline (3.20 ppm), phosphocholine (PC,
3.22 ppm), and glycerophosphocholine (GPC, 3.23 ppm). Tumor tissue extracts studied
using high resolution MRS have revealed that the major contributor to the tCho signal is
PC (Daly and Cohen, 1989). PC is an important precursor to phosphatidylcholine
(PtdCho), the predominant phospholipid in mammalian cell membranes. In fibroblasts,
generation of PC is required for the induction of DNA synthesis by a number of growth
factors including PDGF, FGF, EGF and phorbol esters (Cuadrado et al., 1993). Inhibiting
PC production prior to PDGF or FGF addition eliminates activation of the Raf-1 and
MAP kinase signaling cascades responsible for relaying the mitogenic growth signal
(Jiménez et al., 1995). Microinjection of PC itself is sufficient to induce a mitogenic
response (Cuadrado et al., 1993), although a different paper demonstrated that PC added
to cellular media was not taken up by cells but still exhibited a pro-mitogenic response (T
Chung et al., 1997). Results from this paper suggest that extracellular ATP detection by
the purinergic P2 receptors induces release of mitogenically active levels of PC from
fibroblasts. PC acts synergistically with ATP, insulin, and/or sphingosine-1-phosphate to
stimulate phosphatidylinositol-3’-kinase (PI3K) and pp70s6k, which regulate progression
from the G1 to the S phase of the cell cycle (T Chung et al., 1997). PC levels have been
found using MRS to increase substantially following oncogene transfection, loss of tumor
suppressor function, and immortalization (Aboagye and Bhujwalla, 1999; Mori et al.,
2004). Comparison of spectra from tumor-derived cells versus their normal counterparts
has revealed elevated PC levels in breast (Aboagye and Bhujwalla, 1999; Eliyahu et al.,
2007), glioma (Gillies et al., 1994), ovarian (Iorio et al., 2005), and prostate (Ackerstaff
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et al., 2001) cells. Because it only measures the total steady-state pool of PC, MRS is
unable to detect the relative contribution of the anabolic and catabolic pathways by which
PC is generated.
Free choline can be transported across the cell membrane by a number of transporters
(ChoT), which can be classified into four major groups: high-affinity choline transporters
(CHTs), choline transporter-like proteins (CTLs), organic cation transporters (OCTs), and
organic cation/carnitine transporters (OCTNs). Each transporter group is composed of
multiple genes and splice variants (Michel et al., 2006). Members of each class have been
found at elevated levels in tumors, although the expression of each transporter seems to
differ between cancers (Glunde et al., 2011). CTL1 for example has been reported in
colon cancer (Kouji et al., 2009), lung cancer (Wang et al., 2007), and leukemia
(Fullerton et al., 2006). In a study of breast cancer cells, CHT1 and OCT2 were found to
be the primary choline transporters (Eliyahu et al., 2007). The role of each choline
transporter in each tumor type is still poorly understood, due to the complexity of the
isoforms present in each transporter class.
Upon entering the cell, choline can be incorporated into a variety of important cellular
components, including acetylcholine, betaine, sphingomyelin, or PtdCho (Fig. 1.2). In
healthy individuals, the CHT family is primarily expressed in neurons, which take up
choline and synthesize the neurotransmitter acetylcholine in a one-step pathway catalyzed
by choline acetyltransferase (D Wu and Hersh, 1994). Choline can also be oxidized in the
mitochondria at the hydroxyl position to form the common osmolyte betaine.
Betaine:homocysteine S-methyltransferase transfers a methyl group from betaine to
homocysteine, replenishing the methionine pool needed for the synthesis of the crucial
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methyl donor S-adenosylmethionine (SAM) (Gonzalez et al., 2004). Among other
functions, SAM can be used by phosphatidylethanolamine N-methyltransferase (PEMT)
to methylate phosphatidylethanolamine (PtdEtn) for PtdCho synthesis during choline
deficiency (Cui and Vance, 1996). In humans PEMT is almost exclusively expressed in
the liver (Vance, 2013). The majority of cells in the human body use choline as a head
group for cell membrane lipids. The Kennedy pathway leads to formation of the
diacylglycerophospholipid, PtdCho. PtdCho can then be converted to the sphingolipid
sphingomyelin (SM) via transfer of PC to a ceramide by the enzyme sphingomyelin
synthase (Ullman and Radin, 1974).
Anabolic production of PC occurs during the Kennedy pathway (Fig. 1.2) for PtdCho
biosynthesis (Weiss et al., 1956). Free choline in the cytosolic space is rapidly
phosphorylated to PC by the enzyme choline kinase (ChoK) (Wittenberg and Kornberg,
1953). PC conversion to CDP-choline is the rate-limiting step catalyzed by the enzyme
choline phosphate cytidylyltransferase (CCT) (Kennedy and Weiss, 1956). CCT is
inactive in soluble form but recruited to the nuclear membrane in a highly regulated
fashion (Glunde et al., 2011). Cytidine monophosphate is then replaced with 1,2-sndiacylglycerol (DAG) by the enzyme phosphocholine diacylglycerol transferase (PCT) in
the final step of PtdCho synthesis (Kennedy, 1957).
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Figure 1.2. Phosphatidylcholine catabolic and choline anabolic routes. PtdCho is
synthesized in most cells via the Kennedy Pathway, where choline (bottom center) is
phosphorylated by ChoK, then DAG is added via a CDP-mediated two-step mechanism. PtdCho
can be metabolized at a variety of cleavage sites by the phospholipase enzymes. The byproducts
of both the PtdCho catabolic and anabolic steps have important signaling functions, which can go
awry in diseased tissue. Reproduced from Baykal et. al., 2008, with permission.

PC formation can also occur by a number of catabolic paths, which are mediated by a
class of enzymes known as the phospholipases (Fig. 1.2). PC can be cleaved directly
from PtdCho by PtdCho-specific phospholipase C (PC-PLC), releasing a DAG second
messenger that can go on to activate protein kinase C. While the activation of PC-PLC at
the plasma membrane and the inhibition of its activity by the compound D609 have been
studied, the gene(s) encoding its protein(s) have yet to be identified (Ramoni et al.,
2004). PC can also be derived by phospholipases using indirect methods. These methods
include conversion of PtdCho to free choline and phosphatidic acid (PA) by
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phospholipase D (PLD), and the coordinated activity of phospholipase A2 (PLA2),
lysophospholipase (LPL) and glycerophospholipase:phosphodiesterase (GPC:PDE) to
render free choline. In both cases, the enzyme ChoK is again responsible for conversion
of free choline to PC. These enzymes have been found to be differentially expressed in
some but not all cancers, and much work is still required to fully elucidate their
involvement in PC production (Podo et al., 2011). A number of mitogenic second
messengers are released as byproducts of PtdCho cleavage, including DAG,
lysophosphatidic acid, PA, arachidonic acid, and PC itself (Agwu et al., 1989; Nishizuka,
1992; Moolenaar, 1999; Du et al., 2010).

1.4

Choline kinase

The primary mediator of PC levels in cancer cells is believed to be the enzyme ChoK,
which is responsible for phosphorylation of free choline upon cell entry or release by a
catabolic process. Enhancement of intracellular PC by Ras transformation is a ChoKdependent process, as ChoK inhibitors have been demonstrated to halt these alterations
(Ramírez de Molina et al., 2001). The growth factors that rely on PC production to exert
their mitogenic effects also require ChoK; ChoK inhibition in primary human mammary
epithelial cells blocks EGF, insulin, and hydrocortisone-induced DNA synthesis (Ramírez
de Molina, Báñez-Coronel, et al., 2004). It can therefore be inferred that the production
of PC as a mitogenic second messenger is regulated by ChoK and cannot be salvaged in
most cases by a compensatory catabolic mechanism.
There are three different isoforms of ChoK in mammals coded by two different genes.
CHKA encodes the protein ChoKα, which exists in two splicing variants. ChoKα variant
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2 includes an 18 amino acid insertion between Met150 and Gly151 (Aoyama et al., 2004).
While the importance of this splicing difference is not certain, some evidence indicates it
may impact subcellular distribution (Miyake and Parsons, 2012). The CHKB gene
encodes the protein ChoKβ, which has approximately 60% sequence homology to the
ChoKα isoforms (Aoyama et al., 1998). ChoK is only functional in homodimer or
heterodimer form, and the distribution of each isoform varies widely between tissues.
While the testis and liver exhibit relatively high ChoKα expression, the heart and liver
have the highest ChoKβ protein (Aoyama et al., 2002). Each isozyme is capable of
phosphorylating choline, as well as the structurally similar ethanolamine. Only ChoKα
has been found to have a link to tumor transformation (Gallego-Ortega et al., 2009), but
defects in ChoKβ can lead to muscular dystrophy (Sher et al., 2006). While the ChoKα
protein is more selective for the choline substrate, ChoKβ has higher affinity for
ethanolamine (Gallego-Ortega et al., 2009). CHKA but not CHKB deletion is
embryonically lethal (G Wu et al., 2008), further implicating the ChoKα variants as the
crucial contributors to PtdCho biosynthesis. ChoK α/α complexes have the highest ChoK
activity (higher Vmax and lower Km), β/β complexes have low activity, and α/β dimer
complexes have intermediate catalytic activity (Aoyama et al., 2004; Gallego-Ortega et
al., 2009).
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Figure 1.3. ChoKα phosphorylates choline via an unusual ping-pong mechanism.
306
2+
Unprotonated Asp at the active site of human ChoKα can accept a phosphate group by a Mg coordinated reaction resulting in protonation of the amino acid and subsequent ejection of ADP.
The phosphate-primed enzyme can accept choline, which induces a conformational shift in the
enzyme resulting in PC exit. The deprotonated ChoKα enzyme reverts to its original conformation
and is again ready for ATP binding. Adapted with permission from Hudson et. al., 2013.

ChoK is similar to other kinases in that its N- and C-terminal lobes come together to
form the ATP-binding site, but it is classified as an “atypical kinase” because there is a
flexible ATP-binding loop in place of the glycine-rich P-loop found in typical eukaryotic
kinases (Peisach et al., 2003; Scheeff and Bourne, 2005). It has been known since its
discovery that the conversion of the phosphate group from ATP to choline requires
magnesium ions for reaction coordination (Wittenberg and Kornberg, 1953). It was only
recently reported by Hudson et. al. that ChoK works by an iso double-displacement
mechanism, meaning that no ternary choline-ATP-ChoK complex is formed during
catalysis (Fig. 1.3). Instead, ATP transfers a phosphate group directly to the enzyme at
residue Asp306, which upon protonation causes ADP to leave (Hudson et al., 2013). The
protonated, phosphate-bound Asp306 favors the binding of choline, which causes a
conformational shift in ChoK that deprotonates Asp306 and releases PC in a process that
then makes the original ChoK conformation more favorable. This ping-pong mechanism
was supported by the surprising finding that ChoK has ATPase activity even in the
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absence of choline (Hudson et al., 2013). The active site of ChoK is unlike the cleft-like
structure of most protein kinases; the choline binding site exists in a tunnel-like pocket of
hydrophobic residues with a rim of negatively-charged amino acids (Malito et al., 2006).
Reports generally agree on Km values for choline between 100-180 µM, Km values for
ATP between 410-760 µM, and kcat values for the enzyme of 69-83 s-1 (Malito et al.,
2006; Hong et al., 2010; Hudson et al., 2013).
Heightened ChoK activity was first reported in rat hepatocytes following treatment of
carcinogenic polyaromatic hydrocarbons; reversal of this phenomenon by addition of
transcription inhibitors (cyclohexamide or actinomycin D) suggests the increase in
activity was due to an increase in ChoK protein expression (Ishidate et al., 1980).
ChoKα, but not ChoKβ, expression can also be induced in liver cells by carbon
tetrachloride (CCl4) (Aoyama et al., 2002). This hepatotoxin was later found to cause
upregulation of the oncogenic transcription factor c-jun that binds to an activator protein
1 (AP1) element site in the promoter region of CHKA (Aoyama et al., 2007). Hypoxia
response elements (HREs) in the CHKA promoter region have linked HIF1α activity to
ChoKα expression (Glunde et al., 2008; Bansal et al., 2011). Inhibitors of the
mitochondrial electron transport chain in neuroblastoma cells can increase ChoKα
expression and phospholipase activity, leading to elevated choline metabolites (Baykal et
al., 2008). Additional reports have shown that the oncogene c-Myc can increase ChoKα
expression ultimately leading to higher levels of PC detected using 1H-MRS (Morrish et
al., 2008; 2009). ChoKα activation can be mediated by the oncogenic small GTPase
RhoA and its effectors (Ramírez de Molina et al., 2005). Ras mutation in NIH3T3
fibroblasts was shown to increase ChoK activity via Ral-GDS and PI3K downstream
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pathways (Ramírez de Molina, Penalva, et al., 2002). Treatment of human prostate and
colon carcinoma cells with the PI3K inhibitor PI-103 reduced ChoKα and PC levels,
indicating PI3K is regulative of PtdCho biosynthesis by promoting CHKA expression
(Al-Saffar et al., 2010). In yeast, direct phosphorylation at Ser30 and Ser85 of choline
kinase (CKI) by protein kinase A (PKA) increases PC production (Yu et al., 2002),
although only rudimentary evidence in humans exists to suggest similar regulation of
ChoK by PKA (Wieprecht et al., 1994). Phosphorylation of ChoKα at the Tyr197 and
Tyr333 residues has been reported in human breast cancer cells, and these alterations
increase the activity of ChoKα when in a complex with epidermal growth factor receptor
(EGFR) and c-Src (Miyake and Parsons, 2012). In human breast cancer cells,
extracellular calcium has been used to stimulate ChoK activity and PC formation by a
Rho-dependent pathway (Huang et al., 2009). This is of interest because calcium, along
with other growth factors, is released in large quantities at sites of metastases to bone
(Silver et al., 1988; Hoey et al., 2003).
The diversity of cancer-associated factors that can stimulate ChoK activity establishes
the critical role this oncoprotein plays in tumorigenesis. Overexpression of ChoKα, but
not ChoKβ, is sufficient to drive tumor transformation (Gallego-Ortega et al., 2009).
Amplified ChoKα expression was first reported in breast carcinomas, and these studies
found elevated ChoK activity in 39% of patient-derived tumor specimens (Ramírez de
Molina, Gutierrez, et al., 2002). ChoKα deregulation has since been found in 47% of
colon cancer, 56% of lung cancer, and 48% of prostate cancer tissues (Ramírez de
Molina, Rodríguez-González, et al., 2002). ChoKα over-activity has additionally been
reported in ovary (Iorio et al., 2010), endometrial (Trousil et al., 2014), and pancreatic
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cancers (Penet et al., 2015). A retrospective study of non-small-cell lung cancer patients
who had received prior surgical tumor resection found that individuals with tumor
ChoKα levels 1.91-times higher than healthy tissue had four-year survival rates of just
49%, compared to a survival rate of 71% in patients with ChoKα expression below this
threshold (Ramírez de Molina et al., 2007). ChoKα activity is clinically correlated with
histological tumor grade in breast cancer, and is inversely proportional to estrogen
receptor positivity in patients (Ramírez de Molina, Gutierrez, et al., 2002). This is
significant in that it implicates breast cancer patients resistant to the anti-estrogen
tamoxifen may have pro-survival pathways mediated by ChoK. In murine models of
bladder cancer, ChoKα overexpression is associated with larger, more metastatic tumors
and contributes to a more aggressive carcinoma (Hernando et al., 2009). HDAC
inhibitors Vorinostat, LAQ-824, and belinostat provide the only example running
contrary to this conventional wisdom, in that they induce differentiation and apoptosis in
cancer cells but cause a rise in PC and ChoK levels (Sankaranarayanapillai et al., 2006; Y
Chung et al., 2008; Beloueche-Babari et al., 2010; Ward et al., 2013). ChoKα expression
and activity are otherwise described consistently as robust biomarkers for tumor
aggressiveness in a growing number of cancers, with few exceptions.

1.5

Choline kinase inhibition
ChoKα suppression. There is growing clinical interest in the suppression of ChoKα

activity to ameliorate the pro-growth, drug resistant, and invasive phenotype this enzyme
seems to impart on cancers originating from a wide range of tissues. An siRNA screen of
human kinases and phosphatases which are critical for cell survival found ChoKα knock15"
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down to cause a two-fold increase in apoptosis (MacKeigan et al., 2005). The first study
to explore RNAi knockdown of ChoKα in-depth found reduced proliferative markers and
signs of differentiation in the highly-metastatic triple-negative MDA-MB-231 human
breast cancer cell line (Glunde et al., 2005). Chua et. al. performed an siRNA screen of
more than 90 kinases to identify regulators of Akt, a critical molecular mediator in
metabolism and cell survival pathways. In MDA-MB-468 breast cancer cells, both
ChoKα and ChoKβ activities were found to promote phosphorylation of Akt at Ser473,
activating Akt in a PI3K-dependent manner (Chua et al., 2009). While ChoKα RNAi
silencing prevents mitotic entry and induces apoptosis in HeLa cells, knockdown of
ChoKβ in addition to ChoKα rescues this lethality implying that the ChoKα to ChoKβ
ratio is key to regulating release from G0/G1 arrest (Gruber et al., 2012). The Lacal group
used stable ChoKα knockdown by shRNA and found enhanced PARP cleavage in
cervical, lung, and bladder cancer cells. This study also found ChoKα shRNA induces
apoptosis in MDA-MB-231 cells and tumor xenografts, but is tolerated in untransformed
human mammary epithelial cells (Báñez-Coronel et al., 2008). Suppression of ChoKα
expression also appears to sensitize cancer cells to chemotherapeutics (Mori et al., 2007;
Granata et al., 2014). In 2009, a lentiviral approach to deliver ChoKα shRNA to MDAMB-231 xenografts achieved 80% reduction in ChoKα protein and attenuated PME levels
were detected noninvasively using in vivo 31P MRS (Krishnamachary et al., 2009). An
early study that sought to explain the observation that myo-inositol and choline addition
to growth media reduces de novo PtdCho synthesis found this effect is due to downregulation of ChoKα expression, rather than direct chemical inhibition of the protein
(Hosaka et al., 1990).
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Early inhibitors. In studying the interaction between ChoK and its natural substrates,
early propanol, butanol, and methyl-substituted derivatives of choline were described as
ChoK inhibitors (Shelley and Hodgson, 1970). Wittenburg and Kornberg reported that
ChoK activity could be stimulated by cysteine (Wittenberg and Kornberg, 1953). This
early observation led Brostrom and Browning to study choline phosphorylation in the
presence of the thiol group inhibitors and found ChoK inhibition by both Nethylmaleimide and Ellman’s reagent (Brostrom and Browning, 1973). A preliminary
study as far back as 1974 linked inhibition of ChoK to membrane morphological changes
in cancer cells, and demonstrated anti-tumor activity using purinyl-6-histamine to inhibit
choline phosphorylation (Mayer and Werner, 1974). A comprehensive review of agents
known to inhibit ChoK activity in any way includes a wide variety of Kennedy pathway
intermediates (e.g. ethanolamine, PC, CDP-choline) and choline derivatives (e.g. ethyl
choline mustard, acetylcholine, betaine) (Lacal, 2001). A variety of muscarinic receptor
antagonists (e.g. quinacrine), ATP analogs (5’-AMP, AMP-PNP), and ions capable of
displacing Mg2+ have also been reported, although for many of these agents it is likely
that this effect is non-specific and due to action on the choline transporters, widespread
interaction with ATP-binding sites in kinases, or other metal-dependent enzymes
(Ishidate, 1989). Finally, ChoK is most catalytically efficient at alkaline pH ranges (8.09.5) and can be effectually inactivated in acidic environments (Wittenberg and Kornberg,
1953).
Hemicholinium-3. Since its discovery as a ChoK inhibitor (Ansell and Spanner,
1974), the symmetric dicationic choline-mimetic hemicholinium-3 (HC-3, Fig. 1.4) has
been a prototype for ChoK inhibitors (Hamza et al., 1983). Prior to its study as a ChoK
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inhibitor, HC-3 was used as a research tool for its ability to inhibit acetylcholine
synthesis in the nervous system (Gomez et al., 1970). First discovered in 1954 (Long and
Schueler, 1954), HC-3 was shown to disrupt ChoK activity in the brain by blocking
sodium-dependent high-affinity choline uptake (Yamamura and Snyder, 1973; Guyenet et
al., 1973) and diminishing acetylcholine synthesis (Macintosh, 1961; Gardiner, 1961).
While HC-3 is capable of reducing PC levels and inhibiting growth factor-induced DNA
synthesis in vitro (Jiménez et al., 1995), administering HC-3 at doses necessary for in
vivo ChoK inhibition causes substantial off-target action on the neuronal high affinity
choline transporters as well as acetylcholinesterase (Cannon, 1994). HC-3 toxicity results
in a “curare-like” death due to its disruption of cholinergic neurotransmission (Boobis et
al., 1975). The first exploration of HC-3 derivatives took place in the late-1980s and
found that hydrophobic spacer length was critical in establishing the distance between
quaternary ammonium groups (Tedford et al., 1986; Bhattacharyya et al., 1987; Cannon
et al., 1988; Sheff et al., 1988). A fourteen-atom spacing between the cationic headgroups yielded the most potent modulators of acetylcholine content in the caudate
nucleus, one of the structures that makes up the basal ganglia and controls motor function
(Bhattacharyya et al., 1987). Most tertiary ammonium derivatives are inactive, however
the choline-like oxazinium group can be replaced with 4-methylpiperadine, suggesting
that a hydroxyl group is not essential for choline uptake inhibition (Tedford et al., 1986;
Sheff et al., 1988).
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Figure 1.4. Structures of symmetric ChoKα inhibitors. The oxazinium rings of HC-3 can exist
in open or ring structures, but crystallization studies indicate the closed ring is more favorable in
vitro. Two classes of HC-3 analogs mimic the heterocyclic head-groups with either pyridinium or
quinolinium moieties on each end of a hydrophobic spacer. Electron-donating substituents at the
R-group improve potency against ChoKα. MN58b is a representative of the bis-pyridinium class.
TCD-717 is a bis-quinolinium ChoKα inhibitor currently in clinical trials.

Bis-pyridiniums. The IC50 of HC-3 against purified ChoK is 500 µM, so as new links
between cancer and choline phosphorylation were discovered in the 1990s, it became
clear that more selective and potent ChoK inhibitors were needed. Based upon prior HC3 derivatives, new ChoK inhibitors were soon developed in the lab of Juan Carlos Lacal.
This initial class of bis-pyridinium compounds improved the potency against pure ChoK
and the growth inhibitory concentration in cancer cells by several orders of magnitude
(Hernández-Alcoceba et al., 1997). Quantitative structure-activity relationships (QSAR)
demonstrated that electron-donating groups substituted at the C4-position of the
pyridinium head-groups (Fig. 1.4) give the strongest ex vivo ChoK inhibition, the –NMe2
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moiety is one of the most electron-donating substituents known (Campos et al., 2001).
The most promising of these compounds, MN58b (Fig. 1.4), is effective against a variety
of cancer cell lines, significantly retards xenograft growth, and, most importantly, is more
specific for ChoKα than HC-3 (Hernández-Alcoceba et al., 1999). Improved activity was
found when the 4,4’-biphenyl linker of HC-3 was replaced by a 1,2-ethylene(bisbenzyl)
fragment (Campos et al., 2003). Although tri-pyridinium structures exhibit superior
potency against purified ChoKα, the additional charge on these molecules makes them
impenetrable to the cell membrane and relatively weak anti-proliferative agents (ConejoGarcía, 2003). Likewise, attempts to make these structures more rigid to reduce rotational
bonds and conform to “drug-likeness” principles ultimately led to IC50s as low as 30 nM
in purified recombinant ChoKα, but these bis-pyridinium cyclophane compounds are
ineffective at inhibiting growth of HT29 colorectal adenocarcinoma cells (Conejo-García
et al., 2003). A rigid bi-phenyl linker did yield the most potent compounds, and when
paired with a 4-chloro-N-methylanilino substituent on the pyridinium moiety, gave rise to
a number of promising agents (Conejo-García et al., 2004). Extensive molecular
modeling of these compounds with the crystal structures of ChoKα have helped to
highlight the importance of the linker moiety, distance between quaternary ammoniums,
delocalization of positive charge by electron-donating groups, and steric hindrance
(Janardhan and Srivani, 2006).
Bis-quinoliniums. The first attempt to make HC-3 analogous ChoKα inhibitors found
pyridine derivatives to be the most potent, however insights gleaned from the QSAR
studies of these bis-pyridiniums suggest lipophilicity could be a major factor
disconnecting ex vivo ChoK inhibition from in vitro antiproliferative efficacy (Lacal,
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2001). Additionally, with a better understanding of steric and electrostatic interactions at
the active site, it became attractive to substitute the pyridine moiety with a variety of
substituted quinolinium or isoquinolinium fractions to improve the cell permeability
(Sánchez-Martín et al., 2005). The bis-quinoliniums (Fig. 1.4) have been demonstrated to
have improved antiproliferative properties compared to the bis-pyridinium structures.
This is due to overall greater hydrophobicity, although in both classes the same 3,3′biphenyl linker and electron-donating substitutions have yielded the most potent ChoKα
inhibitors (Sánchez-Martín et al., 2005). These studies found that linker length has less of
an effect on the antiproliferative properties than it does on ChoKα inhibition, and it was
postulated that other mechanisms of cell death besides those induced by the interaction
with ChoKα may exist for these compounds (Campos et al., 2006). Nonetheless, there
have been excellent ChoKα inhibitor candidates derived from this class, which have submicromolar IC50s and GI50s (Gómez Pérez et al., 2012). One clinical candidate, known as
RSM-932A or TCD-717 (Fig. 1.4) has recently completed Phase I clinical trials for
advanced solid tumor treatment (Lacal and Campos, 2015).
Assymmetric inhibitors. The importance of symmetry was questioned even at the
early stages of this field. However, when half-inhibitor fragments were found to be poor
inhibitors and highly toxic, it was proposed that the dimeric form of ChoKα must allow
each di-cationic inhibitor head-group to interact with a unique catalytic site (Lacal, 2001).
With the crystal structures of inhibitors docked at the ChoKα active site having since
been elucidated, the distance between catalytic units is now known to be too great for
these inhibitors to span between bound ChoKα dimers, although the possibility that the
unbound cationic head-group can bind to the choline-binding site of a free ChoKα
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monomer or to the ATP-binding site on the same protein was never excluded (Hong et
al., 2010). In fact, two separate efforts have been made to design asymmetric ChoKα
inhibitors which link pyridinium head-groups with ATP-like structures (Trousil et al.,
2013; Schiaffino-Ortega et al., 2013). In each of these cases, there is little correlation
between the potency of ChoKα inhibition and the antiproliferative effect, most likely due
to toxicities linked to disruption of ATP binding to other critical targets. Use of the
ChoKα structure for in silico screening led to the discovery of N-(3,5-dimethylphenyl)-2[[5-(4- ethylphenyl)-1H-1,2,4-triazol-3-yl]sulfanyl] acetamide (referred to as CK37)
(Clem et al., 2011). Modeling of the active site for structure-directed discovery is now
underway at Vertex Pharmaceuticals, and has already yielded incredibly potent and
kinase-selective ChoKα inhibitors (Falcon et al., 2013; Hudson et al., 2013). These have
proven to be useful tools for studying ChoKα mechanism and how it relates to
tumorigenesis.
Attenuation of enzymatic activity. There are several pharmacodynamic markers of
ChoKα inhibition, which have been identified using a combination of RNAi and small
molecule chemical inhibitors. The earliest studies with bis-pyridinium ChoKα inhibitors
found they are tolerated by untransformed NIH3T3 cells and only cytotoxic following
oncogenic (Ras, Raf, Src, or Mos) overexpression (Hernández-Alcoceba et al., 1997). It
was presumed at this time that ChoKα’s involvement in cell cycle signaling is based
solely on its ability to regulate production of the mitogenic second messenger, PC, and
that the anticancer effect of ChoKα inhibition is primarily due to attenuation of this
growth signal and depletion of substrates required for PtdCho biosynthesis (Lacal, 2001).
Indeed, depletion of PC, tCho, and ChoK activity has been measured using both ChoKα22"
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targeted RNAi and small molecule approaches in both in vitro and in vivo settings
(Hernández-Alcoceba et al., 1999; Glunde et al., 2005; Al-Saffar et al., 2006). While this
is a rational conclusion, it does not explain why normal cells are resistant to apoptosis
under the same conditions.
Cancer cell sensitivity. In 2004, it was discovered in primary lymphocytes that the
ChoKα inhibitor MN58b causes dephosphorylation of the cell cycle checkpoint
retinoblastoma protein (pRb), driving these cells into a reversible quiescent state until
drug removal (Rodríguez-González et al., 2004). Due to defunct cell cycle regulation in
lymphoma cells, the inability to dephosphorylate pRb causes Jurkat cells to continue
proliferating. The cells compensate for inhibited de novo PC production by cleaving the
PC head-group from the abundant membrane sphingolipid, sphingomyelin (RodríguezGonzález et al., 2004). The accumulation of ceramides as a byproduct leads to tumorspecific apoptosis, as confirmed by cleavage of PARP due to caspase-9 activation
(Rodríguez-González et al., 2004). Caspase-3 activation can be detected prior to a loss in
mitochondrial potential and cytochrome-c release, suggesting apoptosis by a non-intrinsic
pathway (Rodríguez-González et al., 2005). MN58b has no effect on other enzymes
involved in the PtdCho anabolic/catabolic cycles, interference in the MAPK pathway, or
DNA-intercalation (Rodríguez-González et al., 2003). Although MN58b has no
measurable effect of MAPK signaling, an independent study found that siRNA
knockdown of ChoKα does inhibit the MAPK cascade by reducing PA levels crucial for
Ras anchorage and activation (Yalcin et al., 2010). To support this hypothesis, this group
developed a ChoKα inhibitor known as CK37 and found disrupted actin cytoskeleton and
membrane ruffling in addition to suppressed signaling pathways downstream of Ras
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(Clem et al., 2011). The only known relationship between ChoKα and the plasma
membrane is recruitment by EGFR in a c-Src dependent manner; whether this occurs
specifically at focal adhesion sites has yet to be explored (Miyake and Parsons, 2012).
This remains an important area of interest, as recent studies suggest that a scaffolding
role, rather than or in addition to PC production, may be responsible for ChoKα’s role in
cancer (Falcon et al., 2013).
Anti-proliferative effect of ChoK inhibitors. The classic understanding of the effects
of ChoKα inhibition began to unravel when a highly specific ChoKα inhibitor developed
in Vertex labs was discovered to dramatically decrease PC pools, but cause a panel of
cancer cell lines to enter a quiescent, rather than an apoptotic state (Falcon et al., 2013).
This work found that reduction of ChoKα protein, not PC levels, is the crucial
mechanism of cell death (Falcon et al., 2013), making it unclear why some but not all
ChoKα inhibitors elicit an antitumor response. The discovery that MN58b and TCD-717,
but not ChoKα siRNA, elicit an endoplasmic reticulum (ER) stress response finally
provided a clue to explain this discrepancy (Sanchez-Lopez et al., 2013). MN58b and
TCD-717 cause a distinct activation of the unfolded protein response in cancer cells by
elevating protein chaperones and the pro-apoptotic transcription factor CHOP (SanchezLopez et al., 2013). Inhibitor-induced apoptosis in cancer cells can be marginally
reversed by addition of ChoKα siRNA, suggesting the conformational changes in ChoKα
elicited by these inhibitors cause the inhibited enzyme to be recognized as a misfolded
protein. This is non-lethal in normal cells due to a more moderate ER-stress response
triggered by the pro-survival transcription factor ATF4 and its downstream network of
genes responsible for ER repair (Sanchez-Lopez et al., 2013). It appears that among the
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molecules capable of blocking the choline-binding site, there is a smaller subset with
antiproliferative activity. This therapeutic response is dependent on an inhibitor’s ability
to trap ChoKα in an inactive position, prompting cancer cells toward apoptosis by
provoking an overly sensitive unfolded protein response. The difference between
cytotoxic (e.g. bis-pyridinium, bis-quinolinium) and cytostatic (e.g. Vertex’s V-11-0711)
ChoKα inhibitors may be the length of the molecule and the ability to extend from the
choline-binding site to one of the adjacent clefts formed by residues which open or close
depending on enzyme conformation (Rubio-Ruiz and Figuerola-Conchas, 2014). The
possibility of undetected off-target binding, however, remains a concern until these
discrepancies are resolved.
In vivo validation of ChoKα inhibition. The difficulty in confirming ChoKα
specificity is due to the contributions from other phospholipid and choline-handling
enzymes that can confound the interpretation of changes in PC levels. Most notably,
drugs with known effects on phospholipase activity have been studied for oncological use
(Ackerstaff et al., 2007). It is known that mitochondrial complex inhibitors are capable of
enhancing activity through the Kennedy pathway (Baykal et al., 2008), a factor that is
especially concerning considering that many ChoK inhibitors feature cationic ammonium
species similar to mitochondrial-targeted agents such as metformin and carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP). A reliable panel of pharmacodynamic
biomarkers of ChoKα inhibition has not been established, due to conflicting cellular
responses to ChoKα targeted RNAi and small molecule inhibitors. It is yet unknown
whether inactivated ChoKα protein is more crucial than PC depletion to these inhibitors’
antiproliferative activities, although there is increasing evidence which supports this
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hypothesis (Falcon et al., 2013; Sanchez-Lopez et al., 2013). Concrete evidence relies on
strategies to detect ChoKα in its native state in the absence and presence of inhibitors.
Unfortunately, choline tracers are dependent on choline transporters and cannot
distinguish choline transport inhibitors from choline phosphorylation inhibitors (Hara et
al., 2006). MRS-based studies can detect steady-state metabolite levels, but enzymes
from many pathways can affect these pools. The Phase-I clinical trial for TCD-717 in
advanced solid tumors had an efficacy outcome measure based upon Response
Evaluation Criteria in Solid Tumors (RECIST), but two years into the trial was amended
to include in vivo MRS-based measurements of tCho to validate patient response
(ClinicalTrials.gov Identifier: NCT01215864). It is unclear how necrosis due to poor
blood supply or general chemotherapeutic effect could be deconvoluted from the ChoKα
inhibitory response, except with advanced chemical shift imaging or follow-up
histological assessment (Horská and Barker, 2010). One approach using systemicallydelivered 11C- or 18F-labeled HC-3 to compare choline distribution in 9L glioma rats
found a tumor/muscle ratio as high as 5, however these were subcutaneous xenografts
and poor tumor delivery was observed relative to the high renal and liver signals (Zheng
et al., 2007). The authors developed this probe to image CHT1 transporters, but this work
still represents the first effort to label a choline-like inhibitor for imaging purposes and
represents an interesting strategy of ChoKα inhibitor validation if a ChoKα specific probe
were identified.
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1.6

Carbocyanine Dyes
The cyanines represent a diverse class of fluorescent molecules that share a common

structure composed of one tertiary nitrogen and one quaternary nitrogen connected by an
odd number of methine groups (alternating single and double bonded carbons). The
terminal nitrogen on each end of this resonant polymethine structure is typically part of a
larger heterocyclic system. The first cyanine was described by Greville Williams in 1865
who mixed quinolone (with an unforeseen lepidine impurity) with amyl iodide and
obtained a brown oil that, when treated with ammonia, became a brilliant “corn flour
blue” substance he termed “cyanine” (Williams, 1856). After investigation by many
colleagues, it was realized the methyl impurity in lepidine provided the central methine
carbon between the quinoline rings (Hoogerwerff and Van Dorp, 1883). As this reaction
became better understood, new isoforms were described with 0 (apocyanines), 1 (true
cyanines), 3 (carbocyanines), and 5 (tricarbocyanine) methine groups between the
terminal rings. When non-similar head-groups flank the methine linker, these structures
are known as isocyanines (Adams and Haller, 1920). These head-groups can be
quinolinium, indolium, thio-indolium, oxa-indolium, pyridinium, imidazolium, and
benzo-indolium rings with infinite substituent groups possible (Doja, 1932). The distance
between the nitrogen atoms is the primary determinant of the wavelength of maximal
light absorption, and it is possible to make general predictions of optimal fluorescence
excitation wavelengths using particle-in-a-box theory (Autschbach, 2007). The
carbocyanines are useful as a class of dyes because the optical properties can be tuned in
a predictable manner and there are many potential sites for functional modifications.
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While the original interest in cyanines was for textile coloring agents, it was quickly
discovered that these compounds make excellent photo-sensitizers in silver halide plates,
allowing photography to advance into an expanded range of wavelengths (Doja, 1932).
Cyanines have since been implemented in a variety of industrial uses which include laser
disk storage, solar energy, paints, and semiconductors (Mishra et al., 2000). The first
widespread use of a cyanine in humans followed clinical approval of indocyanine green
(ICG. Fig. 1.5A) for measurement of cardiac function (Fox et al., 1957). In 1966, the
report of an interaction between a cyanine and DNA questioned the notion that cyanine
derivatives were biologically inert (Kodama et al., 1966). Changes in red blood cell
membrane potential in response to valinomycin can cause quenched aggregation or
fluorescent dissociation of a panel of cationic cyanine dyes (Sims et al., 1974). It was
even found that 3,3’-dipropyl- and 3,3’-diethyl-thiadicarbocyanine are capable of
inhibiting K+ efflux through the Ca2+-dependent K+ transporters (Simons, 1976).
Cyanines with longer lipophilic alkyl chains can incorporate into the plasma membrane
and were used as a stable labeling system for tracking neuronal growth (Honig and
Hume, 1986). When it was discovered that carcinoma cell mitochondria selectively
accumulate cationic dyes such as rhodamine (Bernal et al., 1983), Oseroff et. al. were
able to accomplish similar results using N,N'-bis(2-ethyl-1,3- dioxolane)kryptocyanine
and found that effective photodynamic therapy could be achieved in bladder, colon, and
squamous cancer cells with no light-induced death in normal keratinocytes or kidney
epithelial cells (Oseroff et al., 1986). Since these reports of biological activity, however,
the enthusiasm for cyanines as fluorescent tags attached to antibodies (Folli et al., 1994;
Ballou et al., 1995; Vogel et al., 1996; Ballou et al., 1997), receptor ligands (Becker et
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al., 2001; Tichauer, Samkoe, Klubben, et al., 2012), and natural products (Packard and
Wolf, 1985; Becker et al., 2000; Licha et al., 2000) has far out-weighed the concern or
interest in their pharmacodynamic effects.
A

B

ICG

C

D

E

Figure 1.5. The use of ICG for NIRF-guided surgical resection. (A) ICG is a clinically
approved cyanine with NIRF that binds to serum albumin and can be detected in blood vessels
and lymph nodes. (B) Human tissue scatters and absorbs light in the visible range, but is
relatively transparent to light in the NIR window. (C) To the naked eye, it can be difficult for
surgeons to identify lymph nodes, (D) however, as a blood pooling agent ICG can be used to
identify the sentinel lymph during tumor resection. (E) An overlay of the bright field and NIRF
(green) channels offers a promising new intraoperative imaging tool. Panel (B) used with
permission by Mahmood and Weissleder, 2003. Panels C-E adapted with permission from Crane
et. al., 2011.

More often, cyanines are being used as tools to measure physiological changes as a
result of disease progression. One such application is the formation of hydrocyanine
derivatives using sodium borohydride to reduce cyanines on the quaternary cationic
ammonium group (Kundu et al., 2009). In this uncharged, non-fluorescent state,
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hydrocyanines are more cell-permeable and can be returned to their charged, fluorescent
state by oxidizing agents. A number of commercially-available carbocyanines were
modified to their hydrocyanine form and used to detect reactive oxygen species in
lipopolysaccharide-induced inflammation (Kundu et al., 2009). A new class of cypatederived carbocyanines was recently discovered in the Achilefu lab to have dichromic
fluorescence with emissions at 700 nm in the symmetric state and 800 nm when
asymmetry is introduced by functional group addition. This is a particularly-promising
discovery because cypate-derivatives with serine-mimicking alkyl groups were shown to
undergo phosphorylation by Akt, rendering a measurable alteration in fluorescence which
serves as a read-out of insulin-activated Akt activity (Shen et al., 2013).
There are a number of optical, chemical, and biological properties that are desirable
for a clinically suitable cyanine dye. The observed brightness of a fluorophore is the
product of two factors. The first is the extinction coefficient (ε), which describes the
number of photons a given concentration of dye (c) can absorb. The actual absorbance
(A) of a particular wavelength of light is also dependent on the path length of the beam
through the medium (ℓ), and is described by the Beer-Lambert law: A = εcℓ. The second
factor is the fluorescence quantum yield (Φf), which relates to the efficiency with which
absorbed photons are emitted at a longer wavelength (Rurack and Spieles, 2011). These
factors can be influenced by the solvent system, as can the general solubility of the probe,
thus testing needs to be performed in serum prior to animal studies (SL Gibbs, 2012). The
wavelength of excitation and emission is of particular importance for in vivo fluorescence
measurements, as human tissue has many components which can absorb, scatter, and
fluoresce light, creating a broad range of wavelengths unsuitable for optical imaging
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(Lewis et al., 2002; Mahmood and Weissleder, 2003). Endogenous molecules such as
nucleic acids, fat, water, hemoglobin, and melanin limit light penetration in the UV and
visible range, but within the spectral window known as the near infrared (NIR)
wavelengths (Fig. 1.5B), human tissue is relatively transparent (Hale and Querry, 1973;
Jobsis, 1977; van Veen et al., 2005). Near infrared fluorescence (NIRF) measurement is
becoming a major tool for non-invasive disease measurement, however thus far only ICG
and methylene blue are approved for clinical use. Due to strong binding to serum
albumin, ICG is confined to the vasculature and has been used for retinal angiography,
measuring cardiac output, evaluating hepatic clearance, defining lymphatic architecture,
and delineating tumor margin (Marshall et al., 2010). While ICG’s excitation (760-785
nm) and emission (820-840 nm) are within the therapeutic window, dye aggregation and
photo-instability lead to relatively poor optical properties (Landsman et al., 1976). The
mechanism of accumulation within cancer tissue is non-specific and based upon
enhanced permeability and retention (EPR) within the disorganized vasculature and
insufficient lymphatic system of the tumor (Marshall et al., 2010). Methylene blue is also
a blood pooling agent but exhibits low tumor contrast due to its non-ideal optical
properties (Ex. 668 nm, Em. 688 nm) (Matsui et al., 2010). Methylene blue has been
useful in lymph node mapping (Tuttle, 2004), but ICG remains the best clinical option for
NIRF-guided tumor margin identification (Frangioni, 2008).

1.7

Near infrared fluorescence guided surgery
Surgery remains a crucial part of oncological treatment and cures an estimated 50%

of cancers, despite the fact that the vast majority of tumor resection relies on visual
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recognition and palpation to discern cancerous from normal tissue (De Grand and
Frangioni, 2003). Without the aid of tissue contrast guidance, resection of tumor
boundary tissue and evaluation by histopathology remains the gold standard for
confirming cancer-free margins (SL Gibbs, 2012). This technique is labor-intensive and
time consuming, but necessary to identify tumor outgrowths which can be too narrow for
the naked eye to detect. The need for sentinel lymph node identification and resection for
histological assessment could also be aided by a real-time contrast agent. NIRF-guided
surgery is a promising new field that seeks to pair enhanced cancer-tissue contrast with
the operational simplicity and safety of optical imaging (Frangioni, 2003). Currently the
most advanced technology in this field is the Fluorescence-Assisted Resection and
Exploration (FLARE) system, which consists of a dual bright field and NIRF light
acquisition overlay on a hands-free monitor set up in the surgical suite (Nakayama et al.,
2002; Troyan et al., 2009). With virtually no background signal, intraoperative NIRF
imaging has been used to successfully identify tumor margins (Madajewski et al., 2012)
and sentinel-node positivity (Fig. 1.5C-E) (Kitai et al., 2005; Crane et al., 2011) using a
variety of fluorophores and cancer models (Weissleder and Ntziachristos, 2003).
Britton Chance introduced optical imaging of the breast, using endogenous contrast in
the NIR range created by oxygen levels and blood volume (Nioka et al., 1994). It is now
widely thought that exogenous contrast agents are required to achieve the sensitivity
necessary to justify the use of imaging systems during surgery (Weissleder and
Ntziachristos, 2003). The pharmacokinetics and optical properties of a probe are the two
most important factors that contribute to successful tumor-specific NIRF. There are two
approaches to achieving tumor specificity: target affinity and site-specific activation.
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Fluorophore-conjugated ligands have been designed for a number of cancer-specific
molecules, including somatostatin receptors (Achilefu et al., 2000), folate receptors
(Tung et al., 2002), immunoglobulin proteins (Ballou et al., 1995), carcinoembryonic
antigen (Folli et al., 1994), oncofetal fibronectin isoform (Neri et al., 1997), and EGFR
(Ke et al., 2003). Weissleder expanded the field using fluorescence resonant energy
transfer (FRET) to design quenched fluorophores that could be released upon cleavage by
an enzyme or physiological activity of interest (Weissleder et al., 1999). A number of
enzyme-cleaved probes have since been designed to provide functional measurements of
lysosomal proteases (Weissleder et al., 1999), matrix metalloproteinases (Bremer et al.,
2001), cathepsins B and D (Tung et al., 2000; Marten et al., 2002), and phospholipases
(Mawn et al., 2011). While there are a growing number of such probes under
investigation, the field of intraoperative NIRF imaging is limited by the number of
clinically available imaging agents. Among the obstacles for clinical approval is tumor
selectivity, in vivo sensitivity, barriers to intratumoral probe delivery (pore size,
interstitial pressure), immunogenicity, and efficient clearance (Becker et al., 2001;
Torosean et al., 2013). For this reason, small molecule drugs and imaging agents are still
largely preferred over macromolecules/nanoparticles due to their favorable
pharmacokinetics.

1.8

Scope of thesis
The focus of this work deals with improvement of the available methods to validate

ChoKα inhibitors in vivo. The observation of structural similarity between the
antiproliferative ChoKα inhibitors and the carbocyanines sparked the initial search for a
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fluorescent dye capable of attenuating flux through the Kennedy pathway. The
development of JAS239 as such a candidate is then described, with the in vitro
characterization of its inhibitory and cell tracking capabilities included. Insights gleaned
from JAS239 administration as a diagnostic probe and anticancer drug were then used to
study the specificity of an established inhibitor. The final portion of this thesis describes
the design of a library of JAS239 derivatives with structural modifications made based
upon its described characterization.
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CHAPTER 2
Materials and Methods
2.1 Chemistry Materials
Solvents were purchased from Fisher Scientific. 1,4-Diphenyl-butane was purchased
from Pfaltz & Bauer, Inc. 3,3’-dimethyloxacarbocyanine iodide (DMOCI) and
1,1’,3,3,3’,3’-hexamethylindotricarbocyanine iodide (HITC) were purchased from Acros
Organics. N-(3-Triethylammoniumpropyl)-4-(6-(4-(diethylamino) phenyl) hexatrienyl)
pyridinium dibromide (FM 4-64) was purchased from Life Technologies.
Hemicholinium-3 (HC-3) and indocyanine green (ICG) were purchased from SigmaAldrich. IRDye-800CW carboxylate was purchased from Li-Cor Biosciences. E,EconjMN58b, E,E,E-conjMN58b, TCD-717, cycloJAS239, cycloJAS239.5, cycloHITC,
and cycloHITC.5 were purchased from Peptech Corporation, Bedford, MA. All other
chemicals were purchased from Sigma-Aldrich and used as received. The compounds
were named with ChemBioDraw Ultra (v. 13, CambridgeSoft).
1

H NMR spectra were recorded on a Bruker DMX360 or UNI500 spectrometer in

CDCl3 or CD3OD using tetramethylsilane (TMS) as an internal standard. Chemical shifts
are reported in ppm. Mass spectra were recorded on a Bruker Microflex MALDI-TOF
spectrometer. HPLC analysis was performed by Dr. Popov as described elsewhere
(Kachur et al., 2013). Absorbance and fluorescence spectra were acquired by diluting
each fluorophore in methanol, addition of the solution to a 1 cm wide crystal cuvette, and
measurement in a Molecular Devices Spectra Max M5 plate reader.
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2.2 Cell Culture
Breast Cancer cell lines. The triple-negative MDA-MB-231 human-derived breast
cancer cell line was obtained from American Type Culture Collection (ATCC) in
November of 2011. These cells were expanded and frozen within 3 passage numbers after
receipt. Cells were used within 6 months of resuscitation, and authorized by the ATCC
via the COI assay, STR analysis, and BacT/ALERT 3D. The MDA-MB-231-derived cell
line 4175-Luc+ was isolated from a murine lung metastasis and was generously provided
by Dr. Andy Minn in August of 2013 (Minn et al., 2005). Both cell lines were maintained
in monolayer culture in DMEM (Mediatech, Flemington, NJ) supplemented with 10%
FBS (HyClone Laboratories, Logan, UT), 1% penicillin/streptomycin (Mediatech), and
1% L-glutamine (Mediatech) at 37°C in a humidified atmosphere (5% CO2). The 4175Luc+ cells were maintained in 5 µg/mL blasticidin (Invitrogen), which was removed
during experiments. MCF7 breast cancer cells expressing a Chk-4 clone (MCF7-CK+) or
the empty vector (MCF7-EV) were provided by Drs. Zaver Bhujwalla and Tariq Shah of
Johns Hopkins University in March 2012 (Shah et al., 2010). These cells were cultured in
MEM (Mediatech) supplemented with 10% FBS, 1% penicillin/streptomycin, 1% Lglutamine, and 400 mg/mL G418 sulfate selection agent (Mediatech). G418 was not
included in the culture medium during experiments. All cell lines used were tested upon
receipt and bi-monthly for mycoplasma. Cells were frozen in liquid nitrogen and only
used at low passage numbers.
Glioma cell lines. To assess the toxicity and efficacy of MN58b on growth inhibition
of gliomas, we chose three rat brain tumor cell lines F98, 9L and 9L over-expressing
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EGFRviii (Kapoor et al., 2007). The F98, 9L and 9L-EGFRviii glioma cell lines were
maintained as adherent monolayers cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM, Sigma-Aldrich, St Louis, MO) supplemented with 10% fetal bovine serum
(HyClone, Mississauga, Canada), 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) buffer (Invitrogen; Carlsbad, CA), 200 U/mL penicillin and 200 mg/mL
streptomycin sulfate at 37°C in 5% CO2 in air. Cells were maintained in exponential
growth phase by routine passage twice weekly at 3 x 105 cells per T-75 flask. 9L and F98
cell cultures were tested upon receipt from the lab of Dr. J. Biaglow (Department of
Radiation Oncology at the University of Pennsylvania) in 1999 using the Rat Antibody
Production (RAP) Test performed by Charles River Laboratories (Wilmington, MA) and
re-screened in 2005 using IMPACT III PCR profiling performed by RADIL (Columbia,
MO). Cell lines were used within 6 months of resuscitation and tested bi-monthly for
mycoplasma. The 9L-EGFRviii cell line was cloned from the 9L cells in the laboratory of
Dr. Donald M O’Rourke, Department of Neurosurgery, University of Pennsylvania. We
obtained the 9L-EGFRviii cell line from Dr. Donald M O’Rourke in 2010. No additional
characterization has been performed on this cell line.

2.3 Western Blotting
MCF7-EV and CK+ cells were plated in 10-cm dishes (1.0 x 106 cells) and grown for
24 hours. Proteins were extracted on ice using radioimmunoprecipitation lysis buffer
(Abcam) fortified with a cOmplete Mini, EDTA-free protease inhibitor cocktail (Roche)
and quantified using the BCA Protein Assay Kit (Pierce). Approximately 30 µg total
protein was resolved on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane,
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blocked using nonfat milk, and blotted for ChoKα (Abcam) or GAPDH and imaged using
Luminata Western Chemiluminescent HRP substrates (Millipore). Bands from each of
three separate experiments were quantified using ImageJ software. Mansi Shinde of the
Pharmacology Graduate Group, University of Pennsylvania provided technical support
for electrophoresis, membrane transfer, immunoblotting, and film development.

2.4 1H MRS studies of cellular extracts
Breast cancer cells. MDA-MB-231, 4175-Luc+, MCF7-EV and MCF7-CK+ cells
(~30 x 106) were harvested using trypsin and washed 2x with PBS. Dual-phase
methanol/chloroform/water extraction was performed in a glass centrifuge tube as
described elsewhere (Tyagi et al., 1996; Glunde et al., 2005). Cells were transferred to a
glass centrifuge tube and 4 mL ice-cold methanol was added and cells were vortexed.
After 10 minutes on ice, 4 mL of chloroform was added and the sample was again
vortexed and allowed to settle on ice. After 10 minutes, 4 mL of water was added and the
sample vortexed, and stored at 4°C overnight. Each glass centrifuge tube was then
centrifuged at 20,000 x g at 4°C. The upper aqueous phase was separated, treated with
Chelex beads to remove dicationic ions, roto-evaporated to remove methanol, and
lyophilized to remove water. Samples were resuspended in D2O containing 0.7 µmol of
trimethylsilyl propionate (TSP, Aldrich) as a chemical shift reference and concentration
standard. Fully relaxed 1H NMR spectra were acquired with help from Weixia Liu and
Stephen Pickup of the Small Animal Imaging Facility using an 11.7 T Varian INOVA
high-resolution NMR spectrometer and a 90° pulse width (relaxation delay: 6 seconds;
repetition time: 10.73 seconds; number of scans: 64; data size: 32 K; spectral width:
38"
"

6,000 Hz; temp: 30°C; total acquisition time: 11 minutes 28 seconds).
Brain cancer cells. For consistency between in vitro and ex vivo extract preparation,
the F98 cells grown in culture were prepared for MRS evaluation using perchloric acid
extraction. Cells were seeded (1x105/mL, 150 cm2 flasks) and incubated overnight, media
was aspirated and replaced with fresh media containing 0, 10, and 20 µM MN58b. After
24 hour MN58b treatment, cells were trypsinized, washed and an aliquot was removed
for viability counts. The remaining cells were pelleted and homogenized in 3 volumes of
6% PCA, transferred into an Eppendorf tube and centrifuged (13,000 rpm, 30 minutes,
4°C), neutralized with 3 M potassium hydroxide (KOH, Sigma-Aldrich, St Louis, MO)
and the neutralized samples were lyophilized for 24 hours. Members of the Poptani Lab
in the Department of Radiology performed the PCA extraction and samples were scanned
on a 500 MHz vertical bore NMR scanner (Bruker, Billerica, MA) with the same
parameters used for breast cell extracts.
Spectra were analyzed using Mnova Lite 5.2.5 software (Mestrelab Research,
Santiago de Compostela, Spain) with 0.5 Hz apodization. Following Fourier transform,
spectra were phase-corrected using the TSP peak, which was also used as a chemical shift
reference at 0.0 ppm. Minor baseline correction was applied as needed. Metabolite peaks
were identified on the basis of their chemical shifts (Evanochko et al., 1984). The
following choline-containing metabolites were identified from their N-trimethyl
(+N(CH3)3) resonances: Cho 3.20 ppm (singlet); PC, 3.22 ppm (singlet); and GPC, 3.23
ppm (singlet). Metabolite concentrations were calculated using the signal area in the
proton spectrum, which is proportional to the concentration and the number of protons
contributing to the signal. The metabolite concentrations were calculated and corrected
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for the number of cells in the NMR experiment using the following formula: [(metabolite
peak height /number of protons) /(TSP peak height /number of TSP protons)] x (TSP
concentration /number of cells). The resonances at 3.2 ppm from the choline-containing
metabolites are all composed of 9 protons, as is the 0.0 ppm resonance of TSP.

2.5 ChoK activity 1H MRS assay
MDA-MB-231, MCF7-EV, and MCF7-CK+ cells (~20 x 106) were trypsinized,
washed 2x in ice-cold PBS, and homogenized on ice in 4 volumes of 100 mmol/L TrisHCl (pH 8.0) containing 10 mmol/L DTT and 1 mmol/L EDTA in D2O as described
previously (Iorio et al., 2005). Samples were ultrasonicated 2x for 30 seconds at 4°C,
centrifuged for 30 minutes at 12,0000xg, and the supernatant transferred to an NMR tube.
ATP (Sigma-Aldrich), choline chloride (Sigma-Aldrich), and MgCl2 (Sigma-Aldrich) in
Tris-HCl/D2O buffer were added to the sample with final concentrations of 10, 2.5, and
10 mmol/L, respectively. 1H MR spectra were recorded immediately at 10-minute
intervals for 500 minutes (90° pulse length, relaxation delay: 6.6 seconds; repetition time
10 seconds; number of scans: 60; data size: 16 K; spectral width: 6,000 Hz; temp: 30°C;
total acquisition time 8 hours, 20 min). Choline and PC peaks were fit from Fourier
transformed spectra and were processed in the same manner as the extract data using
Mnova Lite 5.2.5. Data were fit to the linear equation, y = mx + b, where x is time, y is
the area of the PC or Cho peak, and m, the slope, gives the rate of conversion. To reduce
the amount of JAS239 required to treat 20 x 106 cells (grown in 4 x 150 cm2 flasks
containing 25 mL media each), treatment occurred after cells were pooled and
centrifuged, thus 53 nmol of JAS239 were present in the 530 µL NMR sample,
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equivalent to a concentration of 530 nmol/L if treatment were applied to the cells before
trypsinization.

2.6 14C-choline ChoK activity assay
Intact cells. Cells for breast cancer studies were plated at 1.5 x 106 cells/well in 6well dishes and allowed to grow for 48 hours. For glioma cell studies, 5×105 cells/well
were seeded in a 6-well plate and incubated for 24 hours at 37°C. Media was aspirated
and replaced with fresh media containing varying concentrations of ChoK inhibitor or
vehicle control, followed 1 hour later by treatment with 0.5 µCi/mL of [methyl-14C]choline chloride (Perkin Elmer). At the indicated time-points, cells were rinsed with icecold PBS (Mediatech) and fixed in 16% trichloroacetic acid. Samples were scraped,
collected in centrifuge tubes, washed 3x in diethyl ether, lyophilized, and resuspended in
water for TLC separation using a solvent system of 0.9% NaCl: methanol:ammonium
hydroxide (50:70:5, v/v/v). Quantification of the water-soluble choline metabolites was
performed using autoradiography with a FujiFilm FLA-7000 in accordance with
previously established protocols (Hernández-Alcoceba et al., 1999). The Rf values for the
choline metabolites were 14C- choline (0.07), 14C-PC (0.14), and 14C-GPC (0.39).
Cytosolic preps. For 14C-choline tracing studies independent of the choline
transporters, cytosolic preps were made using the same procedure described in the ChoK
activity 1MRS assay, with diH2O used in place of D2O. Approximately 5 x 105 cells were
used per sample. To each sample, drug was added directly at the required concentration.
MgCl2 and ATP were then added with the same final concentrations as in the NMR
assay, whereas choline chloride levels were reduced to 200 µM. Finally, 3 µCi/mL 14C41"
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choline was mixed in the sample. Samples were incubated for 1 hour, then fixed
lyophilized, reconstituted, separated by TLC, and analyzed by autoradiography following
the same procedure used for intact cells. Due to the higher salt content of these samples,
the Rf values for PC (0.08) and Choline (0.28) changed and were determined using
labeled standards.

2.7 Cell viability studies
Trypan exclusion assay. MCF-7 EV and MCF7-CK+ cells were plated at 1.0 x 106
cells/well in 6-well plates. After 2 days, media was replaced with fresh media containing
MN58b or JAS239 at concentrations ranging from 0-20 µM. At 17 hours, cells were
gently rinsed with ice-cold PBS, trypsinized at 37oC, and a 200 µL aliquot was
neutralized with fresh media containing Trypan Blue, and counted using a Neubauer
hemocytometer. Counts were reported relative to untreated EV cells. In all viability and
therapeutic studies of cells treated with JAS239, great attention was paid to protecting the
samples from light, both to minimize probe degradation and the potential of a
photodynamic therapy response.
MTT assay. The MDA-MB-231 and 4175-Luc+ cell lines were plated in triplicate in
96-well plates at 7.5x104 cells/well and incubated overnight. The culture medium was
replaced with media containing varying concentrations of JAS239 or MN58b. After
overnight incubation, 20 µL of 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide; thiazolyl blue (MTT, Sigma-Aldrich, St Louis, MO) in
sterile PBS was added and the cells were again incubated for 2 h. The media/MTT
mixture was removed and replaced with 150 µL dimethyl sulfoxide (DMSO, Fisher
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Scientific, Fair Lawn, NJ), shaken, and the absorbance read at 550 nm using a Spectra
Max M5 plate reader (Molecular Devices, Sunnyvale, CA). Background signal was read
as absorbance at 690 nm and subtracted from each sample reading. For the glioma cell
lines, the same procedure was followed. The MTT assays on the glioma cell lines were
run by Sona Saksena, Ph.D. (Department of Radiology, University of Pennsylvania)
under my guidance, and the raw data from each of the three trials was analyzed by me.

2.8 Epidermal growth factor stimulation
ChoK activity assay. The 9L and 9L-EGFRviii gliosarcoma lines were plated at a
density of 1 x 105 cells/well in 6-well plates. After 24 hours, media was replaced with
DMEM + 0.1% bovine serum albumin (BSA, Sigma-Aldrich). After overnight serum
starvation, the 6-well plates were aspirated and DMEM + 0.1% BSA with and without 20
µM MN58b was added. Epidermal growth factor (EGF, UPenn Cell Center) was
immediately added to half the treatment groups at a final concentration of 200 ng/mL.
The other half in each treatment group received the same volume of PBS. After 1 hour of
incubation, [methyl-14C]-choline chloride was added to each well at a final activity of 0.5
µCi/mL. After a final hour of incubation, media was aspirated, cells were washed in PBS,
and 16% TCA was added to fix each well. PC production was quantified using the
TLC/autoradiography method described above.
MTT assay. The 9L and 9L-EGFRviii cell lines were distributed at 7.5 x 103
cells/well in 96-well plates. After 24 hours, media was replaced with DMEM + 0.1%
BSA. Cells were incubated in serum-starved conditions for 2 days, at which time the
media was replaced with fresh serum-free media containing either 20 µM MN58b or
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saline control, with half of each treatment group receiving 200 ng/mL EGF and the other
half receiving PBS. After 24 hours, 20 µL of 5 mg/mL MTT was added to each well,
incubated 2 hours, and plates were analyzed using the MTT assay procedure described
above.

2.9 Fluorimetry analysis
Uptake competition assay. MDA-MB-231, MCF7-EV, MCF7-CK+ cells were grown
for 48 hours in 6-well plates (1.5 x 105 cells/well). Each well was aspirated and replaced
with fresh media containing JAS239 with or without choline and incubated for 2 hours.
Samples were washed in PBS, lysed in DMSO, and the fluorescence was measured using
a Molecular Devices Spectra Max M5 plate reader with an excitation (Ex.) of 640 nm and
emission (Em.) of 770 nm.
Cell retention assay. MCF7-EV and MCF-CK+ cells were plated in 6-well plates (1.0
x 105 cells/well). After 48 hours incubation, cells were treated with varying
concentrations of JAS239 for 2 hours. Each well was aspirated and rinsed once with PBS.
DMSO (500 µL) was added per well, plates were covered with tin foil to protect from
light and shaken for 30 minutes prior to transfer of 200 µL of sample to a black-walled
clear bottom 96-well plate for measurement of fluorescence in the Spectra Max M5 plate
reader (Ex. 640 nm; Em. 770 nm). To study ChoKα dependent retention, the same cell
conditions were set up and cells were treated with 10 µM JAS239 for 1 hour, rinsed with
PBS, and incubated 15 minutes with fresh media over two separate cycles. After 3 rinses
with PBS, DMSO was added and the same procedure as above was followed to measure
JAS239 accumulation.
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2.10 Confocal microscopy
Live cell analysis. MDA-MB-231 cells were plated at 1.5 105 cells/dish in 35-mm
glass-bottom dishes coated with poly-D-lysine (MatTek Corp.). After 2 days of
incubation, cells were treated with fresh DMEM containing no phenol red and 2 µmol/L
JAS239 and/or 5 µmol/L of the nuclear targeting dye SYTO9 dye (Life Technologies).
The cells were subsequently imaged with assistance from James Hayden of the Wistar
Imaging Facility using a Zeiss LSM 510 META confocal microscope with Ex. 633 nm
and Em. filter 650 to 790 nm.
Immunohistochemistry. MDA-MB-231 cells were plated on sterile 10 mm glass
coverslips placed in 24-well plates and incubated 24 hours. The media was gently
aspirated, the wells were washed with PBS and immersed in 4% paraformaldehyde for 15
minutes. Cells were washed 2x with PBS and incubated 15 minutes on ice in 0.2% Triton
X-100 diluted in PBS. Cells were washed with cold PBS and blocked in 1% BSA diluted
in PBS for 30 minutes. Coverslips were transferred to racks and 200 µM JAS239 was
added evenly along the surface of three coverslips. After 30 minutes, these slides were
washed 2x with PBS, 30 µL of rabbit anti-human ChoKα antibody (ab38290; Abcam) at
1:1000 dilution was added to the top of the slide, and the slides were incubated at room
temperature for 1 hour. A separate batch of three coverslips were first incubated in antiChoKα antibody, rinsed 2x with PBS, then treated with 200 µM JAS239. A control group
receiving anti-ChoKα antibody only were included to ensure that Texas Red fluorescence
emission did not overlap with the JAS239 filter setting. Coverslips from each group were
transferred to wells in a fresh 24-well plate, washed 2x with PBS, and incubated for 40
45"
"

minutes in 200 µL of dilute (1:500) goat anti-rabbit secondary antibody conjugated to
Texas Red (Vector Laboratories; TI-1000). Each well was washed 3x with PBS then
dehydrated using 50%, 70%, and 100% ethanol in successive 10-minute increments. Each
coverslip was air-dried in the dark, mounted with VectaShield (Vector Laboratories) on
slides, and kept at 4°C overnight. Alex Glavis-Bloom of the Yang Lab in the Department
of Cancer Biology assisted with the development of this protocol. Confocal micrographs
were acquired on a Zeiss LSM 510META NLC using Ex. 543 nm and Em. 565-615 nm
for Texas Red and Ex. 633 nm and Em. >650 nm for JAS239. Images were acquired with
help from Andrea Stout and Jasmin Zhao of the Cell and Developmental Microscopy
Core. Background was subtracted from the images in each channel using the Fiji version
of ImageJ. The Coloc 2 plug-in was used to assess colocalization (Dunn et al., 2011) of
the anti-ChoK-α antibody and JAS239 by calculating Pearson’s Correlation Coefficients
and Manders’ Colocalization Coefficients for at least three separate ROIs.

2.11 Animal model and tumor cell implantation
Murine breast xenografts. All animal studies were approved by the Institutional
Animal Care and Use Committee of the University of Pennsylvania. Six week old
syngeneic female athymic nude Foxn1nu/nu mice were acquired from the National Cancer
Institute and housed in a temperature-controlled environment with 12 hour light/dark
cycle. General anesthesia was induced using 2% isoflurane in oxygen for inoculations,
injections, and imaging experiments. All cell lines were trypsinized, counted, washed 2x
with cold PBS, and resuspended in ice-cold Matrigel (BD Biosciences, Bethesda, MD).
For MCF7 inoculations, athymic nude mice were supplemented with 60-day release 0.36
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mg 17β-estradiol tablets (Innovative Research of America, Sarasota, FL) using a trochar
in the nape of the neck. After 1 week of recovery time, 4x106 MCF7-CK+ cells were
inoculated into the left mammary fat pad (which appears on the right when the animal is
in the ventral position) and 4x106 MCF7-EV cells on the contralateral fat pad. MDA-MB231 and 4175-Luc+ tumors were inoculated orthotopically unless specifically noted.
These tumors were grown on the shoulder as subcutaneous xenografts, to allow for the
kidneys to be cloaked during parallel optical imaging studies. Tumor growth was
determined via caliper measurement of the longest (length) and two orthogonal
dimensions (width and height) and tumor volume calculated as length * width * height *
π/6.
Rat glioma model. Manoj Kumar and Ranjit Ittyerah of the Poptani lab were
responsible for rat tumor inoculation, treatment, and tumor resection. These methods are
described in detail elsewhere (Kumar et al., 2015). Six week old syngeneic female Fisher
F344/NCr (120-150 gm weight) rats (n = 13) were purchased from the National Cancer
Institute and housed in a temperature controlled animal facility with a 12 h light-dark
cycle. General anesthesia was induced by intraperitoneal injection of ketamine/xylazine
(80/8.0 mg/kg). The animal was placed on a stereotactic frame. A small burr hole was
made 3-mm lateral and 3-mm posterior to the bregma and 2-mm deep into the right
cerebral hemisphere using a drill bit. F98 tumor cells (5x104) in a 10-µl suspension in
PBS were inoculated over a 5-min period with a Hamilton syringe and a 30-gauge needle
using a stereotactic apparatus. After injection of the cell suspension, the needle was
withdrawn slowly and the wound was closed by suturing the skin. Animals were
monitored periodically for 2 weeks during recovery.
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2.12 In vivo optical imaging
JAS239 biodistribution in 4175-Luc+ bearing mice. One week prior to imaging,
athymic nude mice bearing orthotopic 4175-Luc+ tumors were placed on a lowfluorescence alfalfa-free diet (5V02; LabDiet, St Louis, MO). Mice were anesthetized
with 2% isoflurane and a pre-scan bioluminescence and NIRF (Ex. 745 nm; Em. 800 nm)
image was acquired in an IVIS Spectrum with settings set to Automatic mode (Perkin
Elmer, Hopkinton, MA) to be used as a reference for eliminating auto-fluorescence in
later acquisitions. NIRF is measured in Average Radiant Efficiency, which is a measure
of photons per second (p/sec) corrected for the area (cm2) of the region of interest (ROI)
and the efficiency of the lamp at the sample distance and filter settings used (µWatts
*cm−2 / steradian-1). Bioluminescence is measured in Radiance, which has the units of
p/sec/cm2/sr. Each mouse was injected i.p. with 150 mg/kg of firefly D-luciferin sodium
salt monohydrate (Biosynth, Switzerland) in saline and a time-course imaging sequence
was used to establish that maximal luminescence was reached 15 minutes post-injection.
No luminescence was detected in the NIR range. After 24 hours, a pre-scan
bioluminescence and NIRF image was again acquired to ensure that no residual
luminescence was remaining. Mice were injected via tail vein with either control vehicle
or 20 nmol JAS239 in 100 µL of 0.1% Tween-80 in 50 mM Tris-HCl buffer. Mice were
imaged for NIRF over a time-course of 20 minute increments. After initial hepatic
clearance diminished (approximately 75 minutes), mice were again injected i.p. with Dluciferin and imaged for bioluminescence and NIRF 15 minutes later. ROIs with a 20%
threshold were automatically drawn around the tumor using the bioluminescence image
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in the LivingImage software (PerkinElmer) program, and this region was used to analyze
intratumoral JAS239 accumulation in the NIRF images. Technical assistance was
provided by Julie Czupryna of the Small Animal Imaging Facility.
A different formulation of JAS239 was tested in a separate cohort of mice bearing
orthotopic 4175-Luc+ tumors. Approximately 4 weeks after tumor inoculation, each
animal was injected i.v. with 20 nmol JAS239 dissolved in ethanol and diluted 1:100 in
0.9% saline. The tumor contrast with this 1% ethanol/saline formulation was compared to
the contrast in response to 20 nmol indocyanine green (ICG) injected one week after the
JAS239 was no longer detectable. A new cohort of mice was then inoculated on the back
right shoulder with 4175-Luc+ subcutaneous xenografts. The location of these tumors
allowed us to cloak the lower extremities of the mice and minimize background signal
related to excretion. These mice were each injected with 20 nmol JAS239 in the
ethanol/saline formulation after 4 weeks of tumor growth. Whole-body NIRF imaging of
each mouse was used to determine the time of maximum intratumoral accumulation.
Delivery of JAS239 in hydrocyanine form (hydro-JAS239) was first performed by i.v.
injection in a new cohort of five athymic nude mice with subcutaneous 4175-Luc+
xenografts. Time-course images were acquired using the excitation and emission
parameters for JAS239. After fluorescence in these animals diminished to undetectable
levels, 20 nmol of either JAS239 or hydro-JAS239 was administered by gavage and
NIRF images in the IVIS Spectrum were acquired over a span of 24 hours.
JAS239 in the ethanol/saline formulation was injected into three mice at time points
1, 4, and 24 hours prior to euthanasia by CO2 asphyxiation. Tumor resection from these
mice was then recorded in the integrated imaging device built in the laboratory of Sunil
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Singhal of the Department of Surgery at the University of Pennsylvania. This device
features a screen displaying the overlay brightfield image from a standard webcam with
the NIRF signal detected by a charged coupled device (CCD) camera. Time-stamped
images were recorded as separate files and overlay of the bright light (grey-scale) and
NIRF (green) channels was performed in ImageJ with assistance from Ryan Judy of the
Singhal lab.
As a preliminary experiment, a single athymic nude mouse bearing a 9L glioma
xenograft on the right shoulder was injected with 20 nmol JAS239 in 1% ethanol and
imaged for NIRF (Ex. 710 nm; Em. 800 nm) in a LiCor Pearl by Sona Saksena in the
Delikatny Lab.

2.13 Ex vivo optical imaging
Biodistribution. Once the maximal intratumoral levels of JAS239 were determined
by whole-body NIRF imaging for each vehicle formulation, animals were re-injected
with the same formulation approximately 1 week later (allowing the first dose to clear
entirely). Animals were euthanized 90 minutes after injection with JAS239 in Tween80/Tris buffer or 24 hours after injection with JAS239 in ethanol/saline, as these were the
times of maximal tumor/background fluorescence determined by whole-body NIRF
imaging for each formulation. Tumors as well as relevant organs were resected, placed in
a 24-well plate, and imaged for NIRF in an IVIS Spectrum. ROIs were drawn around
each well and quantified using the LivingImage software. Tumor-to-muscle NIRF ratios
were reported relative to a section of excised quadriceps muscle.
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Diagnostic studies. Twenty mice bearing both MCF7-EV and MCF7-CK+ tumors
were monitored until tumors reached approximately 200 µL. Ten days prior to optical
imaging, mice were switched to low-fluorescence chow. Two mice became moribund
before imaging and three additional mice were excluded from these studies because their
tumor inoculations missed the mammary fat pad. The remaining cohort was separated
with eight mice receiving 20 nmol JAS239 in Tween-80/Tris buffer and seven receiving
20 nmol JAS239 in ethanol/saline. The cohort receiving JAS239 in Tween-80/Tris buffer
was euthanized after 90 minutes, and the tumor-bearing flanks were surgically exposed.
Using an IVIS Spectrum, NIRF from the tumor-bearing fat pads was subtracted from
background muscle signal and the Average Radiant Efficiency reported. The same
procedure in the remaining cohort was performed 24 hours following injection of JAS239
in ethanol/saline.

2.14 In vivo MRI
Animal preparation for MRI scan. Mice were prepared individually for MRI exams
by induction of general anesthesia with 3% isoflurane in oxygen delivered in an induction
chamber. The anesthetized animal was secured to a custom-built restraining device to
minimize motion-induced artifacts. The head was positioned within a nose cone
delivering 2% isoflurane in oxygen. Each limb was secured to a custom in-house
restraining device to minimize motion artifacts. A respiration pillow was placed on the
dorsal side of the body to monitor respiration rate, while a thermister was inserted into
the rectum to measure body temperature. Both sensors were connected to a small animal
monitoring device (SA Instruments Inc, NY, USA) that reported vital signs during
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scanning. A slotted-tube resonator (inner diameter = 11 mm, depth = 9 mm) built inhouse and tuned to 400 MHz was used for 1H spectroscopy and imaging (Poptani et al.,
2003). The tumor of each animal was placed in the coil and the probe was then centered
in the magnet. Body temperature was regulated at 37 ± 1°C by blowing warm air into the
magnet bore through a hose connected to a thermostatically controlled device (SA
Instruments, NY, USA). Animal preparation and MRI/MRS acquisitions were performed
by Manoj Kumar of the Poptani Lab, with my assistance and processing of the data.
In vivo single voxel spectroscopy. Athymic nude mice bearing subcutaneous tumors
(approximately 300 µL in volume) underwent pre-treatment MRS scans in a 9.4 T
horizontal bore magnet equipped with 40 G/cm gradients interfaced to an Agilent DirectDrive console (Agilent, Palo Alto, CA, USA) operating vnmrj 2.3.C software. Multi-slice
gradient and spin echo images were used for tumor localization. T2-weighted spin echo
anatomical images acquired using a spin echo multi-slice (SEMS) pulse sequence
(TR=1000 ms, TE=10.0 ms, number of slices=20, field of view=20x20 mm2, slice
thickness=1 mm, NT=1, matrix size=256x128) were used for voxel selection. A spectrum
was acquired in a 3x3x3 mm3 voxel using a PRESS sequence (TR=3000 ms, TE1=12.68
ms and TE2=10.01 ms, number of averages=128, complex points=4096, and spectral
width=4000 Hz with an acquisition time of 6 min 24 sec). Water suppression was
achieved using variable power and optimized relaxation delays (VAPOR) (Tkac et al.,
1999). An unsuppressed water spectrum was subsequently acquired with 8 averages to be
used as a chemical shift and concentration reference. One week following initiation of
treatment, a post-therapy in vivo single voxel 1H MR spectrum was acquired for each
animal. Pre and post-treatment spectra were processed and analyzed using Mnova Lite
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5.2.5 software (Mestrelab Research, Santiago de Compostela, Spain). The water
suppressed and unsuppressed free induction decays were processed by apodization of 10
Hz followed by Fourier transformation. The spectra were phased and chemical shift and
baseline correction were performed prior to integration of the water (4.7 ppm), tCho (3.2
ppm), PUFA (2.8 ppm), and lipid (1.3 ppm) resonances. The metabolite/water ratio was
determined for both pre- and post-treatment spectra. The percent change in metabolite
concentration was then estimated by the formula: [post-treatment concentration – pretreatment concentration] *100% / pre-treatment concentration.

2.15 Animal treatments
Companion diagnostic evaluation in breast model. MRS was used to establish
baseline tCho levels in a cohort of ten athymic nude mice bearing 4175-Luc+ tumors.
Mice were injected i.p. for 5 consecutive days with either 100 µL saline or MN58b.
Previous studies have reported that a 5 day treatment regimen of 4 mg/kg of MN58b was
sufficient to lower tCho levels in mice (Al-Saffar et al., 2006). However, in our
experience this dose was found to be toxic, thus the MN58b dose was reduced to 2
mg/kg. A follow-up scan was then acquired 1 week after the pre-treatment scan. After
post-treatment scanning, each animal was then injected i.v. with a trace dose (20 nmol) of
JAS239 in ethanol/saline vehicle. After 24 hours, the mice were euthanized and each
tumor was analyzed for NIRF as described above.
Breast tumor growth inhibition. A cohort of fifteen athymic nude mice were
inoculated with 4175-Luc+ tumors and split evenly into three treatment groups. A 2%
DMSO in 0.9% saline vehicle was used to solubilize JAS239 at concentrations required
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for therapeutic injection. Beginning 3 days post-inoculation, animals received a 100-µL
i.p. injection of either control DMSO/saline vehicle, 2 mg/kg MN58b in DMSO/saline
vehicle, or 4 mg/kg JAS239 in DMSO/saline vehicle daily for 5 consecutive days. Tumor
volumes were assessed by caliper measurement for 30 days.
Pharmacodynamic indicators of ChoKα inhibition in breast cancer. A second
cohort of fifteen athymic nude mice was inoculated with MDA-MB-231 cells, which had
previously been used in the literature for MRS assessment of our positive control ChoKα
inhibitor, MN58b (Al-Saffar et al., 2006). When a volume of approximately 300 µL was
reached, tumors were scanned for baseline metabolite levels. Tumor volume estimates
were made based upon the T2-weighted images. The animals were separated randomly
into treatment groups, and for 5 consecutive days each group was injected i.p. with 100
µL of control DMSO/saline vehicle (n = 5), 2 mg/kg MN58b in DMSO/saline vehicle (n
= 4), or 4 mg/kg JAS239 in DMSO/saline vehicle (n = 3). Differences in cohort size are
due to variability in tumor growth rate and the inability to place voxels within posttreatment tumors that were too small, resulting in the animal being removed from further
study. Follow-up MRI/MRS scanning was used to assess tumor growth inhibition and
changes in metabolite levels between treatment groups. Blood was collected from each
animal by cardiac puncture and stored in heparin-coated tubes. Each resected tumor was
embedded in Optimum Cryo-Temperature (Sakura Finetek, Torrance, CA), flash-frozen
in liquid nitrogen, and stored at -80°C for histological assessment. Blood samples were
submitted to the Diagnostic labs of the Ryan Veterinary Clinic for liver profiling and
toxicological assessment.
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ChoK inhibition in glioma tumors. The Poptani group treated ten tumor-bearing
animals with MN58b at 2 mg/kg/day i.p. for 5 days (Kumar et al., 2015). This dose was
calculated using the FDA guidelines for cross-species equivalence, which suggests a 2
mg/kg rat dose is roughly equivalent to a 4 mg/kg mouse dose. A separate cohort of
tumor bearing animals (n = 3) were treated with an i.p. injection of 1 mL saline daily for
5 days. Two animals died during the MN58b treatment resulting in post-MN58b data
from only 8 animals. The death of these animals was most likely due to the tumor burden,
as no overt indications of toxicity were noted as a result of MN58b toxicity: loss of
weight, change in grooming or social habits, fur ruffling, or change in eye color.
The tumor bearing animals were anesthetized with an overdose of ketamine/xylazine.
Following lack of deep tendon responses, the head was decapitated and the brain was
removed from the skull. Tumor tissue and contralateral normal brain tissue were
harvested from each animal under aseptic conditions in a laminar flow hood. PCA
extractions and high-resolution 1H NMR studies were performed on tissue samples from
contralateral normal brain, saline, and MN58b-treated tumor tissue on a 500 MHz vertical
bore NMR scanner (Bruker, Billerica, MA) using the same experimental protocol as
described for cell extracts.

2.16 Histopathology
Tumors were kept frozen (-80°C) in Optimum Cryo-Temperature blocks for 1 week.
For hematoxylin and eosin (H&E) staining, slides were first post-fixed in methanol at 20°C before staining using a Shandon Gemini automated stainer (ThermoFisher). Briefly
slides were rehydrated by immersion in a series of descending ethanol dilutions (100%55"
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70%) then rinsed in water. Slides were stained in hematoxylin (Azer Scientific) for 1 min
followed by a water rinse and dip in acid alcohol (0.1% HCl, 50% EtOH). Slides were
then rinsed in tap water for 15 minutes followed by 1 minute in eosin (Azer Scientific).
Slides were dehydrated in a series of ascending ethanol dilutions (70%-100%) followed
by xylene before cover-slipping with Cytoseal (Fisher Scientific).
For immunohistochemistry of tissue slices, slides prepared from each fresh frozen
tumor were placed directly in pre-cooled (-20°C) methanol and dried for 10 minutes at
room temperature and 5 minutes at 55°C. Slides were then placed in 10% neutral
buffered saline for 20 minutes, rinsed in ddH2O, and rinsed for 5 minutes at room
temperature in 0.1 M Tris Buffer. Caspase-3 (R&D Systems AF835) and Ki67 (Abcam
ab16667) antibody staining was performed on a Bond Max automated staining system
(Leica Microsystems) using the Bond Intense R staining kit (Leica Microsystems
DS9263). The standard kit protocol was followed with the exception that the primary
antibody incubation period was extended to 1 hour at room temperature. Avidin-Biotin
Blocking was added to reduce non-specific binding (Vector Labs SP-2001), and a Peptide
Blocking step was added (DAKO X0909). The Caspase-3 antibody was used at a dilution
of 1:1000 and Ki67 was used at 1:100. Antigen retrieval was performed using E2 (Leica
Microsystems) retrieval solution for 20 minutes. Biotinylated Anti-Rabbit Secondary
(Vector BA-1000) was used at a 1:200 dilution. After staining, slides were rinsed,
dehydrated in a series of ascending concentrations of ethanol and xylene, then coverslipped. Cryo-sectioning and slide-staining was performed by Socrates Agrio-O'Reilly
and Carly David of the CHOP Pathology Core Laboratories.
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Each slide was scanned at 20X magnification using the Aperio Scan Scope OS
(Aperio Technology, Vista, CA). The Image Scope viewing software and nuclear staining
algorithm V.9 (version 9; Aperio Technologies, Inc.) were used to quantify Ki67 and
Caspase-3 positive nuclei in representative regions of each slice. Intensity thresholds and
cell segmentation parameters were optimized by Daniel Martinez of the CHOP Pathology
Core Facility to ensure unbiased manual scoring. The percentage of nuclei with strongpositive staining were reported for each region of interest and averaged among treatment
cohorts.

2.17 Statistical analysis
Data are reported as the mean + standard deviation (SD) of three separate
experiments (n = 3), unless noted otherwise. Probability (P) values were calculated in
Microsoft Excel 2010 (Version 14.0.7128.5000 32-bit) using a 2-tailed Student’s t-test,
except in specified cases. P-values < 0.05 were considered statistically significant.
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CHAPTER 3
Chemical Synthesis
3.1 Introduction
There are a number of limitations to the current approach to identify and validate
ChoKα inhibitors in vivo. Small molecules offer a pharmacokinetic advantage over
macromolecules, but the choline-mimetic 11C and 18F-labeled tracers cannot distinguish
choline transporter inhibition from choline phosphorylation inhibition (Zheng et al.,
2007). This is a limitation because choline transport inhibition can often lead to severe
toxicities (Boobis et al., 1975). Non-invasive MRS evaluation can measure choline
metabolite pools in the steady state, but cannot distinguish ChoKα activity from the
diverse anabolic and catabolic pathways that use choline as a building block. Several bispyridinium and bis-quinolinium small molecules that have been demonstrated to bind to
and inhibit ChoKα in a specific manner (Campos et al., 2006). These ChoKα inhibitors
share many structural features (symmetric terminal heterocyclic groups containing
quaternary ammonium groups connected by a lipophilic linker moiety) with a class of
fluorescent small molecules known as the carbocyanines. In this work, a number of
choline mimetic molecules were prepared, and their optical properties were characterized
to identify possible inhibitors with fluorescence in the NIR range (Fig. 3.1). Three
synthetic approaches were employed: 1) addition of a NIR fluorophore to choline, 2)
modification of the known ChoKα inhibitor called MN58b, and 3) incorporation of
choline-like moieties to a carbocyanine structure.
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PyroCho

JAS239.5

MN58b

JAS259

JAS275

WM-11

2

JAS239

hydro-JAS239

JAS273

JAS274

Figure 3.1. Class of compounds synthesized as potential ChoKα inhibitors. Each of the
above compounds were synthesized in the Delikatny Lab under guidance of Dr. Anatoliy Popov.
These structures represent derivatives of choline, bis-pyridiniums, and carbocyanines.
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3.2 Pyro-Choline
A pyropheophorbide conjugated to a methyl group of choline via a
polyethyleneglycol (PEG) spacer was generously provided by Dr. Anatoliy Popov of the
Department of Radiology at the University of Pennsylvania. This product, named
PyroCho, exists as a dark green solid. Susceptible to photodegradation, PyroCho was
stored at -20oC and reconstituted in stock solutions by measuring the absorbance in a
cuvette and calculating concentration using the Beer-Lambert law and the extinction
coefficient value (at 665 nm) of 50,000 L mol-1 cm-1. There are two absorbance peaks
occurring at 418 nm and 665 nm. Excitation at either absorbance peak results in
fluorescence with maximal emission at 670 nm. Excitation at 660 nm also produces a
second fluorescence at 725 nm that can be used for NIRF optical imaging. Above 10 µM,
the fluorescence is no longer linearly-proportional to concentration due to stacking and
self-quenching of the pheophorbide rings. The calculated partition coefficient (cLogP) of
PyroCho is 6.24 (Table 1).

3.3 MN58b
1,4-Bis(4-bromomethylphenyl)butane. 1,4-Diphenylbutane (2 g, 9.51 mmol) was
added to a mixture of 48% aqueous HBr (4.15 mL, 39.9 mmol) and glacial AcOH (50
mL), followed by 1,3,5-trioxane (0.57 g, 6.34 mmol) and hexadecyltrimethylammonium
bromide (52 mg, 0.143 mmol). The mixture was stirred such that only a single layer
could be seen then heated to a gentle reflux for 8 hours. The volatiles were removed
under reduced pressure. The product was isolated by column chromatography (silica gel,
hexane/benzene 1/1, v/v). The isolated 1,4-bis(4-bromomethylphenyl)-butane (1.959 g,
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yield 52%) was a white solid, mp 119 to 121oC (from acetone). 1H NMR (500 MHz,
CDCl3, δ ppm) 7.04 ppm (AB, A = 7.18, B = 6.89, JAB = 9 Hz, 8H), 4.53 (s, 4H), 2.66 (m,
4H), 1.62 (m, 4H).
1,10 -((Butane-1,4-diylbis(4,1-phenylene))bis(methylene))bis(4(dimethylamino)pyridin-1-ium) bromide (MN58b). The mixture of 4dimethylaminopyridine (238.0 mg, 1.948 mmol) and 1,4-bis(4bromomethylphenyl)butane (385.9 mg, 0.974 mmol) in dry ethanol (30 mL) was heated
and stirred at 160oC in a 45 mL Parr autoclave equipped with a magnetic stirring bar for 3
hours. The white solid product was precipitated twice from ethanol into diethyl ether,
dissolved in deionized water and lyophilized. Yield: 96%, melting point (mp) 103 to
106oC (from water). 1H NMR (360 MHz, CD3OD, δ ppm): 8.21 (dt, J = 7.6 Hz, J = 2.9
Hz, 4H, H-2pyr), 7.29 (dm, J = 7.9 Hz, 4H, Ph), 7.23 (dm, J = 7.9 Hz, 4H, Ph), 7.00 (dm,
J = 7.6 Hz, 4H, H-3pyr), 5.33 (s, 4H, CH2N+), 3.25 (s, 12H, N(CH3)2), 2.64 (m, 4H,
CH2-C6H4), and 1.62 (m, 4H, C–CH2–C).

3.4 WM-11
To explore the effect of introducing a conjugated double bond network between the
quaternary ammonium groups of MN58b, we replaced the 1,4-diphenylbutane linker with
1,4-diphenylbutadiene and proceeded with the same bromination step used in MN58b
synthesis. After 1 hour of heating at 105oC, however, the mixture turned into a black tar.
Several strategies were employed to isolate crystals from the mixture by Dr. Anatoliy
Popov and a student, William Marrero-Ortiz , but these were unsuccessful and it was
determined that the desired product was not present in the mixture. A more stable
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resonant linker using 4-(4-(4-(hydroxymethyl)phenyl)phenyl)phenyl)methanol in place of
1,4-diphenylbutadiene has recently been proposed by Dr. Popov. The 1,4-bis(4(bromomethyl)phenyl)benzene intermediate has been successfully purified, and will soon
be dissolved in ethanol and condensed with 4-dimethylaminopyridine in an autoclave
reaction to produce the MN58b derivative WM-11.
A

B

C

!
Figure 3.2. Colorimetric monitoring during JAS239 synthesis. (A) Cyanine dyes were purified
by silica gel column chromatography and (B) fractions were separated by color. (C) A sample
from each fraction was placed in a cuvette and analyzed for absorbance and fluorescence in a
spectrophotometer.
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3.5 JAS239
1-(2-Hydroxyethyl)-2,3,3-trimethyl-3H-indol-1-ium chloride. A mixture of 2,3,3trimethyl-3H-indole (1,592.3 mg, 10 mmol) and 2-chloroethan-1-ol (1,610.2 mg, 20
mmol) in dry ethanol (15 mL) was heated and stirred at 160oC in a 45 mL Parr autoclave
equipped with a magnetic stirring bar for 4 hours. The purple solid product was
precipitated twice from ethanol with diethyl ether. Yield 86%. 1H NMR (360 MHz,
CD3OD, δ ppm): 7.88 ppm (m, 1H), 7.77 (m, 1H), 7.65 (m, 2H), 4.68 (m, 2H), 4.06 (m,
2H), 1.63 (s, 6H), labile OH and N = C–CH3 protons are in exchange with CD3OD.
MALDI-TOF, m/z: (M-Cl)+ 204.35, calculated for C13H18NO 204.14.
1-(2-Hydroxyethyl)-2-((1E,3E,5E)-7-((Z/E)-1-(2-hydroxyethyl)-3,3dimethylindolin-2-ylidene)hepta-1,3,5-trien1-yl)-3,3-dimethyl-3H-indol-1-ium chloride
(JAS239). A solution of acetic anhydride (112.3 mg, 1.1 mmol) in CH2Cl2 (2 mL) was
added to a cooled (-20oC), stirred suspension of N-((1E,3E,5Z)-5-(phenylimino)penta1,3-dien-1-yl) benzenaminium chloride (142.4 mg, 0.5 mmol) and triethylamine (222.6
mg, 2.2 mmol) in CH2Cl2 (10 mL). The resulting clear solution was stirred for another 3
hours at room temperature (RT) and concentrated under high vacuum. The residue
containing N-phenyl-N-((1E,3E,5Z)-5-(phenylimino)penta-1,3-dien-1-yl)acetamide was
dissolved in ethanol (5.0 mL) and added drop-wise to a refluxing solution of 1-(2hydroxyethyl)-2,3,3-trimethyl-3H-indol-1-ium chloride (360.0 mg, 1.5 mmol) and
anhydrous sodium acetate (200 mg, 2.5 mmol) in ethanol (100 mL). The mixture was
refluxed for 5 hours and concentrated. The product JAS239 was isolated by column
chromatography [silica gel, ethyl acetate–methanol (0–100%)] (Fig. 3.2A). Fractions
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isolated from the column (Fig. 3.2B) were concentrated under high pressure and the
fraction containing pure product (JAS239) was identified by spectrophotometric analysis
(Fig. 3.2C). Yield 19.9%. 1H NMR (360 MHz, CD3OD, δ ppm): 7.93 [t (dd), J = 13.1 Hz,
2H]; 7.58 [t (dd), J = 12.8 Hz, 1H]; 7.46 (d, J = 7.2 Hz, 2H); 7.38 (td, J = 7.4 Hz, J = 1.1
Hz, 2H); 7.29 (d, J = 7.9 Hz, 2H); 7.23 (td, J = 7.2 Hz, J = 0.7 Hz, 2H); 6.53[t(dd), J =
12.6 Hz, 2H]; 6.35 (d, J = 13.7 Hz, 2H); 4.21 (t, J = 5.8 Hz, 4H); 4.92 (t, J = 5.8 Hz, 4H);
1.70 (s, 12H). MALDI-TOF, m/z: (M–Cl)+ 469.56, calculated for C31H37N2O2 469.28.
HPLC: one peak, retention time = 15.22 minutes."

3.6 hydro-JAS239
The hydrocyanine form of JAS239 was prepared using a procedure outlined by
Kundu et. al. Briefly, 1.32 mg JAS239 was dissolved in methanol and a NaBH4 solution
(3 mg dissolved in 0.5 mL methanol) was added drop-wise while stirring. The solution
turned from dark green to yellow in an incremental fashion. After approximately 0.25 mL
NaBH4 was added, the solution became colorless. The methanol was evaporated and 10
mL of dichloromethane and 20 mL distilled water was added to the flask. The mixture
was transferred to a separatory funnel and shaken vigorously. Pressure within the reaction
vessel was relieved carefully. The bottom (organic) layer was added to a fresh flask and
product was extracted from the aqueous phase with two additional dichloromethane
separations. The organic phase was dried over anhydrous sodium sulfate and the
dichloromethane was removed under reduced pressure. The resulting product, hydroJAS239, was used without further purification.
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3.7 JAS239.5
Addition of a benzo-moiety to the indolium group is common for in vivo fluorophore
design because this induces a bathochromic shift of approximately 30 nm, which can help
reduce background autofluorescence. This modification also has the potential to increase
the lipophilicity of the compound, which may make it more cell permeable. We prepared
a JAS239 derivative using 1,1,2-trimethyl-1H-benz[e]indole as a starting indolium for the
head groups. The same synthetic procedure for JAS239 was followed for the synthesis of
JAS239.5. Yield 17.3%. 1H NMR (360 MHz, CD3OD, δ ppm): 8.23 (d, J = 8.3 Hz, 2H); 8.04 (t,
J = 13.3 Hz, 1H); 7.98 (d, J = 8.6 Hz, 4H); 7.68-7.56 (m, 6H); 7.47 (td, J = 7.4 Hz, J = 1.1 Hz,
2H); 6.57 (t, J = 12.6 Hz, 2H); 6.38 (d, J = 14.0 Hz, 2H); 4.33 (t, J = 5.8 Hz, 4H); 3.99 (t, J = 5.4
Hz, 4H), 1.90 (s, 12H).

3.8 JAS259
To improve the water solubility of JAS239, replacement of the dimethyl-substituted
carbon at the C3 position of the starting indolium salt with sulfur was proposed. The
same procedure described for JAS239 was followed using 2-methylbenzothiazole in
place of the trimethyl-indolium group. Following successful alkylation with 2chloroethanol, the benzothiazole head group was dissolved in ethanol and heated under
reflux conditions in the presence of sodium acetate and the precursor linker group (Nphenyl-N-((1E,3E,5Z)-5-(phenylimino)penta-1,3-dien-1-yl)acetamide) using the same
procedure described for JAS239 synthesis. The sulfur group was found to be thermolabile
at high temperatures and the desired product was not detected by spectrophotometric
analysis. A previous report in the literature (Okoh et al., 2014) described a similar
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benzathiazole-based cyanine synthesis and found that the condensation reaction of the
head group and acetylated linker could be achieved at room temperature without
degradation. After this adjustment was made to the second synthetic step, 2-(2((1E,3E,5E)-7-(3-(2-hydroxyethyl)-1,3-benzothiazol-2-ylidene)hepta-1,3,5-trienyl)-1,3benzothiazol-3-ium-3-yl)ethanol chloride (JAS259) could be purified by column
chromatography. Yield 15.7%. 1H NMR (360 MHz, CD3OD, δ ppm): 8.33-8.23 (m, 6H), 8.02
(t, J = 13.1 Hz, 1H); 7.94-7.80 (m, 4H); 6.57 (t, J = 12.6 Hz, 2H); 6.37 (d, J = 13.7 Hz, 2H); 4.93
(t, J = 5.4 Hz, 4H); 4.07 (t, J = 5.4 Hz, 4H).

With the knowledge gained from synthesis of JAS259, a derivative using oxygen in
the place of sulfur was designed (JAS275). In place of the indole starting group in
JAS239, a 2-methylnaphth(2,1-d)oxazole was used. Alkylation with 2-chloroethanol was
carried out following a similar scheme to that reported for JAS239 synthesis. Similar to
the JAS259 precursor, the reduced steric hindrance in this sulfur derivative (relative to
the dimethyl-substituted carbon group in JAS239) allowed for the alkylation reaction to
be run at room temperature, rather than in an autoclave. The oxygen within this
heterocyclic system proved to be too reactive under these conditions, and the reaction
failed to produce the desired hydroxyethylated ring structure.

3.9 JAS273 and JAS274
To explore the importance of the hydroxylated alkyl chain, two JAS239 derivatives
were prepared with either hydroxypropyl (JAS273) or hydroxybutyl (JAS274) alkyl
substitutions. For JAS273, preparation of the 1-(3-hydroxypropyl)-2,3,3-trimethyl-3Hindolium iodide precursor was performed in accordance with methods described
previously (Darwish et al., 2010). Alkylation of 2,3,3-trimethylindolenine with 3-iodo-166"
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propanol in toluene was heated at reflux (130°C) for 2 hours. The color was observed to
change from yellow to dark rose. The intermediate product was precipitated by addition
of excess hexane. The acetylated linker group prepared for JAS239 synthesis was used
for linkage of the hydroxypropyl-trimethyl-indolium head groups. The acetylated linker
group, two times excess of the indolium group, and excess sodium acetate were heated in
ethanol under reflux conditions (100oC) overnight while protected from light. A similar
synthetic procedure was followed for preparation of JAS274 with 4-iodo-1-butanol as a
precursor.

3.10 PepTech compounds
After the initial synthetic strategies for MN58b and JAS239 derivatives were
designed with guidance from Dr. Popov and shown feasible, we turned to the PepTech
Corporation (Bedford, MA) to synthesize a small library of analogs. These compounds,
outlined in Figure 3.3, represent two major strategies. A variety of linker groups were
used to make resonant MN58b analogs. In these compounds, cis (Z) and trans (E)
conformations were explored. Movement of the quaternary ammonium groups from the
outer ring moieties to the inner rings gave a stronger likelihood of fluorescence, as these
compounds have a linker group whose structure was derived from the fluorophore
viologen. As an additional positive control to be used in conjunction with MN58b, TCD717 was synthesized. The second modification strategy involved cyclization within the
linker group of JAS239. Similar “cyclo” derivatives have been described in the literature
with improved fluorescence quantum yield compared to the non-cyclized counterpart
(Yang et al., 2010). To test the importance of the choline mimetic alkyl groups, the
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hydroxyethyl moieties were replaced with methyl groups and represent the cyclized
version of 1,1’,3,3,3’,3’-hexamethylindotricarbocyanine iodide (HITC).

TCD-717

(E,E)-conj MN58b

(E,E,E)-conj MN58b

cycloJAS239

(Z,Z)-conj MN58b
cycloJAS239.5

(Z,E)-conj MN58b
cycloHITC
(E,E)-viologenMN58b

cycloHITC.5
(E,E,E)-viologenMN58b

Figure 3.3. Second generation JAS239 analogs contracted to PepTech Corporation. The
structures above were designed as next generation fluorescent ChoKα inhibitors. TCD-717 was
also synthesized as an additional positive control. Due to unstable intermediate groups, the
synthesis of Z-conformation (Z,Z and Z,E) and viologen MN58b derivatives was not feasible.
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3.11 Results
The structural similarities between the bis-pyridinium/quinolinium ChoK inhibitors
and the carbocyanine dyes led us to hypothesize that similar pharmacologic activity could
exist between the 2 classes of compounds. To test our hypothesis, we designed a
carbocyanine dye substituted with choline-like N+-CH2-CH2-OH moieties at the nitrogen
atom of the indolium ring. The synthesis of the carbocyanine precursor, 1-(2hydroxyethyl)-2,3,3-trimethyl-3H-indol-1-ium chloride, was performed in ethanol within
an autoclave at high temperature to shorten the reaction time considerably from previous
reports in the literature (Ye et al., 2003). Stable 2-chloroethan-1-ol was used as the
alkylating agent, rather than the unstable and more expensive bromo or iodo derivatives,
to increase the yield and stability of the intermediates. In the final step, we modified a
previously reported procedure for the synthesis of C7-carbocyanine (Ye et al., 2003) to
run at a higher temperature by replacing methanol with ethanol as the solvent. This
allowed a reduction in the condensation time from 16 to 5 hours. The reaction can be
supervised by colorimetric monitoring as depicted in Figure 3.4A. The final compound,
JAS239, demonstrated NIR fluorescence, with an excitation maximum at 740 nm and
emission at 770 nm (Fig. 3.5). As a measurement of water solubility, the cLogP was
calculated in ChemBioDraw Ultra (Version 13.0.0.3015) to be 3.37 (Table 1).
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Figure 3.4. Synthetic pathway for the preparation of prototype ChoKα inhibitors. (A)
o
o
JAS239 synthesis: (a) 2-chloroethan-1-ol, autoclave 160 C, 4 hr; (b) Ac2O, Et3N, DCM, -20 C-RT,
3 hr; (c) AcONa, EtOH, reflux, 5 hr. (B) MN58b synthesis: (d) HBr, cetyltrimethylammonium
bromide [C16H33N(CH3)3Br], acetic acid, reflux, 8 hr; (e) N,N-dimethylpyridin-4-amine, EtOH,
o
autoclave 160 C, 3 hr. Synthesis was designed and performed with guidance of Anatoliy Popov.

JAS239

Figure 3.5. Optical properties of JAS239. Dissolved in methanol, JAS239 has maximal
absorption at 745 nm and maximal fluorescence emission at 775 nm.
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Table 1. Calculated Partition Coefficients for synthesized structures.

Compound
PyroCho
JAS239
MN58b
hydro-JAS239
JAS239.5
JAS259
E,E-conjMN58b
E,E,E-conjMN58b
TCD-717
cycloJAS239
cycloJAS239.5
cycloHITC
cycloHITC.5

cLogP
6.24
3.37
1.24
7.29
5.72
2.74
0.63
1.23
7.47
4.42
6.77
6.81
9.16

To compare the 2 classes of compounds, we synthesized MN58b as a positive control.
The synthesis of MN58b has been reported in 2 papers where it was referred to as
Compound 41 (Campos et al., 2002; Conejo-García et al., 2011). In this Chapter, we
include a detailed description of the synthesis of the intermediate 1,4-bis(4bromomethylphenyl)butane (Fig. 3.4B), which was not provided in the original papers
(Goodson and Goodwin, 1948; Cram and Steinberg, 1951) or in either of the papers
describing the synthesis of MN58b (Campos et al., 2002; Conejo-García et al., 2011). In
addition, we have improved upon the synthesis of MN58b (Fig. 3.4B) by using an
autoclave method following the phase transfer catalyzed bromomethylation (Mitchell and
Iyer, 1989). This decreases the reaction time from 192 hours (Conejo-García et al., 2011)
to 3 hours with 50% yield and cLogP of 1.24 (Table 1). The melting point of our MN58b
product differs from that in (Conejo-García et al., 2011), where it is reported as 161oC to
163oC, but is consistent with the values of 98oC to 100oC when the compound was
71"
"

crystallized from water (Campos et al., 2002). Our attempts to make MN58b derivatives
with a resonant structure, such as WM-11, have thus far failed to yield a final product.
Reduction of JAS239 by sodium borohydride eliminated the characteristic dark green
color of the dye and this colorless hydro-JAS239 (Fig. 3.6) could be separated from its
fluorescent parent compound by extraction in an organic solvent. The transition from a
hydrophilic to a hydrophobic state was successfully predicted by its cLogP of 7.29 (Table
1). Inclusion of an additional benzyl moiety to the JAS239 head group (JAS239.5)
resulted in the expected 30 nm bathochromic shift in absorbance (Ex. 775 nm) and
fluorescence (Em. 815 nm) maxima. The theoretical cLogP was calculated to be 5.72
(Table 1), confirming increased hydrophobicity from the two ring additions. The
indolium head group of JAS239 was replaced with a benzothioazole heterocycle, and the
fluorescence spectrum of JAS259 showed maximal absorbance at 755 nm and emission at
785 nm. The cLogP was determined computationally to be 2.47 (Table 1). When the
indolium head group was replaced with a naphthoxazole, however, the starting
heterocyclic ring was unstable during the alkylation step, resulting in a number of
impurities. A comparison of the 1H NMR spectra from the final product mixture and the
starting naphthoxazole compound revealed that this ring degradation lowered the reaction
yield to less than 25% of the desired product. For JAS273 and JAS274, the absorbance
and fluorescence properties of each set of reaction products were assessed by
measurement in a cuvette. No bathochromic shift in absorbance was observed when
product absorbance spectra were compared to the starting materials. No fluorescence was
detected in the near infrared wave range for either compound.
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Figure 3.6. Colorimetric comparison of JAS239 before and after reduction. JAS239
dissolved in 1% ethanol is dark green (left). Following reduction with NaBH4, the resultant hydroJAS239 is colorless.

A

B

Figure 3.7. UV fluorescence of MN58b and JAS239 derivatives. Frozen vials of (clockwise
from top left) water, TCD-717, E,E-conjMN58b, E,E,E,-conjMN58b, cycloHITC.5, cycloHITC,
cycloJAS239.5, and cycloJAS239 are pictured under (A) white light and (B) UV light. UV
fluorescence is detected in the E,E-conjMN58b and E,E,E,-conjMN58b vials. Background
fluorescence is also observed from the parafilm wrapping.
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Seven compounds in total were successfully synthesized by the PepTech Corporation,
including 1,1’-(((1E,3E)-buta-1,3-diene-1,4-diylbis(4,1-phenylene))bis(methylene))bis(4(dimethylamino)pyridin-1-ium) chloride (PTC1452-01); 1,1’-(((1E,3E,5E)-hexa-1,3,5triene-1,6-diylbis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridin-1-ium)
chloride (PTC1452-02), 1,1’-((1,1’-biphenyl)-4,4’-diylbis(methylene))bis(4-((4chlorophenyl)(methyl)amino)quinolin-1-ium) bromide (PTC1452-07); 1-(2hydroxyethyl)-2((E)-2-((E)-3-((E)-2-(1-(2-hydroxyethyl)-3,3-dimethylindolin-2ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)3,3-dimethyl-3H-indol-1-ium iodide
(PTC1452-08); 3-(2-hydroxyethyl)-2((E)-2-((E)-3-((E)-2-(3-(2-hydroxyethyl)-1,1dimethyl-1H-benzo[e]indol-2(3H)-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)1,1dimethyl-1H-benzo[e]indol-3-ium iodide (PTC1452-09); 1,3,3-trimethyl-2-((E)-2-((E)-3((E)-2-(1,3,3-trimethylindolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)3H- indol1-ium iodide (PTC1452-10); 1,3,3-trimethyl-2-((E)-2-((E)-3-((E)-2-(1,3,3-trimethyl-1Hbenzo[e]indol-2(3H)-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)1H- benzo[e]indol-3ium iodide (PTC1452-11). These will be referred to as E,E-conjMN58b (non-fluorescent;
cLogP = 0.63), E,E,E-conjMN58b (non-fluorescent; cLogP = 1.23), TCD-717 (nonfluorescent; cLogP = 7.47), cycloJAS239 (Ex. 748 nm, Em. 787 nm; cLogP = 4.42),
cycloJAS239.5 (Ex. 784 nm, Em. 843 nm; cLogP = 6.77), cycloHITC (Ex. 743 nm, Em.
783 nm; cLogP = 6.81), and cycloHITC.5 (Ex. 779 nm, Em. 840 nm; cLogP = 9.16),
respectively. The synthesis and analysis of these compounds can be found in Appendices
1-7. E,E-conjMN58b and E,E,E-conjMN58b did not exhibit fluorescence within the NIR
range, however, when frozen and imaged under a UV lamp, fluorescence could be
detected (Fig. 3.7). Attempts to synthesize MN58b derivatives with the Z-conformation
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proved untenable due to double bond isomerization during the palladium-catalyzed
reduction of the alkyne groups in the precursor compound. The viologen-based MN58b
derivatives failed at the final condensation step.

3.12 Discussion
The goal of this study was to develop an NIR fluorescent choline mimetic by
exploiting the structural similarities between the existing bis-symmetric inhibitors and the
carbocyanine dyes. Taking into consideration the structural properties established by the
Lacal group for ChoK-specific inhibition (Sánchez-Martín et al., 2005), we developed an
autoclave Menshutkin alkylation method for carbocyanine synthesis, which successfully
reduced the time required to alkylate the ammonium group of the indolium moiety by 11
hours (Arlauckas et al., 2014). Choline-mimetic hydroxyethyl alkyl groups were attached
at the ammonium sites within the heterocyclic head groups on either side of a 7-carbon
spacer. The 7-carbon spacing is important because it imparts fluorescence in the NIR
range, outside the range of autofluorescence. We then adapted the autoclave method to
establish a rapid and high-yield synthesis of MN58b, the most-effective ChoK inhibitor
in the literature.
A number of JAS239 derivatives were prepared in an effort to test the effect of
hydrophilicity, absorbance wavelength, and alkyl chain length. The hydro-JAS239
compound was hydrophobic and colorless, consistent with our expectations for
hydrocyanine modification. These properties have the theoretical potential to improve the
permeability to the cell membrane and to reduce background signal from dye that is not
cell-associated. However, these dyes also rely on being oxidized in cells or tissues in
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order to be observed with fluorescence imaging. Similar attempts at synthesizing an oxa
derivative were unsuccessful due to degradation of the reaction intermediate. A modified
version of this synthesis running at -20°C is currently being explored in our group, but
the product has yet to be isolated due to the time required for reaction completion.
Similarly for compounds JAS273 and JAS274, where the alkyl chain of the choline
mimetic was extended to 3 and 4 carbons, it is thought that impurities caused by
cyclization of the alkyl group prevented the condensation reaction from occurring.
Cyclization within the linker group seems to have yielded stable and bright JAS239
(cyclo) derivatives, and this minimization of rotational bonds may improve the
pharmacokinetics of these probes (Lipinski, 2003).
While the syntheses of many resonant MN58b derivatives were unsuccessful, the
E,E-conjMN58b and E,E,E-conjMN58b compounds are promising ChoKα inhibitor
candidates. Detection of fluorescence in the solid state opens the possibility that binding
of these less rigid molecules to a stable active site may stabilize the structure and impart
fluorescence, albeit not at ideal wavelengths for in vivo imaging purposes.
The number and variety of previously reported ChoK inhibitors suggests that there
exists a certain degree of flexibility in the functional groups and spacers, which can yield
effective candidate therapeutics. The major concerns for analogs of HC-3 in vivo are that
they (i) will nonspecifically target normal tissue; (ii) will disrupt choline uptake into
normal cells, which can lead to neuronal toxicity; or (iii) will be prone to DNA
intercalation, resulting in ChoK-independent cell death. The inherent fluorescence of a
carbocyanine-based inhibitor greatly simplifies the process of excluding candidates that
inhibit choline phosphorylation, but are not properly delivered to the intended tissue or
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subcellular compartment. The ability to track the cellular uptake of these fluorophores
using fluorimetry and confocal microscopy also permits the determination of potential
interactions with choline transporters, which could affect the interpretation of the efficacy
of ChoK inhibition in vitro. This is also important because compounds that inhibit
choline transport have been shown to lead to respiratory paralysis in animals. The broad
excitation range of JAS239 and its fluorescence in the NIR window wherein breast tissue
is relatively transparent makes it possible to study (i) plasma half-life, biodistribution and
tumor localization; (ii) cellular uptake pathways and kinetics; and (iii) subcellular
localization by in vitro and ex vivo microscopy.
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Chapter 4
JAS239 characterization in breast cancer cells
4.1 Introduction
Upregulation of choline kinase alpha (ChoKα) has been correlated with histologic
tumor grade and resistance to antiestrogen therapies in breast cancer, ultimately
indicating a poorer prognosis (Ramírez de Molina, Gutierrez, et al., 2002). ChoKα
catalyzes the conversion of choline to phosphocholine (PC), an important second
messenger and the first step in the biosynthesis of the predominant membrane
phospholipid, phosphatidylcholine (PtdCho). ChoKα activity can be enhanced by a
number of clinically relevant oncogenes (Bhakoo et al., 1996; Ramírez de Molina,
Penalva, et al., 2002; Ramírez de Molina et al., 2005), growth factors (Warden and
Friedkin, 1984; Cuadrado et al., 1993; Jiménez et al., 1995), transcription factors
(Aoyama et al., 2007; Glunde et al., 2008), and carcinogens (Ishidate et al., 1980).
Furthermore, ChoKα overexpression alone is sufficient to induce malignant
transformation (Ramírez de Molina et al., 2005). The 9 chemically equivalent protons in
choline yield a strong singlet resonance detectable by proton magnetic resonance
spectroscopy (1H MRS). MRS studies have found increasing PC and total choline (tCho)
levels as breast cell lines progress from normal to immortalized, to oncogene
transformed, to malignant (Aboagye and Bhujwalla, 1999). In vivo 1H MRS studies have
identified choline accumulation in 83% of breast lesions (Katz-Brull et al., 2002).
Furthermore, alterations in choline and lipid metabolism detected by MRS are predictive
of tumor response to certain therapies (Negendank, 1992; Delikatny et al., 2011).
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Figure 4.1. Cellular mechanisms affecting the intracellular pool of PC. Choline (Cho) uptake
via Cho transporters (ChoT) and entry into the Kennedy pathway of PtdCho biosynthesis (black)
by which Cho is phosphorylated by ChoK (EC 2.7.1.32), then converted to CDP-Cho and PtdCho
by choline phosphate cytidylyltransferase (CCT; EC 2.7.7.15) and phosphocholine diacylglycerol
transferase (PCT; EC 2.7.8.2), respectively. The four catabolic routes: (ii) membrane
sphingomyelin (SM) hydrolyzed by sphingomyelinase (SMase; EC 3.1.4.12; green) to PC and
ceramide; (iii) PtdCho deacylation to lyso-PtdCho (LPC), GPC, and Cho (yellow) by
phospholipase A2 (PLA2; EC 3.1.1.4), and lysophospholipase (EC 3.1.1.5) or phospholipase A1
(PLA1; EC 3.1.1.32), and GPC: phosphodiesterase (GPC:PDE; EC 3.1.4.2), respectively; (iv)
PtdCho hydrolysis directly to Cho and phosphatidic acid by phospholipase D (PLD; EC 3.1.4.4;
red); (v) PtdCho hydrolysis directly to PC and diacylglycerol via PtdCho-specific phospholipase C
1
(PLC; EC 3.1.4.3; blue). H MR-visible Cho metabolites that contribute to the composite tCho
peak are in boxes.

In vivo 1H MRS is limited by spectral resolution, with the tCho peak representing a
composite resonance consisting of free choline, PC, and glycerophosphocholine (GPC).
Phosphorus (31P) MRS is capable of distinguishing the phosphomonoester PC from the
phosphodiester GPC, but 31P-MRS is relatively insensitive requiring large voxels in vivo.
In addition, direct PC measurements are not always accurate descriptors of ChoKα
activity because of the catabolic formation of PC by the phospholipase and
sphingomyelinase enzymes (Fig. 4.1). There have been efforts to hyperpolarize choline
with the intention of monitoring ChoKα activity (Gabellieri et al., 2008; Sarkar et al.,
2009); however, this approach is limited by the polarization lifetime of 15N and has yet to
be demonstrated feasible in intact cells or in vivo tumor models. Radiolabeled 11C-choline
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(Contractor et al., 2011) and 18F-choline (Bansal et al., 2008) are proving to be useful for
positron emission tomography (PET) imaging in tumors that are not FDG avid, such as
the prostate. However, isotope-labeled choline analogs are also dependent on the
complex families of proteins responsible for choline transport (ChoT: high-affinity
choline transporters, choline transporter-like proteins, organic cation transporters, and
organic cation/carnitine transporters). Upregulation of these proteins has been
demonstrated in some cancers but their involvement remains, for the most part, poorly
understood (Eliyahu et al., 2007; Glunde et al., 2011). An alternative method to
noninvasively detect ChoKα status would be useful to aid in clinical tumor assessment.
ChoKα has garnered clinical attention as a biomarker of tumor malignancy, leading to
its study as a treatment target. Silencing ChoKα via RNAi has been shown to reduce cell
proliferation (Glunde et al., 2005), enhance the sensitivity of aggressive cell lines to 5fluorouracil (Mori et al., 2007), and reduce tumor growth rates (Al-Saffar et al., 2006) in
breast cancer models. The choline mimetic, hemicholinium-3 (HC-3), has long been
known to inhibit ChoKα, but also interrupts neuronal choline transport and
acetylcholinesterase activity (Ansell and Spanner, 1974). Its neurotoxicity at doses
relevant for ChoKα inhibition (Cannon, 1994) led to the development of molecules
capable of blocking choline phosphorylation without causing respiratory paralysis
(Hernández-Alcoceba et al., 1997). The most potent and specific ChoKα inhibitors to
date have been established by the Lacal lab and were identified from quantitative
structure–activity relationship studies of bis-pyridinium (Campos et al., 2001) and bisquinolinium (Sánchez-Martín et al., 2005) HC-3 mimetics (Fig. 4.2). These studies found
that lipophilicity enhances antiproliferative activity but must be optimized because of
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trade-offs in solubility. The top candidates identified were symmetric and featured 2
aromatic heterocyclic head groups, containing quaternary ammonium elements, attached
by a linker of optimized length (Campos et al., 2006). Many of the bis-pyridinium and
bis-quinolinium structures feature electron-donating functional groups, which stabilize
the positive charge and increase activity (Campos et al., 2001). Effective inhibitors have
been identified from compounds with aromatic or aliphatic linkers, which can be used to
optimize the antiproliferative properties.

Figure 4.2. Templates for ChoKα-specific inhibitors. The bis-pyridinium (top) and bisquinolinium (middle) structures with electron-donating functional groups (R) and aromatic or
aliphatic linkers. A novel template for ChoK inhibitors is proposed based upon the carbocyanines
(bottom), whose fluorescence properties are determined by linker length and are substitutable at
the A and R positions.

1,10-((Butane-1,4-diylbis(4,1-phenylene))bis(methylene)) bis(4(dimethylamino)pyridin-1-ium) bromide (MN58b) is the best-characterized bispyridinium ChoKα inhibitor, having been demonstrated to be effective against breast,
colon (Al-Saffar et al., 2006), bladder (Hernando et al., 2009), and cervical cancer, as
well as squamous cell carcinoma, histiocytic lymphoma, and chronic myeloid leukemia
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models (Hernández-Alcoceba et al., 1999). As part of their transformation, cancer cells
are thought to acquire an addiction to PC, which sensitizes them to ChoKα-targeted
inhibition. MN58b treatment causes a temporary cell-cycle arrest in normal cells because
of dephosphorylation of the checkpoint protein pRb. Active (unphosphorylated)
retinoblastoma protein (Rb) prevents G1 to S-phase transition. Tumor cells are often
insensitive to this growth arrest and attempt to bypass ChoKα blockade by excising the
PC group from sphingomyelin for further PtdCho production, releasing ceramides as a
by-product (Rodríguez-González et al., 2004). The accumulation of ceramides, in
addition to attenuation of the proliferative PC signal, leads to tumor-specific apoptosis
(Kolesnick, 2002). TCD-717, developed by TCD Pharma, is the best candidate among the
bis-quinolinium compounds and has completed a phase I dose escalation clinical trial for
solid tumor treatment (Ramírez de Molina et al., 2011).
We sought to test the hypothesis that carbocyanine-derived HC-3 mimetics could be
adapted to the established criteria for effective ChoKα inhibition (Fig. 4.2). The
carbocyanine dyes contain a number of structural similarities to existing ChoKα
inhibitors, including symmetric heterocyclic head groups containing quaternary
ammonium moieties connected by an aliphatic spacer. A preliminary experiment run by
Daniel Leung in our lab used 31P MRS to demonstrate that the addition of either HC-3 or
dimethyloxacarbocyanine iodide (DMOCI; also abbreviated as CyDy) was capable of
attenuating the conversion of choline to PC in a perfused cell model of prostate cancer
(Fig. 4.3). This provided early evidence that this strategy is feasible and led to a search
for fluorophores with better optical properties that could inhibit PC production.
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31

Figure 4.3. Time dependent increases in PC resonances measured in P NMR spectra.
DU145 cells grown on Biosilon beads were perfused in the presence of 2 mM choline (open
circles). Time-dependent changes in PC concentration relative to beta-nucleoside triphosphate
(β-NTP) were measured in real time in live cells following addition of hemicholinium-3 (HC-3,
black circles) or DMOCI (CyDy, grey squares) to the perfusion media. Both the prototypical
choline mimetic, HC-3, and the carbocyanine, DMOCI, are capable of attenuating choline
phosphorylation (n = 1). Experiments were carried out by Daniel Leung of the Delikatny Lab.
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Figure 4.4. Choline metabolite and ChoKα levels in cultured cell models. (A) Western blots
(insert) and quantification confirm that higher levels of PC are accompanied by increased
expression of ChoKα. (B) MR spectra and (C) quantification of aqueous extracts of the cell lines.
MDA-MB-231 and 4175-Luc+ have higher levels of PC than MCF7-WT. Overexpression of
ChoKα leads to an increase in PC levels. Assistance with Western blots provided by Mansi
Shinde of the Klein Lab, and technical support for MRS experiments provided by Weixia Liu of the
Small Animal Imaging Facility. Preparation and MRS of 4175-Luc+ extracts performed by Michael
Chiorazzo of the Delikatny Lab.
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We report here the development of a new prototype ChoKα inhibitor, JAS239, with
both potent antiproliferative activity as well as fluorescence in the near-infrared (NIR)
range. The optical properties of NIR fluorophores are ideal for in vivo optical imaging, as
human tissue (water, hemoglobin, fat) has minimal absorbance in this wavelength range
(650–900 nm). Although fluorescent kinase inhibitors in the visible range have been
reported (Kim et al., 2010; Yenugonda et al., 2011; Kim et al., 2011), our approach using
NIR fluorophores potentially allows for the imaging of kinase expression and function in
vivo.

4.2 Results
The levels of ChoKα expression and choline metabolite concentrations were
determined in a panel of breast cancer cell lines. Western blots (Figure 4.4A) show that
the estrogen-receptor positive MCF7-EV cell line has a lower expression of ChoKα than
the triple-negative and metastatic MDA-MB-231 cell line. Figure 4.4B shows 1H MR
spectra of the aqueous fraction of chloroform:methanol:water extracts prepared from the
4 cell lines. As previously reported (Shah et al., 2010), the non-metastatic MCF7-EV
cells show lower levels of PC, the enzymatic product of ChoKα, compared to the
metastatic MDA-MB-231 cells.!The ChoKα overexpressing cell line, MCF7-CK+, shows
a 2.3-fold increase in PC levels accompanied by high expression of ChoKα. The 4175Luc+ cell line has slightly lower PC levels than the parent MDA-MB-231 cells (Fig.
4.4C), but comparable expression of ChoKα. ChoKα activity assays were performed
using 14C-labeled choline added to intact cells followed by extraction, thin layer
chromatography (TLC) and autoradiography (Figure 4.5A). These assays show that
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choline is rapidly phosphorylated to PC upon cell entry as a trapping mechanism, and that
catabolic breakdown of PtdCho to GPC becomes detectable after 16 hours. Figure. 4.5B
shows that MCF7-EV cells have the lowest relative activity of the tested cell lines, and
that ChoKα overexpression enhanced the production of 14C-PC. ChoKα activity was also
determined using an NMR-based assay on cytosolic preparations. The NMR spectra of
MCF7 cell cytosolic preparations (Fig. 4.6A) demonstrate the rise in the PC peak (3.22
ppm) at the expense of the choline peak (3.20 ppm) after choline, ATP, and Mg2+ ions
were added. The PC and choline peak integrals were plotted over time (Fig. 4.6B) and
regressions were fit to the linear portion of the curve to estimate ChoKα activity (Fig.
4.6C). Both the radiotracing and the NMR assays directly measure choline depletion and
the simultaneous increase in PC. Both assays show that over-expression in MCF7-CK+
significantly increased ChoKα activity to levels similar to MDA-MB-231 cells.
A screen of potential fluorescent inhibitor-like compounds was performed using 1H
NMR. Here MCF7 cells were used as a source for cytosolic ChoKα, as they have low
baseline levels of PC. 1H NMR was used to assess ChoKα activity in the presence and
absence of inhibitor (Fig. 4.7). MN58b added to the NMR tube at a final concentration of
10 µM was found to reduce ChoKα activity by 57%. FM 4-64 at 10 µM caused an
unexpected 50% increase in ChoKα choline phosphorylation (not shown), and doubling
the final concentration to 20 µM resulted in only a 3% reduction. For DMOCI (3,3’dimethyloxacarbocyanine iodide), addition of 100 µM caused a 50% increase in PC
formation. The NIR fluorophore HITC caused a 9% increase in ChoKα activity in this
cytosolic model. These values represent single trials, as this experiment is too time
intensive and expensive to justify the pursuit of ineffective compounds. In the presence of
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100 µM JAS239, a 26.2% reduction in ChoKα activity (P = 0.02) was observed in MCF7
cells (Fig. 4.7). ChoKα overexpressing MCF7-CK+ cells demonstrated no significant
change in ChoKα activity (P = 0.20) when exposed to the same concentration of JAS239
(Fig. 4.7). Further studies were performed on JAS239 using MN58b as a positive control.
A

B

14

Figure 4.5. C-choline radiotracing assay for ChoK activity. (A) Cells were pulsed with 1 µCi
14
of C choline for the times indicated. Extracts were separated by TLC and analyzed by
autoradiogram. (B) Quantification of autoradiograms shows increased ChoK activity in MCF7CK+ relative to MCF7-EV control. Mouse adaptation of the 4175-Luc+ cell line did not result in
significant changes in ChoK activity when compared to the parent MDA-MB-231 cell line. Values
represent + SEM for 3 separate experiments, P < 0.05.
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Figure 4.6. H NMR ChoK assay. (A) Superimposed H spectra obtained over 500 min following
2+
addition of choline, Mg , and ATP to cytosolic extracts of MCF7 WT cells show increases in PC
at the expense of choline. (B) The corresponding PC and Cho peak integrals were plotted over
time and linear regression of the early portion of (B) yields an estimate of ChoK activity in the
breast cancer cell panel. (C) Quantification shows that ChoKα overexpression increases activity
in MCF7 cells to levels of MDA-MB-231 cells, whereas no effect was caused by expression of the
empty vector (MCF7-EV). *P < 0.05
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Figure 4.7. ChoK inhibition by fluorescent choline mimetics measured by NMR. PC
1
production in cytosolic preparations from MCF7 cells was measured using H NMR. Drastic
reduction of PC production is observed following MN58b addition. Neither FM 4-64, DMOCI, or
HITC are capable of inhibiting ChoK activity (n = 1). JAS239 causes significant reduction in PC
production (n = 3) in MCF7-EV cells. Overexpression of ChoKα variant 1 reverses the inhibition
by JAS239.

JAS239 was able to inhibit the phosphorylation of 14C-labeled choline in MDA-MB231 triple-negative breast cancer cells with an IC50 of 4.6 µM at 17 hours of treatment,
comparable to the IC50 of 2.3 µM observed for MN58b (Fig. 4.8A). Treatment with 10 or
20 µM JAS239 for 17 hours or longer resulted in a statistically significant reduction in
MDA-MB-231 viability as measured by Trypan blue exclusion (Fig. 4.8B). The
antiproliferative EC50 of JAS239 at 24 hours is 13.3 µM, as measured by the Trypan
exclusion assay. Figure 4.8C shows that the reduction in choline phosphorylation
occurred as early as 2 hours after treatment at 10 and 20 µM, before any significant loss
in cell viability was observed. By 17 hours, significant losses in both ChoKα activity and
cell viability were found (Fig. 4.8D). Addition of 2 mM exogenous non-labeled choline
to MDA-MB-231 cells was able to rescue the inhibition of ChoKα by JAS239 (10 µM),
whereas 0.2 mM had no effect (Fig. 4.8E). By 17 hours, exogenous choline at 0.2 and 2
mM was unable to outcompete JAS239 (Fig. 4.8F).
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Figure 4.8. JAS239 is a competitive inhibitor of ChoK in MDA-MB-231 cells. (A) Cell
14
treatment for 17 hr with MN58b or JAS239 inhibits C-choline phosphorylation with an IC50 of 2.3
and 4.6 µM, respectively. (B) Cell viability determined by Trypan blue exclusion in response to
JAS239, where ‡ indicates cell reduction (P < 0.05) versus untreated control at 2 and 17 hr and #
indicates cell reduction (P < 0.05) versus untreated control at 17 and 24 hr. (C) 2-hr exposure to
14
JAS239 causes inhibition of C-choline phosphorylation with no effect on cell viability. (D) After
14
17 hr exposure to JAS239, both inhibition of C-choline phosphorylation and reduction in viability
14
is observed. (E) Exogenous choline addition at high concentrations rescues
C-choline
phosphorylation in cells treated with 10 µM of JAS239 for 2 hr. (F) By 17 hr, exogenous choline
14
addition does not significantly change C-choline phosphorylation in cells treated with 10 µM of
JAS239. Data plotted as % control + SD for three separate experiments. *P < 0.05.

Direct comparison of JAS239 and MN58b in each of the 4 breast cancer cell lines
was then performed. The potency of ChoKα inhibition in intact cells was assessed using
14

C-PC production in 1 hour. Trypan blue exclusion was used to measure cytotoxicity at

17 hours. Accelerated flux through ChoKα was observed in MCF7-CK+ cells, and
MN58b normalized this aberrant flux to levels comparable to that of the control MCF7EV cell line (Table 2, Fig. 4.9A). MN58b was more than twice as potent as JAS239 at
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this early time point in both cell lines (Table 2, Fig. 4.9A,B). After overnight treatment,
there was little difference in the EC50s as determined by Trypan exclusion between
MN58b (Table 2, Fig. 4.10A) and JAS239 in the MCF-7 EV and CK+ cell lines (Table 2,
Fig. 4.10B).
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Figure 4.9. Characterization of ChoKα in a panel of human breast cancer cell lines. (A-D)
14
Dose-response curves comparing the effect of MN58b (A, C) or JAS239 (B, D) on C-choline
phosphorylation in MCF7-EV and MCF7-CK+ cells (A, B) or MDA-MB-231 and 4175-Luc+ cells
(C, D). Values are reported as a percentage of the untreated EV group (for MCF7 cells) or
untreated MDA-MB-231 group (for MDA-MB-231 and 4175-Luc+), and represent + SEM for 3
separate experiments.
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Figure 4.10. Breast cancer cell viability in response to ChoK inhibitors. (A,B) Cell viability
measurements via Trypan blue exclusion demonstrate comparable cytotoxicity in MCF7-EV and
MCF7-CK+ cells (A, B) exposed overnight to either MN58b (A) or JAS239 (B). MTT assays were
performed on MDA-MB-231 and 4175-Luc+ (C, D) cells exposed to MN58b (C) or JAS239 (D).
Values are reported relative to untreated control groups and represent + SEM for 3 separate
experiments.

Table 2. Potency of MN58b and JAS239 in a panel of breast cancer cell lines.

Cell Line
MCF7-EV
MCF7-CK+
MDA-MB-231
4175-Luc+

IC50 (µM)
MN58b
JAS239
3.85 + 0.42 11.1 + 5.64
2.36 + 0.28 10.3 + 2.48
4.36 + 1.37 9.92 + 0.22
4.59 + 0.55 9.89 + 0.24
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EC50 (µM)
MN58b
JAS239
3.29 + 0.48 4.04 + 0.55
6.86 + 0.43 5.33 + 0.84
14.26 + 4.6 27.2 + 7.9
20.7 + 6.4
35.0 + 21.6
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Figure 4.11.
C-choline radiotracing to distinguish choline transport from choline
phosphorylation. (A) MCF7-CK+ (CK) cells have higher PC levels than MCF7-EV (EV) cells. (B)
Despite higher flux through the Kennedy pathway, at 16 hr the CK cells have less GPC than EV
cells indicating that GPC is rapidly converted back to PC when ChoKα is overexpressed. (C-F)
14
MCF-7 CK or EV cells were given either MN58b (left) or JAS239 (right). C-choline was added 1
14
14
hr after MN58b (C & E) or JAS239 (D & F) and the C-PC (C & D) and C-GPC (E & F) levels
estimated after 16 hr. While little difference in PC depletion is observed between the two drugs,
14
JAS239 does not deplete C-GPC pools in EV cells. Overexpression of ChoKα rescues this
effect. Values are reported relative to untreated MCF7-EV and represent + SD for 3 separate
experiments.
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No significant difference in PC production (IC50) was found between the MDA-MB231 and the derivative 4175-Luc+ cell lines following 2 hours of MN58b treatment
(Table 2, Fig. 4.9C). Similarly, the mouse adapted and metastasis derived 4175-Luc+ cell
line did not show altered sensitivity to JAS239 when PC production was compared to
MDA-MB-231 cells (Table 2, Fig. 4.9D). The first attempt to characterize EC50s in the
4175-Luc+ cell lines indicated that these cells were more resistant and required higher
dosage. At high doses, it became difficult to distinguish JAS239 staining from Trypan
blue during counting. For this reason, we switched assays from Trypan exclusion to the
more automated MTT assay after ensuring that there was no overlap in absorbance
readings between the formazan product and JAS239. As was found in radiotracing
assays, MN58b was a more potent inhibitor of cell growth than JAS239 (Table 2, Fig.
4.10C). A similar, although more variable, trend existed in 4175-Luc+ cells (Table 2, Fig.
4.10D).
After 16 hours of 14C-choline treatment, PtdCho breakdown could be detected using
the formation of 14C-GPC as an indicator of phospholipase activity (as shown in Fig. 4.5).
In MCF7 cells, it became apparent that ChoKα overexpression rapidly recycled this
product back to 14C-PC, which helped to maintain high levels of 14C-PC (Fig. 4.11A) and
resulted in diminished pools of 14C-GPC (Fig. 4.11B). Addition of MN58b (Fig. 4.11C)
or JAS239 (Fig. 4.11D) was capable of reducing 14C-PC pools after 16 hours of tracing.
In MN58b-treated MCF7-EV or MCF7-CK+ cells, the 14C-GPC pools were diminished
to a similar degree (Fig. 4.11E). Interestingly, in the MCF7-EV cell line, JAS239 did not
affect 14C-GPC pools except at concentrations of 20 µM, at which point the cells were
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presumed to undergo apoptosis. This result was reversed when ChoKα was over
expressed (Fig. 4.11F).
Fluorimetry was used to observe the uptake of JAS239 into MCF7 cells after 2 hours.
The uptake of JAS239 was concentration-dependent, and no difference in uptake was
observed when ChoKα was overexpressed (Fig 4.12A). To determine probe retention, a
series of washout phases were included following JAS239 administration, however only
moderate differences were found (Fig 4.12B).
A

B

Figure 4.12. Effect of ChoKα expression on JAS239 uptake and retention. (A) JAS239
uptake over 2 hr is linear for MCF7 cells, and no change in uptake is detected following ChoKα
overexpression. (B) Only moderate increases in JAS239 retention are observed in MCF7-CK+
cells compared to the MCF-EV control. Cell uptake was measured in a fluorimeter using
excitation 640 nm and emission 770 nm, and corrected for cell number. Studies were performed
in triplicate; error bars represent + SEM.

JAS239 uptake was also analyzed using MDA-MB-231 cells treated for 2 hours at
varying concentrations. Fluorescence accumulation was linear within the entire
therapeutically relevant dose range (Fig. 4.13A). Addition of exogenous choline did not
obstruct the uptake of JAS239 into these cells (Fig. 4.13B). MDA-MB- 231 cells treated
with JAS239 for 2 hours and stained for 30 minutes with the nuclear stain SYTO9 were
analyzed using fluorescence confocal microscopy. A distinct separation of SYTO9 (Fig.
4.13C) and JAS239 (Fig. 4.13D) fluorescence was observed, indicating that the
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localization of the novel probe was confined to the cytosolic space, appearing diffusely in
the cytoplasm, as well as in punctate perinuclear spots (Fig. 4.13E).
Fixed MDA-MB-231 cells were treated with a rabbit anti-human ChoKα antibody
followed by a goat anti-rabbit antibody conjugated to Texas-Red. Fluorescence confocal
micrographs from the Texas-Red channel and the NIR channel were acquired and merged
(Fig. 4.14, top row). An average Pearson’s Correlation Coefficient of -0.31 + 0.1 was
found for three experiments and confirmed that no overlap between the Texas-Red and
JAS239 channels occurred (Fig. 4.15A). Confocal micrographs (Fig. 4.14, middle row) of
fixed JAS239-stained MDA-MB-231 cells probed with the ChoKα-specific antibody
revealed strong colocalization (Pearson’s Correlation Coefficient = 0.88 + 0.02) between
JAS239 and ChoKα (Fig. 4.15A). Of the ChoKα-positive pixels analyzed, 89 + 9% were
located in pixels also positive for JAS239 (Fig. 4.15B). Likewise, 89 + 10% of JAS239positive pixels were also positive for ChoKα (Fig. 4.15C). When fixed cells were pretreated with ChoKα antibody, marked reduction in JAS239 retention was detected (Fig.
4.14, bottom row). Reduced JAS239 signal relative to noise caused a lower Pearson’s
Correlation Coefficient (0.49 + 0.04; Fig. 4.15A), although 84 + 4% of the regions which
were ChoKα-positive were also JAS239-positive (Fig. 4.15B), and 87 + 2% of the
JAS239-positive pixels were ChoKα-positive (Fig. 4.15C). This demonstrates that the
JAS239 that was retained in these cells was still associated with ChoKα, although the
intensities of the two channels followed a different distribution trend. These results are
consistent with JAS239 being out-competed by the antibody for binding sites.
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Figure 4.13. Uptake and subcellular localization of JAS239. (A) MDA-MB-231 cells treated
with varying concentrations of JAS239 for 2 hr demonstrate linear increases in relative
fluorescence intensity (RFI; excitation 640 nm, emission 770 nm). (B) A fluorimetry study
demonstrating that addition of exogenous choline to MDA-MB-231 cells could not outcompete
uptake of JAS239. Fluorescence confocal micrographs show MDA-MB-231 cells stained for 30
min with (C) the nuclear stain Syto9, (D) 2 µM of JAS239, and (E) merged images. Error bars
represent + SD for three separate experiments. Images were acquired in the Wistar microscopy
core with assistance from James Hayden.

"

96"
"

ChoK

Merge

Ab JAS239

JAS239

Ab

Ab

JAS239

Figure 4.14. JAS239 colocalizes with ChoKα. Fixed and permeabilized MDA-MB-231 cells
treated with a ChoKα-specific antibody followed by a Texas Red-conjugated secondary antibody
(Ex. 543 nm; Em. 565-615) were assessed by confocal microscopy (top row). In cells stained with
JAS239 followed by the ChoKα antibody (middle row), strong colocalization between the JAS239
(Ex. 633 nm; Em. >650 nm) and ChoKα is observed. Cells incubated with antibody prior to
JAS239 staining (bottom row) no longer retain the NIRF probe. Scale bars represent 35 µm. This
protocol was developed with help from Alex Glavis-Bloom of the Yang Lab and images were
acquired in the CDB microscopy core with assistance from Jasmin Zhao.
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Figure 4.15. Correlation coefficients to quantify JAS239/ChoKα colocalization. (A) JAS239
is strongly correlated with ChoKα, unless fixed cells are pre-incubated with ChoKα antibody. (B)
Manders’ Colocalization Coefficients for the Texas-Red channel confirm the majority of ChoKα is
bound by JAS239 when JAS239 is present. (C) Manders’ Colocalization Coefficients calculated
for the JAS239 channel indicate that the majority of JAS239 present intracellularly is codistributed with ChoKα. Values represent + SEM for 3 fields of view.

98"
"

4.3 Discussion
To identify a candidate NIR fluorophore capable of disrupting PC production, a panel
of breast cancer cells was first characterized for ChoKα expression, activity, and native
choline levels. A 1H NMR activity assay was used to explore ChoKα kinetics in response
to a pulse of choline in the presence of!excess ATP and Mg2+. Choline depletion in MCF7
cells was precisely mirrored by PC formation, confirming the inactivation of competing
enzymes by the reducing environment of the cell lysis buffer. The enzymatic rate of
ChoKα determined by this assay (6.25 nmol PC produced / 106 cells / hour) was
consistent with estimates for ChoK activity in ovarian cancer cells (Iorio et al., 2005) and
the observation that 14C-choline phosphorylation is nearly instantaneous upon cell entry.
This assay was used to identify potential ChoKα inhibitors, because in the absence of
choline transporters, phospholipases, or other members of the Kennedy pathway (Iorio et
al., 2005), this assay can provide a true measure of ChoKα catalytic rate.
The potent inhibition of ChoKα by MN58b reported in the literature (Lacal, 2001)
was confirmed in MCF7 cytosolic preparations. DMOCI, however, was incapable of
inhibiting ChoKα activity, despite preliminary studies from our lab that found a possible
effect in perfused cells. This suggests choline transport inhibition may have influenced
the reduction in PC observed in that model system. Neither FM 4-64 nor HITC had an
inhibitory effect in the ChoKα activity assay. On the other hand JAS239 caused a
significant reduction in ChoKα enzymatic rate, albeit at a higher concentration. These
530 µL samples were highly concentrated with cytosol from 20 x 106 cells. As a
reference, the same molar quantity of JAS239 dispersed in the cellular media of 20 x 106
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cells would be at a relatively dilute concentration of 0.53 µM. Moreover, the inhibitory
effect of JAS239 in MCF7 EV cells could be rescued by ChoKα overexpression, thus
confirming ChoKα to be the primary target of JAS239 that leads to the reduction in
choline phosphorylation observed in this assay.
Using 14C-choline as a radiotracer, JAS239 was found to inhibit ChoKα activity at
concentrations higher than, but comparable to MN58b, as indicated by reduced
production of 14C-PC. ChoKα inhibition occurred at 2 hours, before the onset of cell
death, and was reversible by addition of unlabeled choline, indicating that JAS239 acts as
a competitive inhibitor. After 17 hours, choline addition was unable to reverse the effects
of JAS239 on choline metabolism, suggesting that irreversible alterations to the Kennedy
pathway or downstream pathways had already occurred. Because MN58b and JAS239
are charged small molecules that may be impermeable to the cell membrane, we
performed the 14C-choline radiotracing studies in intact cells to ensure the ChoKα
inhibition observed in cytosol could be replicated in vitro. The improvement in JAS239
potency relative to MN58b in intact cells is presumably due to JAS239 being more cell
permeable with one less cationic charge.
We next verified the efficacy of JAS239 in a panel of human breast cancer cells
representing different germ lines (epithelial and mesenchymal), tumor stages (estrogenpositive and triple-negative), derivation (mouse-naïve and mouse-adapted), and ChoKα
expression (low, medium, and high). ChoKα inhibition in intact cells was assessed at 2
hours of treatment, as this is sufficient time for PC formation but too early for
phospholipase involvement or observable cell death. Due to the number of samples this
required, we lowered the cell media volume from 3 mL per well to 2 mL per well, thus
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lowering the amount of radioactive waste produced per sample. In all cell lines, MN58b
was at least twice as potent. This was mirrored in the MDA-MB-231 and 4175-Luc+ cell
viability data after 17 hours of treatment, however the MCF7 cell lines were more
sensitive to JAS239 than would be expected from the IC50s. The IC50 at 2 hours for the
MDA-MB-231 cells doubled from 4.6 µM to 9.92 µM when the cell media was decreased
from 3 mL to 2 mL, reflecting the reduction in total drug molecules interacting with the
same number of cells per sample.
Against pure yeast ChoKα, the average reported IC50s of the bis-pyridinium and bisquinolinium ChoKα inhibitors were 37.1 and 33.9 µM, respectively; the antiproliferative
activities, EC50s, in HT-29 cells were 19.7 and 3.7 µM, respectively (Campos et al.,
2001; Sánchez-Martín et al., 2005). Although determined in different systems, the
measured IC50 of 4.6 µM for JAS239 represents potency comparable or better than 85%
of the reported bis-pyridinium–based ChoKα inhibitors, and 61% of the bis-quinolinium
compounds. The EC50 values are also comparable, although determined using different
assays in cell lines of different tissue origin. The action of JAS239 against MDA-MB-231
cells suggests ChoKα inhibition may be an effective strategy in triple- negative breast
cancers, which are often therapy resistant. Its potency suggests that further modifications
based upon the carbocyanine template, and subsequent structure–activity
characterization, may yield compounds highly specific to ChoKα.
An interesting difference in how MCF7 cells respond to treatment with MN58b and
JAS239 was observed after 16 hours of radiotracing. Based upon the evidence that
ChoKα overexpression causes depletion of 14C-GPC by promoting its conversion back to
14

C-PC, we hypothesized that ChoKα inhibition would reduce PC levels and not deplete
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14

C-GPC. We found JAS239 did not deplete the 14C-GPC pool in MCF7-EV cells,

whereas MN58b caused depletion of both the 14C-PC and the 14C-GPC pools. This
suggests some of the inhibitory effect of MN58b on PC formation may be due to choline
transport inhibition in these cells. Further radiotracing studies with inhibitors added
following 14C-choline addition and measurement of choline efflux from the cells are
needed to better understand this mechanism.
The uptake of JAS239 into intact MDA-MB-231 cells was analyzed by fluorimetry
and was found to be both rapid and linearly proportional to the concentration of probe
added; no quenching of signal intensity was observed even when high therapeutic doses
were used. Moreover, the uptake into MCF7 cells was linearly dependent on
concentration and independent of ChoK overexpression. Furthermore JAS239 appears to
enter cells independent of the choline transporters, as exogenous choline addition had no
effect on probe uptake. The ability to separate ChoKα expression from choline uptake is
an advantage to using fluorescent ChoKα inhibitors. Reported observations made using
MRS and PET tracers measure the effects of both choline transport and phosphorylation
together. Our approach may yield a companion diagnostic that would aid in identifying
patients best suited for ChoKα inhibitor-based therapies. Overexpression of ChoKα
resulted in only moderate enhancement of JAS239 retention. The MCF7-CK+ cells were
previously reported by Shah et. al. to have elevated drug and dye (Rhodamine 123) efflux
capabilities, which may be a confounding factor to consider when interpreting the results
from this assay (Shah et al., 2010).
The inherent optical properties of this small molecule inhibitor allow for study of
subcellular localization by fluorescence confocal microscopy. JAS239 collects in the
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cytosolic space where ChoKα is active (Hosaka et al., 1990) and is excluded from the
nucleus where DNA intercalation, mutagenesis, and nonspecific cell death would
otherwise be confounding factors. Using confocal microscopy of fixed MDA-MB-231
cells, JAS239 staining was compared with immunohistochemical ChoKα assessment.
Colocalization of the probe with ChoKα was observed, indicating a direct interaction that
could be blocked when the N-terminal antibody was bound ahead of time.
Our results have indicated that JAS239 enters breast cancer cells independent of the
choline transporters and competes with choline at the active site of ChoKα. The
development of a small molecule kinase inhibitor with NIR-fluorescence confers the
ability to noninvasively track the biodistribution of this probe with NIR optical imaging
(Yang et al., 2010), greatly reducing the number of animals required for detailed
pharmacokinetics studies. ChoKα expression can be up to 15-fold higher in malignant
compared with non-transformed breast cells (Glunde et al., 2005), thus imaging agents
targeted to this biomarker may benefit from substantial signal-to-noise.
We describe here a novel strategy for reporting ChoKα expression, which has been
clinically correlated to histologic tumor grade and estrogen receptor status in breast
cancer. As interest in ChoKα inhibition for cancer therapy expands, these compounds
have the unique potential to serve as companion diagnostics to identify patients most
likely to benefit from this therapy and to make ongoing minimally invasive evaluations of
their response.
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Chapter 5
JAS239 characterization in breast tumor models
5.1 Introduction
Choline kinase alpha (ChoKα) has become the subject of intense interest for its utility
as an oncogenic biomarker as well as an anticancer therapeutic target (RodríguezGonzález et al., 2003). During malignant transformation, cells sequester high levels of
PC which become detectable using magnetic resonance spectroscopy due to the 9
chemically-equivalent protons on the methyl groups adjacent to the quaternary nitrogen
(Negendank, 1992; Aboagye and Bhujwalla, 1999). Heightened ChoKα activity has been
identified in approximately 40% of human breast tumor specimens (Ramírez de Molina,
Gutierrez, et al., 2002).
Inhibitors of ChoKα have been developed as tools to study the involvement of this
enzyme in malignant transformation. Shutting down de novo phospholipid biosynthesis
leads to lower levels of pro-mitotic second messenger Kennedy pathway intermediates,
increased ceramide levels, and a de-stabilized endoplasmic reticulum membrane. The
most potent of these agents, TCD-717, is a promising anti-cancer drug (Sanchez-Lopez et
al., 2013) being evaluated in clinical trials (Lacal and Campos, 2015). MN58b, a dicationic ChoKα inhibitor, has been demonstrated to be lethal to lymphoma cells, but to
cause a reversible cell cycle arrest in normal cells (Rodríguez-González et al., 2004).
Although the mechanism by which ChoKα inhibition ultimately leads to cell death may
not fully be related to the enzymatic function (Falcon et al., 2013), measures of tCho
levels are still the primary method of validating novel ChoKα inhibitors. A limitation of
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this approach is that tumor necrosis can lead to deceptive decreases in tCho in MR
spectra and measurement of secondary biomarkers is required (Horská and Barker, 2010).
PET and hyperpolarized choline tracers may be useful to identify ChoKα inhibition, but
choline tracer accumulation can be blocked by choline transport inhibitors (Gomez et al.,
1970) which have known toxicities (Boobis et al., 1975). Measuring ChoKα expression
and inhibition remains a difficult task that is complicated further by the complex
contributions of the phospholipases, organic cation transporters, and sphingomyelinases
to choline metabolite levels.
Our group synthesized a small molecule choline mimetic with inherent NIRF which
effectively attenuates choline phosphorylation with no observable interaction with the
choline transporters (Arlauckas et al., 2014). This concept originated when the
observation was made of structural similarity between the carbocyanines and the
symmetric, bis-heterocyclic ChoKα inhibitors. This carbocyanine derivative called
JAS239 is the first described kinase inhibitor with fluorescence in the near infrared
wavelength range, wherein human tissue is relatively transparent (Jobsis, 1977). For this
reason, NIRF optical imaging probes can be detected through several millimeters, and
under certain conditions, centimeters of tissue (van de Ven, 2008). There is a particular
need for more specific agents to assist surgeons in distinguishing tumor from normal
tissue (Mahmood and Weissleder, 2003), and intraoperative imaging is an expanding
field for which NIRF offers a relatively cheap method of delineating tumor margin and
assessing lymph node involvement (De Grand and Frangioni, 2003). In this Chapter we
test JAS239 as a ChoKα targeted optical imaging probe in murine models of cancer in the
breast, which in humans, is a relatively homogenous, NIRF-transparent, and compressible
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tissue (Busch et al., 2013). Following in vivo characterization of the diagnostic potential
of this probe, JAS239 was then employed at higher doses, in conjunction with MN58b, to
study the therapeutic potential of ChoKα inhibition.

5.2 Results
Athymic nude mice were used for inoculation with human derived breast cancer cell
lines, which were injected into the mammary fat pad and monitored via caliper
measurement for orthotopic tumor formation. In 30 days, tumors derived from MCF7EV, MCF7-CK+, MDA-MB-231, and 4175-Luc+ cell lines reached volumes of 24 + 5,
170 + 30, 7.9 + 3.1, and 700 + 150 µL, respectively (Fig. 5.1). Due to their rapid in vivo
growth that could additionally be monitored with bioluminescence imaging, 4175-Luc+
tumors were the early focus of this work.
A

B

Figure 5.1. Tumor growth patterns in human breast cancer derived cell lines. (A) ChoKα
overexpression accelerates tumor growth in an MCF7-derived orthotopic xenograft model. (B)
Orthotopically inoculated 4175-Luc+ derived tumors exhibit accelerated growth in volume
compared to orthotopic MDA-MB-231 xenografts. Values represent + SEM for 5 animals per
cohort.
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Figure 5.2. Bioluminescence of 4175-Luc+ tumors delineates tumor margin for NIRF
measurement. (A) Two representative 4175-Luc+ tumor-bearing mice imaged for bioluminescent
2
Radiance [p/sec/cm /sr] 15 min after injection of luciferin. (B) Bioluminescence was used to draw
an ROI (blue line) around the tumor margin, and was confirmed to be undetectable in the NIR
filter range. (C) Mice injected with either control vehicle (left) or JAS239 were administered
luciferin after 75 min and imaged 15 min later for bioluminescence to define tumor ROIs.
Heightened radiance was observed in JAS239 mice presumably due to absorption of photons by
JAS239 and emission at a longer, more tissue transparent wavelength. (D) Tumor margin (blue)
defined by bioluminescent imaging of 4175-Luc+ tumors shows no NIRF in the vehicle-injected
mouse (left) but intratumoral NIRF in the right mouse injected with Tween-80/Tris Buffer. Renal
excretion of JAS239 is also seen outside the tumor boundaries. (E) Average Radiant Efficiency
2
2
[p/sec/cm /sr]/[µW/cm ] was quantified in each ROI (4 animals in JAS239 cohort). (F) The tumor
NIRF (right mouse) begins to diminish relative to the renal signal 95 min after JAS239 injection.
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Bioluminescence emitted by mice bearing 4175-Luc+ orthotopic tumors was
measured 15 min following luciferin injection (Fig. 5.2A). This signal was used to
delineate the tumor margins (in blue) using the Auto ROI tool in the LivingImage
software and was used during NIRF imaging to ensure that the bioluminescent signal did
not overlap with the NIR range (Fig. 5.2B). The next day, mice were treated with control
vehicle (left mouse) or 20 nmol JAS239 in Tween-80/Tris buffer (right mouse). Luciferin
injection and bioluminescence imaging was again used to delineate tumor margin (Fig.
5.2C), and no NIRF signal was detected in the control-treated animals (Fig. 5.2D, left
mouse; n = 5). In the JAS239-injected animals, NIRF was emitted both from the tumor
and from the kidneys (Fig. 5.2D, right mouse; n = 4). NIRF emission at 800 nm was over
an order of magnitude stronger (5.4 + 1.1 x106 vs. 4.8 + 0.9 x105
[p/sec/cm2/sr]/[µW/cm2]) in JAS239-injected animals vs. control (P = 0.001, Fig. 5.2E).
Maximum NIRF contrast between the tumor and background was achieved 90 minutes
post-JAS239 injection, as the tumor vs. renal fluorescence diminished after this time due
to probe excretion (Fig. 5.2F).
Approximately one week later, mice from this cohort were again injected with the
same JAS239 formulation, euthanized 90 minutes later, and the major organs were
resected and imaged for NIRF (Fig. 5.3A). The biodistribution of JAS239 is consistent
with the renal signal detected in whole animals, however the signal from other internal
organs (liver in particular) was higher than would be expected from the whole-body
images (Fig. 5.3B). The tumor contrast seen in whole-body NIRF images probably arises
because of the relative depth of these organs, compared to the surface tumor.
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Figure 5.3. NIRF imaging for biodistribution of JAS239 in Tween-80/Tris formulation. (A)
Organs from 4175-Luc+ tumor bearing mice (n = 4) were resected 90 min following injection with
JAS239 in Tween-80/Tris imaged for NIRF. (B) NIRF was measured for each organ and the
2
2
Average Radiant Efficiency [p/sec/cm /sr]/[µW/cm ] was quantified for comparison.

A cohort of five athymic nude mice bearing orthotopic 4175-Luc+ tumors were
injected with 20 nmol JAS239 dissolved in an ethanol/saline solution. NIRF imaging
found that background signal from the liver and kidneys was too high to achieve optimal
tumor contrast (Fig. 5.4A). After JAS239 had cleared, 20 nmol of ICG was dissolved in
the same vehicle and imaged for NIRF after 15 minutes, 45 minutes, 4 hours, and 24
hours (Figure 5.4B). While tumor fluorescence was detected, cloaking the internal organs
was necessary to improve contrast (Fig. 5.4C).
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Figure 5.4. Limitations of whole body optical imaging. (A) NIRF imaging was performed on
athymic nude mice (n = 5) 24 hr after i.v. injection with JAS239 in an ethanol/saline formulation.
Poor fluorescence contrast is observed in orthotopic 4175-Luc+ tumors, due to high liver and
renal signal. (B) Biodistribution of clinically-approved ICG was then imaged to confirm high
fluorescence background was due to limitations of the model. The tumor (white arrow) is barely
distinguishable at 0.25, 0.75, 4, or 24 hr post-injection. (C) With orthotopic breast tumors, even
ICG requires cloaking of the excretory organs (n = 3).
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Figure 5.5. NIRF imaging for biodistribution of JAS239 in ethanol/saline formulation. (A)
Delivered in an ethanol/saline formulation, maximal intratumoral JAS239 (white arrow) relative to
background is achieved 24 h post-injection. (B) Tumors (white arrow) were implanted on the right
shoulder to allow organs involved in JAS239 excretion to be cloaked. (C, D) Resected organs 24
hr post-injection of JAS239 were imaged for NIRF (C) and the Average Radiant Efficiency
2
2
[p/sec/cm /sr]/[µW/cm ] was quantified (D). (E) Tumor-to-muscle ratio was measured using
quantified NIRF. Cohort size was 5 animals and values represent + SEM. Total JAS239 delivered
was 20 nmol/animal.

We inoculated a third cohort of five athymic nude mice with subcutaneous 4175Luc+ tumors high on the right flank as distant from the kidneys as possible. This cohort
was injected with JAS239 in ethanol/saline. Fluorescence from the kidneys was the
dominant source of NIRF signal (Fig. 5.5A). Intentional placement of these tumors on the
shoulders allowed us to cloak the lower extremities and isolate the tumor for NIRF
imaging (Fig. 5.5B). The tumor signal relative to noise was highest at the 24-hour time
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point and the organs in these animals were resected and imaged to estimate JAS239
biodistribution (Fig. 5.5C). Compared to the Tris/Tween vehicle, the hepatic signal from
this formulation dropped nearly one order of magnitude, from 4.8 + 1.5 x108 to 5.4 + 0.3
x107 [p/sec/cm2/sr]/[µW/cm2], drastically reducing the background signal (Fig. 5.5D). At
this time, a nearly two-fold tumor-to-muscle ratio was found (Fig. 5.5E).
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Figure 5.6. Biodistribution of hydro-JAS239 using NIRF imaging. (A) A cohort of athymic
nude mice (n = 5) bearing 4175-Luc+ tumors on the right shoulder were imaged for NIRF (Ex.
745 nm; Em. 800 nm) following i.v. injection of 20 nmol hydro-JAS239. (B) Using an excitation
745 nm and emission 820 nm filter set, intratumoral hydro-JAS239 can be detected in the cloaked
animals.
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Figure 5.7. Bioavailability study of hydro-JAS239 and JAS239. Athymic nude mice bearing
4175-Luc+ tumors on the right shoulder were administered hydroJAS239 (left mouse) or JAS239
in ethanol/saline (right mouse) by gavage. NIRF images were acquired (A, B) 10 min, (C, D) 30
min, (E) 4 hr, or (F, G) 24 hr post-delivery from the (A, C, E, F) right orientation or (B, D, G)
ventral orientation. (H) Animals were then euthanized and the intraperitoneal cavity was exposed
to reveal that hydro-JAS239 is cleared after 24 hr, whereas JAS239 is retained in the stomach
and intestines.
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A modified hydrocyanine form of JAS239 (hydro-JAS239) was created in our lab.
When the resonant cyanine structure is chemically reduced, the molecule is nonfluorescent and non-polar until an oxidizing agent such as a free radical is introduced. We
sought to test if this non-polar variation would alter the pharmacokinetics or improve the
signal-to-noise ratio. Injected intravenously, hydro-JAS239 ultimately distributed in the
body in a pattern similar to JAS239 with high liver and renal accumulation early with
progressively more of the total probe being directed toward renal clearance after 1 hour
(Fig. 5.6A). After 24 hours, the majority of the probe was cleared by the kidney (Fig.
5.6A) and undetected in the tumor even when the animal was cloaked (Fig. 5.6B).
Interestingly, when keeping the excitation wavelength constant, but increasing the
emission wavelength from 800 nm to 820 nm, there was weak signal detected in the
tumors (Fig. 5.6E). Administration of either hydro-JAS239 (n = 3) or JAS239 (n = 1) by
gavage found neither probe to be orally available; the hydrocyanine modification did not
enhance bioavailability but accelerated clearance from the body (Fig. 5.7).
A small (n = 3) cohort of athymic nude mice bearing 4175-Luc+ orthotopic tumors
was dissected under the custom-built intraoperative NIRF imaging equipment in the
Singhal laboratory. The highest background fluorescence from internal organs was found
1 hour following JAS239 injection (Fig. 5.8A). This signal, as well as reflectance from
the bright-field camera, limited the distinction between and tumor and normal tissue
during resection (Fig. 5.8B). The tumor was seen to have elevated JAS239 in comparison
to muscle, once the two tissues were isolated (Fig. 5.8C). After 4 hours, signal from the
liver diminished (Fig. 5.8D), but the tumor contrast was also reduced (Fig. 5.8E). By 24
hours, residual JAS239 could still be detected in the intact mouse (Fig. 5.8F) and in an
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isolated tumor sample (Fig. 5.8G). A visualization of the equipment used for this pilot
study is provided in Figure 5.8H.
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Figure 5.8. NIRF-guided surgical resection of breast tumors. Athymic nude mice with 4175Luc+ tumors were injected with 20 nmol JAS239 (A-C) 1 hr, (D, E) 4 hr, or (F, G) 24 hr prior to
euthanasia. (B) Resection of each tumor was recorded simultaneously with a brightfield camera
and a NIR CCD camera. The overlay was merged with help from Ryan Judy and Jack Jiang in
the Singhal Lab. The highest tumor (white arrow) to muscle (white circle) ratio is observed at (C)
1 hr, whereas this software is not sensitive enough to detect significant NIRF signal in tumors
from the (E) 4 hr and (G) 24 hr time points at this trace dose. (H) A depiction of the NIRF imaging
technology designed in the laboratory of Dr. Sunil Singhal is provided.
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Figure 5.9. NIRF imaging for JAS239 accumulation can detect genetic overexpression of
ChoKα. (A) Athymic nude mice were inoculated with MCF7-EV (left mammary fat pad) and
MCF7-CK+ (right mammary fat pad) cells. (B) Tumor-bearing fat pads were surgically exposed
and imaged for NIRF 24 h following JAS239 injection in an ethanol formulation. (C) Quantified
2
2
Average Radiant Efficiency [p/sec/cm /sr]/[µW/cm ] of resected fat pads for each of 7 animals
reveals enhanced JAS239 retention in ChoKα-overexpressing tumors. (D) Quantified Average
Radiant Efficiency of fat pads bearing MCF7-EV or MCF7-CK+ tumors show increased
fluorescence 90 min after injection of 20 nmol in a Tween-80/Tris buffer. Values represent + SEM
for 8 animals.

The effect of genetic overexpression of ChoKα on JAS239 retention was studied in a
cohort of mice bearing orthotopic MCF7-EV and MCF7-CK+ tumors (Fig. 5.9A).
Optical imaging of the surgically-exposed mammary fat pad revealed distinct JAS239associated NIRF within the confines of the orthotopic tumor, and the tumor margins
could clearly be delineated (Fig. 5.9B). JAS239 accumulation 24 hours post-injection (in
ethanol/saline) was elevated 38 + 17 % (Paired Student’s t-test: P = 0.044) in the MCF7CK+ tumors compared to the contralateral MCF7 EV tumors (Fig. 5.9C). JAS239 in
Tween-80/Tris buffer imaged 90 minutes post-injection yielded a similar difference in
116"
"

NIRF between exposed MCF7-EV and MCF7-CK+ fat pad tumors (Paired Student’s ttest: P = 0.024), although only a 19 + 8% increase in radiance was observed at this 90minute time point (Fig. 5.9D).
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Figure 5.10. NIRF imaging for JAS239 accumulation can detect pharmacologic inhibition of
ChoKα. (A) Representative T2-weighted MRI image of a 4175-Luc+ tumor used to plan 3x3x3
3
mm voxel placement. (B) MRS spectra expanded for investigation of the choline-containing
region to compare control (black) and MN58b-treated (red) tumors. (C) MN58b-treatment
prevents the increase in intratumoral tCho (3.2 ppm) observed between scans in the control
cohort. (D) NIRF of the exposed saline (left) or MN58b-treated (right) tumors (E) was quantified
2
2
[p/sec/cm /sr]/[µW/cm ] and prior ChoKα inhibition diminishes JAS239 retention significantly. For
saline and MN58b groups, n = 5. Values are reported as + SEM. Acquisition and processing of
MR data was done in collaboration with Manoj Kumar of the Poptani group.
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MN58b treatment in 4175-Luc+ tumors was then used as a model for pharmacologic
inhibition of ChoKα. In vivo MRS (Fig. 5.10A) was used to verify that MN58b caused a
25 + 30 % reduction in tCho after a 5-day dose regimen at 2 mg/kg/day i.p. (Fig. 5.10B).
The change in tCho in response to MN58b was significantly lower (P = 0.044) than that
of the control-treated animals, which actually experienced an increase (48 + 18 %) in the
tCho resonance (Fig. 5.10C). Animals in this MRS-validated cohort then underwent
JAS239 injection and follow-up NIRF imaging (Fig. 5.10D) which revealed a reduced
accumulation (P = 0.01) of the ChoKα-targeted optical imaging probe in tumors treated
with the ChoKα inhibitor MN58b (Fig. 5.10E).
JAS239 was tested for its ability to act as a therapeutic and inhibit tumor growth.
Three days after orthotopic inoculation of athymic nude mice with 4175-Luc+ tumors, a
5-day intraperitoneal (i.p.) dose treatment regimen was started. Tumor volume
measurements began 12 days after inoculation. Both 2 mg/kg/day MN58b-treatment (P =
0.008) and 4 mg/kg/day JAS239-treatment (P = 0.009) resulted in animals bearing
significantly smaller tumors on average compared to control animals (Fig. 5.11) at this
time. One week later the control cohort’s tumors averaged 298 + 40 µL, which were
significantly larger than both MN58b-treated tumors (135 + 16 µL, P = 0.010) and
JAS239-treated tumors (132 + 41 µL, P = 0.012). Even by day 26, both the MN58b (372
+ 35 µL) and JAS239 (368 + 77 µL) cohorts had significantly smaller (P = 0.021 and
0.022, respectively) tumors than the vehicle-treated group (677 + 96 µL).
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Figure 5.11. MN58b and JAS239 slow breast tumor growth. Treatment for 5 consecutive days
with 2 mg/kg of MN58b (n = 4) or 4 mg/kg of JAS239 (n = 5) significantly reduced the growth rate
of orthotopically-implanted 4175-Luc+ tumors, compared to control animals (n = 4).

To study the therapeutic effectiveness of JAS239 in later-stage tumors, tCho was
measured as a pharmacodynamic marker of ChoKα inhibition. MDA-MB-231 xenografts
were used because prior characterization of MN58b in this model (Al-Saffar et al., 2006)
allowed for the confident use of this inhibitor as a positive control. T2-weighted images
were acquired and used for MRS voxel placement (Fig. 5.12A-C) in each tumor.
Following baseline scans, mice were divided into treatment cohorts and injected daily for
5 days with either vehicle control (Fig. 5.12D), 2 mg/kg MN58b (Fig. 5.12E), or 4 mg/kg
JAS239 (Fig. 5.12F). Post-treatment 1H MR spectra were acquired and tCho was
measured in the control vehicle-treated group to increase by 63 + 27% during the
treatment course (Fig. 5.12D&G). Significant reductions in tCho levels compared to
control were measured in response to MN58b (-25 + 13 %, P = 0.006, Fig. 5.12E&G) and
JAS239 (-64 + 25 %, P = 0.004, Fig. 5.12F&G).
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Figure 5.12. Evaluation of MN58b and JAS239-treated tumors using MRS. (A-C) T2-weighted
images of MDA-MB-231 tumors acquired for tumor volume measurement and placement of 3x3x3
3
mm voxels. (D-F) MR spectra acquired within the selected voxels before and after treatment. (G)
Change in tCho (3.2 ppm) within MDA-MB-231 tumors was measured to show progressive tCho
increase in (A, D) saline-treated animals (n = 5). Reductions in tCho in response to 5 days of (B,
E) 2 mg/kg MN58b (n = 4) or (C, F) 4 mg/kg JAS239 (n = 3) are observed. (H) PUFA resonances
at 2.8 ppm are unchanged in the control cohort and increase in response to both MN58b and
JAS239, but not significantly. (I) Lipid resonances at 1.3 ppm are unchanged. (J) Vehicle-treated
tumors grew during the treatment regimen, whereas both MN58b and JAS239 treated cohorts
were unchanged. Values reported as + SEM, * indicates P < 0.05 compared to control group. MR
data was collected in collaboration with Manoj Kumar of the Poptani group.
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A trend of an elevated polyunsaturated fatty acid (PUFA) resonance, a measure of
tumor apoptosis, after MN58b (190 + 120 %, P = 0.12) and JAS239 (150 + 130 %, P =
0.21) treatment was observed, although these values were not statistically significant
compared to control (5.79 + 50 %) due to high intra-cohort variability (Fig. 5.12H). High
variability was also observed in the lipid peak at 1.3 ppm but no significant increases in
lipid were found (Fig. 5.12I). MRI-based volume measurements indicated that vehicletreated tumors grew in volume by 27 + 16 % during the week between the pre-treatment
and post-treatment MRS scans (Paired t-test: P = 0.009), whereas MN58b-treated and
JAS239-treated tumors grew only 6.5 + 14% and 3.0 + 2.3 % during the same time span
(Fig. 5.12J). These volume increases were not statistically significant in MN58b-treated
(Paired t-test: P = 0.44) or JAS239-treated (Paired t-test: P = 0.36) tumors.
Figure 5.13 depicts a summary of the toxicological assessment of the MDA-MB-231bearing mice from this experiment, revealing no significant effects except for an
elevation of blood urea nitrogen in the MN58b-treated animals (29.5 + 0.5 mg/dL)
compared to control animals (20.0 + 3.0 mg/dL) (P = 0.012). Tumors from these animals
were harvested for histological assessment immediately after follow-up MRI/MRS
scanning. Evaluation of H&E slides (Fig. 5.14, left column) prepared from tumor slices
of the untreated cohort measured an average cell density of 8,800 + 200 cells/mm2. Both
MN58b and JAS239 caused significant reduction in cell density compared to control,
with values of 5900 + 800 cells/mm2 (P = 0.007) and 5600 + 800 cells/mm2 (P = 0.01),
respectively (Fig. 5.15A). MN58b (55 + 5 %, P = 0.026) and JAS239 (46 + 11 %, P =
0.034) treatment significantly reduced the percentage of Ki67-positive cells compared to
the high percentage of proliferative cells (78 + 1 %) in the vehicle treated group (Fig.
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5.14, middle column). Consistent with reduced cell number and proliferation, higher
Caspase-3 levels (Fig. 5.15, right column) were detected in MN58b (72 + 6 %, P = 0.016)
and JAS239 (76 + 6 %, P = 0.015) treated tumors than in control tumors (21 + 8 %).
Ki67-positive nuclei (Fig. 5.15B) and Caspase-3-positive cells (Fig. 5.15C) were
quantified in different regions of each tumor and averaged among treatment cohorts.

*

Figure 5.13. Renal damage associated with MN58b is not seen in JAS239-treated mice. A
profile of enzyme function and blood metabolite levels reveals MN58b animals had elevated
blood urea nitrogen (BUN) relative to control animals. No signs of elevated albumin, alanine
transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (AlkPhos), gammaglutamyl transferase (GGT), bilirubin, or cholesterol changes were found in response to MN58b or
JAS239 treatment. Three animals were included per cohort and values represent + SEM. *
indicates P < 0.05.
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Figure 5.14. Histological assessment of tumors reveals reduced cell density, lower
proliferation, and elevated apoptosis in response to ChoKα inhibitors. H&E staining (left
column) of MDA-MB-231 tumor xenografts reveals lower cell density in MN58b (middle row) and
JAS239 (bottom row) treated tumors compared to vehicle-treated tumors (top row). Reduced
Ki67-positive nuclei (middle column) and heightened Caspase-3 positive cells (right column) are
also found in MN58b and JAS239 treated tumors. Scale bars represent 200 µm. Preparation and
digital scanning of the slides were performed by members of the CHOP Pathology Core facility
under direction of Daniel Martinez.
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Figure 5.15. Histological assessment of ChoKα-inhibited MDA-MB-231 tumor sections
reveals apoptosis and overall reduction in viable cells. (A) Significant reduction in cell density
is observed in both MN58b and JAS239 treated tumors relative to control. (B) Lower Ki67
positivity is found in MN58b and JAS239 treated tumors, indicative of a reduction in proliferative
cells. (C) Elevated Caspase-3 in MN58b and JAS239 treated tumors relative to control indicate
apoptosis in response to ChoK inhibition. * indicates P < 0.05.
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5.3 Discussion
In Chapter 4, we reported the development of JAS239, a ChoKα inhibitor whose
inherent NIRF makes it possible to detect its interaction with cancer cells. While in vitro
data can often be promising, translation to in vivo models is crucial for a true assessment
of the feasibility of this technology. In this Chapter, we investigate further the utility of
JAS239 to detect ChoKα expression in murine models of breast cancer. JAS239 is a
cationic small molecule and this resulted in an unsurprising accumulation and clearance
through the kidneys. An initial flush was observed in the liver where ChoKα is naturally
abundant (Brophy and Vance, 1976) but this is also the site of first-pass metabolism.
While most metabolic modifications of the probe would be expected to alter the optical
properties (Shen et al., 2013) and make JAS239 undetectable in the NIRF range, there is
much work related to characterizing the metabolism and clearance of this probe that will
be the focus of future studies.
With the guidance of bioluminescence imaging in the 4175-Luc+ tumor xenografts,
intratumoral JAS239 NIRF was detectable but eventually drowned out by renal excretion
of the intact probe. Despite its clinical utilization as a NIRF contrast agent (Marshall et
al., 2010), even ICG required cloaking of the internal organs to achieve optimal in vivo
tumor contrast. By moving tumors to the shoulders away from the kidneys, intratumoral
JAS239 accumulation could similarly be visualized by cloaking the internal organs. We
prepared hydro-JAS239 as an activatable form of JAS239 in an effort to minimize the
interference from non-specific signal, but chemical modification of JAS239 to its nonpolar hydrocyanine form did not improve its tumor specificity, biodistribution, or
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bioavailability. A NIRF intraoperative imaging system was capable of discriminating
tumor from normal tissue, but only when isolated from the intraperitoneal organs. These
results do not disparage the translational utility of JAS239, as clinical optical imaging is
not a whole-body but rather a tissue or region-specific measurement.
While the biodistribution studies show JAS239 can be detected in other major organs,
the tumor/muscle ratio suggests that measurements confined to the breast region are
robust enough to distinguish malignant from normal tissue. This was verified when the
tumor-bearing mammary fat pads of JAS239-injected mice were surgically exposed and
imaged for NIRF. JAS239 accumulation was found to be a reliable identifier of ChoKα
overexpressing tumors in matched MCF7-EV and CK+ tumors. As an analysis of this
imaging strategy’s utility in validating a previously studied ChoKα inhibitor, we treated
tumor-bearing mice with MN58b or saline control. MRS evaluation before and after
therapy was used as a benchmark to verify MN58b’s efficacy in vivo. While MRS
required 1 hour per mouse—including set-up, anesthesia, shimming, and scanning—
before and after therapy, the optical imaging technique could be performed on up to 5
mice at a time and required a much less cumbersome procedure involving one i.v.
injection and follow-up surgery 24 hours later. The parallel use of both techniques told a
more complete story: that MN58b bound ChoKα (blocking JAS239 accumulation) and
attenuated flux through the Kennedy pathway (lowering tCho signals). It is important to
note that a greater difference in measured biomarker was observed between treated versus
untreated tumors using MRS measurement, although lower variability in the optical
imaging method resulted in stronger statistical confidence.
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To explore JAS239’s therapeutic properties, its ability to inhibit tumor growth and
attenuate tCho in murine breast xenografts was determined. In orthotopic MDA-MB-231
breast tumors, JAS239 significantly reduced the tumor growth rate to the same degree as
MN58b. When dosed at 4 mg/kg, MN58b showed some toxicity despite a previous report
(Al-Saffar et al., 2006) that this dose was used to lower PC levels in nude mice. No
observable or measurable toxicity was found using 4 mg/kg JAS239, and 2 mg/kg
MN58b appeared tolerable but post-mortem toxicological studies revealed evidence of
elevated blood urea nitrogen indicative of impaired renal excretion in these mice. Both of
these drugs were capable of reducing intratumoral tCho and increasing apoptosisassociated PUFAs (Hakumäki et al., 1999). In control tumors, rising tCho was an
indicator of progression during the week between pre and post-therapy scanning. Tumor
status was also evaluated by histological methods that identified high cell number and
proliferative index. Both ChoK inhibitors effectively reduced the cell number by reducing
proliferation and inducing widespread apoptosis.
Expanding interest in ChoKα inhibitors for cancer therapy has raised the need for
rapid and reliable methods to validate these therapies in vivo. There have been concerns
expressed with the reliability of RECIST measurement alone as a marker of treatment
responsiveness (Jaffe, 2006). An addendum to the first clinical trial of TCD-717 in clinic
was made to include MRS evaluation of tCho levels as a supplemental response indicator
(Clinical Trials identifier: NCT01215864). MRS is the current gold standard for choline
measurement in vivo due to its specificity, non-invasive acquisition, and feasible
inclusion following MRI for RECIST measurements. To understand the degree to which
choline metabolites represent a real biomarker of tumor progression and response to
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therapy, it would be beneficial to design secondary methods of identifying the oncogenes
that contribute to heightened choline in cancerous tissue. ChoKα has been reported
throughout the literature as a key contributor to aberrant choline metabolism (HernándezAlcoceba et al., 1997). Its regulative role in cell growth and division directly links the
Kennedy pathway to cancer malignancy (Ramírez de Molina, Báñez-Coronel, et al.,
2004). To measure ChoKα in whole tumors would provide an estimate of histological
tumor grade, an indicator of tumor vs. normal tissue, and a secondary validation method
for evaluating ChoKα inhibitors in the clinic.
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Chapter 6
Choline Kinase Inhibition as a Glioma Treatment Strategy
6.1 Introduction
Glioblastoma (GBM), the most common primary brain malignancy in adults, is an
aggressive and locally invasive tumor. Despite advances in surgery, radiation, and
chemotherapy, overall survival of patients affected by GBM has only marginally
increased in recent decades from 6 to14 months post-diagnosis (Candolfi et al., 2007).
This is partly due to a lack of effective therapeutic options and limited availability of
robust and sensitive methods to assess therapeutic response. As survival with GBM is
limited, it is critical to determine the efficacy of therapy early in treatment. An increased
understanding of the molecular mechanisms underlying oncogenesis has led
contemporary drug discovery programs to be aimed predominantly at signal transduction
pathways and molecules that drive cancer initiation and progression (JB Gibbs, 2000).
Elevated ChoKα activity has been associated with enhanced synthesis of PC in many
cancer cell types and has been proposed as a potential target for anticancer therapy
(Glunde et al., 2011). ChoKα catalyzes the phosphorylation of choline, consuming ATP
in the presence of Mg2+, yielding PC in a process mostly independent of the rate of net
PtdCho biosynthesis (Kennedy, 1957; Aoyama et al., 2004). Several agents such as
growth factors, chemical carcinogens and oncogenes can induce ChoKα activation in
malignant cells, leading to an accumulation of PC (Jiménez et al., 1995; Ramírez de
Molina, Penalva, et al., 2002; Aoyama et al., 2007).
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A novel molecular therapeutic strategy focused on ChoKα inhibition has recently
been developed, resulting in the characterization of a group of compounds with inhibitory
activity against ChoKα (Hernández-Alcoceba et al., 1997; Lacal, 2001; Ramírez de
Molina, Rodríguez-González, et al., 2004). The inhibition of ChoKα using small
molecule inhibitors such as MN58b is a promising new treatment strategy against solid
tumors (Hernández-Alcoceba et al., 1999). MN58b is an anticancer drug previously
reported to inhibit ChoKα activity resulting in attenuated PC levels, reduced proliferation
of cancer cells in vitro, and growth delay of human tumor xenografts (RodríguezGonzález et al., 2003; Ramírez de Molina, Báñez-Coronel, et al., 2004). ChoKα has
recently been discovered to be activated at the plasma membrane by EGFR in breast
cancer cells (Miyake and Parsons, 2012). Although the existence of a similar mechanism
in brain cells is unknown, EGFR mutations are common oncogenic drivers in GBM; one
of the most common mutations, EGFRviii, is constitutively active and unresponsive to
ligands (Gan et al., 2013). There is a strong need to obtain precise surrogate biomarkers
to effectively evaluate therapeutic response in GBM.
1

H MRS provides a method of measuring changes in choline-containing tumor

metabolites to serve as a pharmacodynamic biomarker of ChoKα inhibition and
therapeutic response. Al-Saffar et al. have reported the efficacy of MN58b on
subcutaneously implanted colon and breast cancer models (Al-Saffar et al., 2006),
however, there are no reports of MRS studies of ChoKα inhibitor-treated brain tumor
tissue. In this work, the sensitivity of a brain cancer cell panel to ChoKα inhibition was
measured by radiotracing and viability studies. We next carried out an exploration of
ChoKα activity in a model of EGFRviii-mutated rat GBM cells, and studied the effect of
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epidermal growth factor (EGF) on ChoKα activation and inhibition. Following this, rats
bearing intracranial GBM tumors were treated with i.p injection of MN58b for 5
consecutive days and the resected tumors were assessed using 1H MRS. The feasibility of
JAS239-assisted NIRF detection of ChoKα was tested in pilot studies. The goal of the
present study was to monitor changes in choline-containing metabolites in an intracranial
model of rat glioma in response to ChoKα inhibition.

Figure 6.1. MTT assay demonstrating inhibition of cellular viability of F98, 9L and 9LEGFRviii cell lines with MN58b. 24 hr MN58b exposure significantly reduces the viability of the
F98, 9L and 9L-EGFRviii cells in a dose dependent manner. The data was normalized to
untreated control cells and represents the average ± SEM of 3 separate experiments performed
in quadruplicate. Assay run by Sona Saksena of the Delikatny Lab under my guidance.

6.2 Results
MN58b was screened for its ability to inhibit the viability of a panel of rat brain
tumor cell lines using the MTT assay. MN58b treatment significantly reduced the
viability of the F98, 9L and 9L-EGFRviii cells in a dose dependent manner, with GI50s of
20 ± 3 µM, 9 ± 3 µM and 47 ± 2 µM, respectively (Fig. 6.1). The phosphorylation of 14Clabeled Cho (Rf = 0.07) was measured using TLC and autoradiography in cell extracts.
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14

C-PC (Rf = 0.14) production in the F98, 9L, and 9L-EGFRviii cells was quantified,

plotted, and fitted to determine IC50s of 2.6 ± 0.7 µM, 1.8 ± 0.5 µM, and 1.8 ± 0.3 µM,
respectively (Fig. 6.2A,B). No statistical difference in ChoKα inhibition was found
between these groups.

Figure 6.2. Effect of MN58b on ChoK activity in tumor cells. Autoradiography of TLC14
14
separated C-choline containing metabolites (A) allows for the quantification of C-PC and
demonstrates a dose-dependent reduction of choline phosphorylation in response to MN58b
treatment. The graph (B) shows a dose dependent reduction of ChoK activity in the F98, 9L and
9L-EGFRviii cell lines. Error bars represent + SEM of 3 separate experiments.
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The addition of EGF to serum-starved 9L and 9L-EGFRviii cells had no impact on
cell growth (Fig. 6.3A) or ChoKα activity (Fig. 6.3B). Addition of 20 µM MN58b
dramatically reduced viability and 14C-PC production, both in serum-starved and EGFstimulated conditions (Figure 6.3A,B). Constitutive EGFR downstream signaling due to
EGFRviii overexpression did not result in any perceivable change in ChoKα activity, and
these cells were less viable than wild-type 9L cells suggesting they are more serumsensitive.
A

B

Figure 6.3. 9L gliosarcoma cell response to EGF stimulation and MN58b inhibition. (A) MTT
assays show no effect of EGF in 9L or 9L-EGFRviii cells following serum starvation. MN58b at 10
µM significantly reduces viability in each condition. (B) MN58b effectively inhibits ChoK activity in
both cell lines in the presence or absence of EGF, which has no effect on ChoK activity. Error
bars represent + SEM of 3 separate experiments.
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Since 14C-radiotracing demonstrated similar treatment response from all three cell
lines, we chose F98 cells for further study because they most closely resemble human
GBM (Bryant et al., 2008). Tumors derived from the 9L cell line are a gliosarcoma and
do not exhibit the necrotic areas seen in GBM (Huszthy et al., 2012). 9L-EGFRviii is
similar to a GBM but is not as well characterized compared to the F98 tumor model
(Kapoor et al., 2007). Cellular extracts were prepared from F98 cells treated with 0, 10 or
20 µM MN58b and analyzed by NMR to determine changes in PC and GPC levels (Fig.
6.4A). Analysis of the choline-containing peaks showed lower PC levels in response to
MN58b compared to saline-treated cells (Fig. 6.4B). We observed significantly reduced
PC concentrations in cells treated with either 10 µM MN58b (5.9 ± 0.7 nmol/107 cells) or
20 µM MN58b (7 ± 4 nmol/107 cells, P = 0.049) compared to saline-treated cells (19 ± 2
nmol/107 cells, P = 0.004). We also observed higher GPC concentration in cells after 10
µM MN58b treatment (6.6 ± 2.0 nmol/107 cells, P = 0.911) and a further increase after 20
µM MN58b treatment (12 ± 8 nmol/107 cells, P = 0.532) compared to saline-treated cells
(6 ± 2!nmol/107 cells) but this difference was not statistically significant (Fig. 6.4B).
Inhibition of the anabolic pathway of choline metabolism has been reported to increase
GPC at the expense of PC (Aboagye and Bhujwalla, 1999). The PC/GPC ratio was thus
calculated for each treatment group, and both 10 µM (0.9 ± 0.4, P = 0.012), and 20 µM
MN58b-treated cells (0.57 ± 0.08, P = 0.007) demonstrated significantly lower PC/GPC
ratios as compared to saline-treated cells (3.0 ± 0.6) (Fig. 6.4C).
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Figure 6.4. In vitro NMR of F98 cell extracts. (A) Untreated cells display high levels of PC (3.22
ppm) and low levels of GPC (3.23 ppm) (top spectrum); 10 µM MN58b reduces the PC
resonance relative to GPC (middle spectrum) and 20 µM MN58b further reduces this ratio
(bottom spectrum). (B) A bar graph showing the quantitation of PC and GPC from untreated, 10
and 20 µM MN58b-treated cells (C). The PC/GPC ratio demonstrates differences between
untreated, 10 and 20 µM MN58b-treated cells. Error bars represent + SEM of 3 separate
experiments. * indicates P < 0.05. Cells were treated and harvested by Ranjit Ittyerah in the
Poptani Lab and spectra were analyzed with assistance from Manoj Kumar.
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High-resolution 1H NMR of F98 tumor extracts also demonstrated changes in PC and
GPC values in MN58b-treated tumors (Fig. 6.5A), following the trends observed in
cultured cells. Significantly lower PC levels were observed in MN58b-treated tumors
(0.33 ± 0.06 nmol/mg, P = 0.019) compared to saline-treated tumors (0.59 ± 0.06
nmol/mg). The saline-treated tumors demonstrated significantly higher PC (P = 0.030)
than normal brain (0.30 ± 0.09 nmol/mg). Significantly higher GPC was also observed in
MN58b-treated tumors (0.44 ± 0.05 nmol/mg, P = 0.009) compared to normal brain (0.23
± 0.05 nmol/mg). The GPC in saline-treated tumors (0.40 ± 0.03 nmol/mg, P = 0.015)
was significantly higher than contralateral normal brain. However, the GPC concentration
between saline-treated and MN58b-treated tumor was not significantly different (P =
0.593). When the PC/GPC ratios were computed, a significantly lower PC/GPC ratio was
observed in MN58b-treated (0.76 ± 0.09, P = 0.05) than saline-treated tumors (1.5 ± 0.3)
(Fig. 6.5B). However, there was no significant difference in the PC/GPC ratio between
MN58b-treated (P = 0.124) and normal brain (1.4 ± 0.4) (Fig. 6.5C).
In a pilot study, injection of 20 nmoles JAS239 i.v. into a mouse bearing a 9L-derived
xenograft led to levels detectable by NIRF optical imaging (Figure 6.6A). Because a
subcutaneous, rather than orthotopic, xenograft was used, this model does not accurately
account for the major obstacle of the blood-brain barrier. A different mouse bearing an
MDA-MB-231 breast tumor was injected with 4 mg/kg JAS239 in 1% ethanol for 5
consecutive days as part of a separate study. The biodistribution data from this bulk
dosage of JAS239 shows no evidence of JAS239 in brain tissue (Fig. 6.6B).
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1

Figure 6.5. Ex vivo NMR of glioma extracts. (A) Representative in vitro H NMR spectra from
perchloric acid extracts of saline-treated (bottom) and MN58b-treated F98 tumors (top). The
zoomed region (inset) is the spectral region from the choline-containing metabolites. Bar graph
(B) demonstrates changes in PC and GPC levels from contralateral normal tissue, saline-treated
tumors and MN58b-treated tumors. Bar graph (C) demonstrates the PC/GPC ratio in the 3
groups. Asterisk (*) represents significant differences with a P-value of < 0.05. Error bars
represent + SEM. The Poptani group handled all animal work for this experiment.
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Figure 6.6. JAS239 in glioma models. (A) An athymic nude mouse with a 9L glioma xenograft
was injected with 20 nmol JAS239 by Julie Czupryna of the Small Animal Imaging Core. NIR
optical images were acquired by Sona Saksena of the Delikatny Lab using a LiCOR Pearl 4 hr
after injection (Ex 710 nm, Em 800 nm). (B) A separate mouse with an MDA-MB-231 tumor was
injected for 5 consecutive days with 4 mg/kg JAS239 and the organs were separated for NIRF
imaging in an IVIS Spectrum. (C) No JAS239 accumulation can be detected in the brain.
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6.3 Discussion
In this section, the effect of the choline kinase inhibitor MN58b on choline
metabolism was examined in a glioma model. High ChoKα activity was found in cultured
tumor cells and this corresponded with elevated PC levels found in cells and in tumor
tissue extracts, confirming that PC is a viable biomarker for ChoKα-driven oncogenic
transformation. The significant decrease in cellular ChoKα activity after treatment with
MN58b indicates that inhibition of ChoKα may be an effective adjuvant in the treatment
of gliomas.
Three different glioma cell lines were studied in vitro and their sensitivity to MN58b
was observed via MTT and ChoKα assays. We observed the phosphorylation of 14Clabeled choline using a TLC-based ChoKα assay and found inhibition of ChoKα activity
in a dose dependent manner. While MN58b inhibited 14C-PC production with similar
potency in each of the three cell lines, the EGFRviii mutation imparted some resistance in
terms of increased viability compared to wild-type 9L cells, which express very little
EGFR. Because ChoKα has been reported to interact with EGFR in breast cancer cells
(Miyake and Parsons, 2012), it was intriguing to explore the effect of the constitutivelyactive EGFRviii mutation found in a considerable proportion of GBM patients (Gan et
al., 2013). The 9L gliosarcoma line are known to be relatively insensitive to EGF
stimulation!(Tichauer, Samkoe, Sexton, et al., 2012), but high levels of EGF (200 ng/mL)
has been reported to induce a 29% increase in cell growth (Guo et al., 2006). Our studies
were unable to replicate the claim that EGF can stimulate 9L glioma cells, and further
found no link between EGFR activity and ChoKα activation.
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Higher choline levels may be suggestive of increased malignant potential, increased
membrane turnover or activation of oncogenic signaling (Podo et al., 2011). In F98 cell
extracts high PC levels and PC/GPC ratios were seen using high resolution 1H NMR. We
observed a decrease in PC and non-significant increase in GPC in response to MN58b
treatment, showing the effectiveness of ChoKα inhibition on choline metabolite levels.
MN58b treatment resulted in significant reduction of the PC/GPC ratio in both cellular
and tumor tissue extracts, which is consistent with previously reported results (Al-Saffar
et al., 2006). These results were paralleled in the in vivo model. A decrease in PC and in
PC/GPC ratio was found in tumor extracts. Both PC and GPC were elevated in the extract
spectra of tumors relative to contralateral tissue, although the contralateral PC/GPC ratio
was also not significantly different from saline-treated tumor extracts even though their
absolute levels were much lower. This variability was higher in tissue than in cells
because gliomas are often histopathologically heterogeneous and have components of
varying grades of malignancy and necrosis within the tumor.
Although the promising pilot study with JAS239 suggests that it can be detected in
subcutaneous glioma xenografts, the lack of evidence that it passes the blood-brain
barrier makes this only speculative at this point. Because brain cancers can often lead to
permeabilization of the blood brain barrier, orthotopic GBM tumors would be an
interesting JAS239 application to explore further. The ability of MN58b to inhibit the
growth and metabolism of orthotopically implanted F98 tumors indicate that ChoK
inhibitors can traverse the blood brain barrier, although whether this is due to a
compromised barrier is yet to be determined. The advantage of an inherently fluorescent
drug is the ease with which biodistribution studies can be performed, allowing follow-up
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studies to be planned or modified based upon simple measurements in pilot tracer studies.
These studies could be useful in detecting compromised blood brain barriers, or in aiding
the delineation of tumor margins during surgical resection. At this preliminary level,
inclusion of JAS239 in these expensive and time-consuming rat GBM models could not
be justified, although further pursuit of this strategy is warranted.
ChoKα is particularly interesting as a therapeutic target in GBM because of its link to
hypoxia. Glunde et al. reported increased total choline and ChoKα activity in a prostate
cancer model and established a correlation between hypoxia, choline metabolites, and
Chokα activity (Glunde et al., 2008). These authors also suggested that hypoxia-inducible
factor-1 alpha (HIF-1α) activation of hypoxia response elements (HREs) within the
putative ChoKα promoter region can increase ChoKα expression within hypoxic
environments, consequently increasing cellular PC and tCho levels within these
environments. Hypoxic tumor microenvironments pose a problem for adjuvant
treatments; cancer cells located in hypoxic environments undergo adaptive responses,
which render them resistant to radiation and chemotherapy, resulting in recurrence
(Moeller et al., 2004). Such resistance to treatment contributes to the incidence of cancer
recurrence. Variations in the extent and degree of hypoxia/necrosis in combination with
variable angiogenic patterns represent a considerable problem in radiotherapeutics and
antiangiogenic management of GBM. Thus, it is plausible to hypothesize that inhibition
of ChoKα activity by a specific ChoKα inhibitor may help in reducing the survival
pathways which allow GBM tumors to thrive in hypoxic microenvironments, making
them more sensitive for chemo and radiation therapy. Conflicting evidence shows a
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decrease in choline phosphorylation in hypoxic prostate cancer cells, although this
appears to arise from other isoforms of HREs affecting ChoKα activity in human brain
tumors (Bansal et al., 2011). Thus, there are a number of avenues to explore regarding
the link between radiation-resistance and ChoKα expression.
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Chapter 7
Conclusion
7.1 Potential applications
The studies outlined in this work have led to several insights into the advantages and
shortcomings of our approach to target ChoKα with small molecule theranostics.
Theranostics is an emerging field that developed out of the molecular imaging and
pharmaceutical industries based upon their shared need for target specificity.
Applications of this technology for cancer imaging and therapy have previously been
described, but these approaches have focused primarily on nanoparticle drug delivery
agents tagged to molecular imaging contrast agents (Kelkar and Reineke, 2011). The
nanoparticle revolution is promising, but has failed thus far to make a large impact in
clinical applications, with the exception of liposomal formulations of some relatively
insoluble anticancer drugs, such as doxorubicin (Chen et al., 2011). For molecular probes
and therapeutic agents, small molecules continue to be preferred, due to a precedent in
industry, the well-defined pharmacokinetics of small molecules, and a relatively straightforward FDA approval process. Our approach has identified a prototype small molecule
that can provide diagnostic information at low doses, and therapeutic benefit at higher
doses (Fig. 7.1).
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Figure 7.1. Model of Theranostic Mechanism of ChoKα Inhibitors. Diagnostic: Breast cancer
cells are known to express higher levels of ChoKα (blue), which subsequently leads to increased
accumulation of fluorescent inhibitor (red). Non-invasive optical imaging of these molecular
beacons could therefore be used to detect ChoKα status. Therapeutic: ChoKα inhibitors cause
apoptosis selectively in cancer cells, while eliciting reversible cell cycle arrest in normal cells. This
is a self-reporting therapy because the level of accumulated fluorescence would diminish in
response to treatment.

While the idea of fluorescent kinase inhibitors is not unprecedented (Kim et al.,
2010), this project represents a conceptual leap in clinical applicability because it
describes the first example of a kinase-targeted small molecule whose fluorescence fits
within the near infrared wavelength range required for in vivo detection. The original
conception for this project was to design a probe capable of non-invasively reporting
tumor stage based upon measurement of the fluorescence emitted from a ChoKαretentive agent. As we became more familiar with the target and the breast tumor model,
the expectations for clinical translation were augmented to better fit the capabilities of
this technology. As an example, the anabolic nature of ChoKα is a disadvantage
compared to catabolic targets for which a conjugated quencher-fluorophore system can
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be “cleaved” by the mechanistic action of the molecular target (Mahmood and
Weissleder, 2003). Designed as an “always-on” fluorophore, the expectations for JAS239
and similar probes have been tempered to account for interfering signal emitted from
non-diseased tissues responsible for metabolism and excretion. In the case of the
carbocyanines, the high background signal from the kidneys may have been predicted
due to the cationic nature of these small molecules. By adapting our models and either
cloaking the intraperitoneal organs or isolating the tumor-bearing tissue, we were still
capable of making true measurements of disease status, but also introduced a new
application for this technology centered around fluorescence-guided surgical aid.
For its tumor-associated fluorescence, JAS239 is being developed in our lab as an
intraoperative NIRF contrast agent for delineation of tumor margin. In addition to this
application, however, specific measurements of ChoKα status were also found to be
feasible in these studies. Heightened NIRF was observed in tumors that geneticallyoverexpress ChoKα, although the difference in JAS239 accumulation may not be
sufficiently robust to use this technology for determination of breast cancer tumor grade.
An in vivo xenograft model with minimal ChoKα expression would be preferred to the
MCF7-EV cell line, however such tumors have yet to be identified in the literature.
Where JAS239 may be most useful is in the in vivo validation of new ChoKα inhibitors.
Current methods rely on in vivo MRS to measure the composite tCho peak at 3.2 ppm,
despite the complexity of pathways which contribute to choline metabolism. Alternative
strategies using radiolabeled choline tracers are also being developed to mitigate these
concerns, but tracer retention can be influenced by choline transport inhibition and may
falsely identify agents with neurotoxic side effects. JAS239 itself has been well-tolerated
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in animals and appears to be a true pre-clinical candidate capable of reducing tCho levels,
inducing tumor apoptosis, and slowing tumor growth.

7.2 Next generation inhibitors
The proof-of-concept goals for this project were achieved using JAS239, however,
for translation into more sophisticated breast cancer models this technology would
benefit from improved potency against ChoKα. A new collaboration with Dr. Arnon
Lavie at the University of Illinois at Chicago will make pure human ChoKα available for
exploring new inhibitors. Additionally, this group will attempt co-crystallization of
ChoKα with JAS239 to provide a better understanding of the interaction between protein
and inhibitor. During this planning process, a set of next generation carbocyanines and
MN58b-derivatives were designed by our group. After successful synthesis of prototype
derivatives, the remaining compounds were outsourced to PepTech Corporation for
synthesis. Although not all of the originally-designed structures could be produced, we
are still in possession of a small compound library to screen against ChoKα.
Pilot studies are already underway to characterize the activity of these compounds. It
was disappointing to not detect NIR fluorescence in solutions of the two resonant
derivatives of MN58b (E,E-conjMN58b and E,E,E-conjMN58b), however, detection of
fluorescence in the solid state means that we cannot rule out potential imaging utility in
whole cell applications. Additionally, a number of strongly fluorescent JAS239
derivatives were synthesized with rational modifications to several parameters involved
in pharmacokinetic behavior (e.g. hydrophobicity, structural rigidity, functional group
replacement). While awaiting pure human ChoKα, a modified ChoKα activity assay was
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developed to measure 14C-choline phosphorylation in cytosolic preparations from MDAMB-231 cells. Using this assay, remarkable activity was found for the MN58b derivative
compounds, comparable to previously established inhibitors such as HC-3, MN58b, and
TCD-717 (Fig. 7.2). Surprisingly little activity was found for any of the NIR fluorescent
compounds. Most notably, 10 µM JAS239 induced only a 14% reduction in PC
formation, despite our findings outlined in Chapter 4 using whole-cell radiotracing and
cytosolic NMR assays.
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Figure 7.2. Screen of ChoK inhibition in cytosolic preparations. C-PC production in
cytosolic preparations was used as an indicator of ChoK activity in MDA-MB-231 cells. Dicationic
compounds are the most effective ChoK inhibitors in the absence of cell membrane components.
Fluorophore-derived compounds elicit minimal ChoK inhibition in the cytosol. Error bars represent
+ SEM of 3 separate experiments. Experiments were run with assistance from Michael Chiorazzo
and Alejandro Arroyo of the Delikatny Lab.
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Figure 7.3. Comparison of JAS239 and MN58b in MCF7 cytosolic preparations. (A) ChoK
inhibition in cytosolic preparations of MCF7-EV and MCF7-CK+ cells is only observed in the
presence of MN58b. (B) In the absence of the reducing agent DTT, JAS239 more effectively
inhibits ChoK, but high variability is found due to protease activity. MN58b is equally as effective
in the absence of DTT. Error bars represent + SEM of 3 separate experiments.
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To further explore JAS239 activity in the context of this membrane-free environment,
we screened JAS239 and MN58b at 5 and 50 µM concentrations in MCF7-EV and
MCF7-CK+ cytosolic preparations (Fig. 7.3A). JAS239 was again found to be ineffective
in this assay, and the presence of dithiothreitol (DTT) became a concern. DTT is a
reducing agent included in the lysis buffer to inactivate enzymes that have disulfide
bonds critical to maintaining a catalytically-active structural conformation. As a reducing
agent, however, it was not clear if JAS239 would remain pharmacologically active in this
reducing environment, considering its conversion to a non-polar hydrocyanine state under
strong reducing conditions (see Chapter 3, Section 6 on hydro-JAS239 synthesis). The
same reaction conditions were followed as in Figure 7.3A, but without addition of the
DTT and EDTA stock to the lysis buffer. These experiments demonstrated 44% reduction
in ChoKα activity in the presence of 50 µM JAS239, but there was high experimental
variability presumably due to the fact that denaturing proteases and counteracting
phospholipases were no longer inactive in the absence of these crucial lysis buffer
components (Fig. 7.3B). A logical step would be to add a protease inhibitor in an effort to
minimize degradation of ChoKα during the reaction period. While DTT removal helped
to restore JAS239 activity against ChoKα, it did not restore potency to levels observed in
intact cells. Mass spectrometry analysis will be performed on JAS239 before and after
DTT treatment to assess possible structural changes caused by this reducing agent.

7.3 Unexplored mechanisms of choline kinase inhibition
The data above indicate that JAS239 is more potent against ChoKα in intact cells, an
unexpected result that may be due to several possibilities. The first possibility is that the
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rapid uptake of JAS239 in intact cells observed using live-cell fluorescence microscopy
(Fig. 4.13) caused higher local JAS239 concentrations within the cytosolic space and led
to greater potency. Consistent with this hypothesis, MN58b is remarkably potent in
cytosolic preparations, but the dicationic nature of this molecule causes the cell
membrane to act as a greater barrier to MN58b entry, lowering its potency in vitro. The
actual potency of MN58b against ChoKα in intact cells may be even less, considering our
preliminary evidence which attributes some of MN58b’s effect on14C- PC production to
its inhibition of choline transport (Fig. 4.11). Choline phosphorylation by ChoKα is a
mechanism cells use to trap this essential nutrient, in a manner similar to glucose
phosphorylation by hexokinase. Its potential off-target effect on choline transporters has
never previously been reported, although Rodríguez-González et al. observed reduced
choline uptake in MN58b-treated cells; this effect was explained by citing a reduction in
choline phosphorylation and, thus, cellular trapping (Rodríguez-González et al., 2003).
Interaction with choline transporters does help to explain the respiratory paralysis
observed in mice treated with 4 mg/kg MN58b (Chapter 5) and in previous generation
ChoK inhibitors.
The possibility for off-target effects of JAS239 cannot be ruled out, although the
binding specificity demonstrated using immunohistochemistry techniques in fixed cells
provides strong evidence against this. Off-target inhibition of choline transport would
explain why JAS239 is most effective at reducing PC production in intact cells. Confocal
microscopy and fluorimetry have detected no identifiable interaction with the plasma
membrane or the choline transporters. An antagonistic effect on upstream regulators of
ChoKα (such as Ras or RhoA) could also explain the inactivity in cell lysates, although
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upstream growth signals are only known to cause changes in ChoKα expression, not
activity. It is not likely that significant transcriptional changes could occur within the 1hour treatment period used in radiotracing studies. For this same reason, JAS239’s effect
on PC accumulation cannot be due to an indirect action on the phospholipase enzymes
due to the duration of time that would be required for the choline tracer to be
incorporated into PtdCho. The quaternary ammonium group of JAS239 led to concerns
that DNA intercalation or mitochondrial uncoupling may contribute to the molecule’s
antiproliferative effects. DNA intercalation was ruled out as a mode of antiproliferative
activity when JAS239 was found to be excluded from the nucleus. Measurements of
JAS239 viability (EC50) were substantially lower in Trypan exclusion assays, which
measure plasma membrane integrity, than in MTT assays, which measure mitochondrial
integrity. This difference in potency between the two assays suggests that mitochondrial
toxicity is not the driving factor in JAS239’s antiproliferative effect.
It has recently been suggested that ChoKα’s contribution to tumorigenesis is through
a non-catalytic mechanism, most likely related to its newly reported scaffolding function
(Falcon et al., 2013). For ChoKα to not be the direct target of JAS239, the probe would
likely bind to a protein currently unknown to form a scaffolding complex with ChoKα.
This possibility could explain the colocalization between JAS239 and ChoKα, but would
not explain why exogenous choline addition rescues the inhibitory effect of JAS239, nor
could it explain the reversal of JAS239 binding by a ChoKα antibody. We observed no
evidence of ChoKα recruitment to the plasma membrane in our immunohistochemistry
studies, but JAS239 may be a useful tool in the effort to characterize ChoKα’s binding
partners.
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7.4 Future studies
Screening for ChoKα inhibition and antiproliferative effects is currently under way
for the JAS239 and MN58b derivatives. Identification of interesting candidates will then
be co-crystallized with ChoKα and structure-activity relationships will then be assessed.
Many molecular biology tools that were not available at the start of this project, such as
ChoKα-specific antibodies, siRNA, and ELISA kits, are now commercially available.
These offer new and specific strategies to explore ChoKα inhibitors at a level of detail
that was not previously possible. We believe the most promising application for JAS239
derivatives is in NIRF-guided tumor resection. Use of an inducible orthotopic tumor
model would allow small tumors to be resected from mice. Disease-free margins from
animals with tumors resected by naked eye could be compared to those resected by
NIRF-guidance; the result of such studies could provide further evidence to support the
utility of these probes. For therapeutic assessment, studies of new dose formulations and
treatment regimens may identify a strategy that stops or reverses tumor growth. Finally,
testing synergistic effects with existing drugs that target compensatory pathways could
validate ChoKα inhibition as a clinically viable treatment option.
In summary, JAS239 remains the most effective small molecule ChoKα-targeted
theranostic. Its interaction with ChoKα is most likely at the choline binding site, although
further studies with the pure enzyme are needed to understand this mechanism. The
single cationic charge on JAS239 may be the reason it is only half as potent as the
dicationic inhibitors such as MN58b. By removing one quaternary ammonium group,
however, JAS239 shares less structural features with HC-3 and is better tolerated than
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MN58b in mice. The single charge also appears critical for fluorescence in less rigid
structures. With fluorescence in the NIR wavelength range, attenuation of the Kennedy
pathway, and a low toxicity profile, JAS239 is a promising multi-functional small
molecule for identification and treatment of cancer. The use of a dye as a signal
transduction inhibitor represents a return to the paradigm of the therapeutic “magic
bullet”, although our modernization of Ehrlich’s postulation more closely resembles a
diagnostic beacon fired from a NIRF gun.
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APPENDIX 1

Synthesis and characterization of E,E-conjMN58b (PTC1452-01)

154"
"

155"
"

156"
"

157"
"

158"
"

APPENDIX 2

Synthesis and characterization of E,E,E-conjMN58b (PTC1452-02)
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APPENDIX 3

Synthesis and characterization of TCD-717 (PTC1452-07)
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APPENDIX 4

Synthesis and characterization of cycloJAS239 (PTC1452-08)
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APPENDIX 5

Synthesis and characterization of cycloJAS239.5 (PTC1452-09)
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APPENDIX 6

Synthesis and characterization of cycloHITC (PTC1452-10)
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APPENDIX 7

Synthesis and characterization of cycloHITC.5 (PTC1452-11)
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